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Abstract 
 
Cancer cachexia is responsible for one third of cancer–related deaths and 
contributes to the death of many others. More than 80% of cancer patients are 
cachectic towards the end of life. Despite intensive research, the mechanisms of 
cancer cachexia are still poorly understood.  It is our hypothesis that identification of 
early changes in gene expression in cachexia will lead to an improved 
understanding of the mechanism that trigger this important problem in cancer 
patients.  
Thus, to shed light on the mechanisms involved in the major cachexia target tissues, 
we investigated the entire transcriptome in muscle and fat to identify altered 
expression of genes in cancer patients with and without cachexia. 
Samples of rectus abdominis muscle and visceral fat were collected at surgery from 
patients exhibiting 5-10% weight loss prior to surgery, compared with stable-weight 
patients. Analysis of all expressed genes was carried out using next generation 
sequencing (Illumina HiSeq 2500). Also, selected differentially expressed genes 
were confirmed using real time RT-PCR.  
In muscle, 30 genes showed highly significant changes in expression (25 
downregulated and 5 upregulated: P<0.0005 - P<0.00001, FDR 0.2). Analysis of the 
25 downregulated genes involved included 7 that are involved with metabolism (5 of 
which are mitochondrial); 4 with signaling; 4 with ubiquitination; and 3 with 
intracellular trafficking. There was marked downregulation of multiple genes involved 
in glycogen metabolism which correlates with the lack of glycogen, muscle 
weakness, and fatigue; characteristic of cachexia. The 5 upregulated genes include 
2 involved with calcium signaling and 2 with cell matrix interactions. Expression of 
genes previously thought to be important in cachexia, including several inflammatory 
cytokines, was not significantly different. FBXO32, which encodes atrogin-1, 
upregulated in an in vitro cachexia model, was actually downregulated. No 
transcripts for the dermicidin gene, which contains the sequence that codes for the 
backbone peptide of proteolysis-inducing factor, were detected. Expression of 
myostatin was significantly decreased as was its receptor (ACVR2B), possibly 
reflecting end organ adaptation to tumor produced myostatin.  
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In visceral fat, expression of 6 genes were downregulated and 10 upregulated with 
high statistical significance (P<0.001-0.0002). Several of these encode metabolic 
enzymes. Of genes in fat previously implicated in cachexia, such as hormone 
sensitive lipase and adipose tissue triglyceride lipase, were unchanged. In contrast, 
leptin was significantly downregulated and the zinc-α-2-glycoprotein (lipid mobilizing 
factor) was significantly upregulated as expected.  
These studies confirmed that for a multifactorial condition, genome wide 
transcriptome analysis is the method of choice to explore the disease complexity. 
They explain some documented evidence in cachexia pathogenesis, highlight 
ambiguous data from animal models, and reveal unexpected changes in gene 
expression that underlie the pathophysiology of the cachectic state in cancer. These 
results bring reliable, representable, and consistent data from the clinic and back to 
the bench with more focused insights to be investigated and verified.  
Keywords: Cancer cachexia, wasting, skeletal muscle, adipose tissue, RNA 
sequencing, real-time RT-PCR. 
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 )cibarA ni( tcartsbA dna eltiT
 
دراسة تسلسل كبمل التعبيرات الجينية مه بلجزيئية للمرحلة الأولية للهزال تحديد الآليبت ا
  بلسرطبنبخزعبت عضلية ودهنية مه مرضى مصببيه 
 الملخص
هو أحد و ،مباشر عن ثلث وفٌات السرطانالهزال أو الدنف المصاحب للسرطان مسإول بشكل 
. ً أٌامهم الأخٌرةمرضى السرطان من الهزال ف % من08. ٌعانً أكثر من باقً الوفٌاتالمسببات ل
لقد تم بناء هذه . لمرضى السرطان لا زالت مجهولة فإن آلٌات الهزال ،بالرغم من الأبحاث المكثفةو
الجٌنً فً المراحل الأولٌة للهزال ستساهم فً تطوٌر  الدراسة على فرضٌة أن تحدٌد متغٌرات التعبٌر
 الفهم للآلٌات المحفزة لهذه المشكلة عند مرضى السرطان.
فإن الهدف من هذه الأطروحة هو تسلٌط الضوء على الآلٌات المسببة للدنف فً الأنسجة  ،لذلك
) فً emotpircsnarTعن طرٌق دراسة كامل التعبٌرات الجٌنٌة "الترانسكرٌبتوم" ( ،المستهدفة
بهدف تحدٌد الجٌنات المتماٌزة تعبٌرٌا لمرضى السرطان اللذٌن ٌعانون  ،الأنسجة العضلٌة والدهنٌة
 . لا ٌعانون منه ومقارنتهم بمرضى سرطان ،من الهزال
أثناء  )taf larecsiv( والدهون الحشوٌة sinimodba sutcer(( تم جمع عٌنات من العضلات القطنٌة
وتمت مقارنتها  ،من أوزانهم قبل إجراء العملٌة %5-01للمرضى الذٌن خسروا  المجدولة العملٌات
كافة الجٌنات بدراسة تسلسل الجٌنً ر تحلٌل مستوى التعبٌتم . أوزانهم ثابتةبقٌت من الذٌن آخرٌن ب
 animullIز (باستخدام جها )gnicneuqes noitareneg txeN( تقنٌات عالٌة الإنتاجٌةبواسطة 
مجموعة مختارة من الجٌنات باستخدام تفاعل البولٌمٌراز  النتائج على تؤكٌدتم كما و). 0052 qeSiH
 .)RCP-TR emit-laeR(المتسلسل اللحظً 
منها  52جٌن ( 03أظهرت نتائج الدراسة فً الأنسجة العضلٌة تغٌرات هامة للغاٌة فً التعبٌرات ل 
جٌن  52). تحلٌل ال  )10000.0-5000.0˂P ,2.0 RDFٌةمنها مفعل: القٌمة الاحتمال 5بٌنما  ،مثبط
عة عملٌات أٌض من هذه السب 5) (msilobatemمنها ٌساهم فً عملٌات الأٌض ( 7المثبط أظهر أن: 
فً عملٌات التحلٌل البروتٌنً  4 ،)gnilangisفً تؤشٌر الخلٌة ( 4 ،فً المٌتوكوندرٌا)
). كما gnikciffart ralullecartniفً حركة سٌر البروتٌنات داخل الخلاٌا ( 3و  ،)noitanitiuqibu(
والتً بدورها تفسر  ،عدٌد من الجٌنات المشاركة بؤٌض الجلاٌكوجٌنا واضحا للأظهرت الدراسة تثبٌط
وهً أعراض أساسٌة مصاحبة  ،نهاكإوما ٌصاحبه من ضعف و سبب نقص الجلاٌكوجٌن بالعضلات
 2و  ،شٌر الكالسٌوممنها ٌساهم فً تؤ 2جٌنات المفعلة أظهر أن:  5فإن تحلٌل ال  ،لللهزال. فً المقاب
 بتفاعلات نسٌج الخلٌة الخارجً.
د ٌُعتق والتً كان  –للسٌتوكٌنات المسببة للالتهاب من ناحٌة أخرى، فإن بعض التعبٌرات الجٌنٌة 
. كما أن الجٌن الملاحظ ٌُذكر لم تظهر أي تغٌٌر –أن لها تؤثٌرا فً الهزال سابقة دراسات حسب 
وجد مثبطا. كما لم  )1-nigorta ;23OXBF( وهو )ortiv niتفعٌله بالعدٌد من الدراسات المختبرٌة (
) nitatsoym). كما أن التعبٌر الجٌنً لجٌن ال (nidicimredي تعبٌر جٌنً لجٌن ال (أٌتم الكشف عن 
مما قد ٌعكس  ،وجدا مثبطٌن على غٌر المتوقع ،)B2RVCAعلٌه (بالإضافة للمستقبل الذي ٌعمل 
 ) المنتج من الورم السرطانً. nitatsoymاحتمالٌة وجود تكٌف من الأنسجة العضلٌة لتؤثٌر ال (
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أظهرت نتائج الدراسة تغٌرات هامة للغاٌة فً التعبٌرات  ، فقد الحشوي أما بخصوص النسٌج الدهنً
هذه ). تحلٌل )2000.0-100.0˂Pمنها مفعل: القٌمة الاحتمالٌة  01بٌنما  ،منها مثبط 6جٌن ( 61ل 
لهزال ادراسات ٌة. مقارنة نتائج هذه الدراسة بنزٌمٌة فً العملٌات الأٌضلإالجٌنات أظهر مشاركتها ا
 dna esapil evitisnes enomroh( إنزٌمات اللٌباسٌس ظهور أي تغٌٌر علىالسابقة أظهر عدم 
بروتٌن بٌنما  ،) كان مثبطاnitpelهرمون اللٌبتٌن ( فإن بالمقابل ).esapil edirecylgirt esopida
 كما هو متوقع.  بشكل واضح، ) كان مفعلاnietorpocylg-2-α-cniz(
راسة لد مثلىالطرٌقة الكما أظهرت أن أن الهزال متعدد الأسباب.  نتائج هذه الدراساتأثبتت 
عن طرٌق دراسة تسلسل كامل التعبٌرات الجٌنٌة. هذه الدراسة  ًمراض هواستكشاف تعقٌدات الأ
ج الدراسات وألقت الضوء على بعض الغموض فً نتائ ة،الموثقة بدراسات سابق دلائلالشرحت بعض 
أظهرت نتائج غٌر متوقعة لتطور مرض الهزال لمرضى السرطان. وكما  .على حٌوانات التجارب
تعكس الصورة نظرا لثبات بٌاناته وتناسقها، والتً هذه النتائج هً بمثابة نموذج ٌمكن الاعتماد علٌه 
 لٌتم بحثها و التحقق منها بشكل أفضل مخبرٌا.  ،السرٌرٌة لهإلاء المرضى بشكل أدق
 
 ،النسٌج الدهنً  ،العضلات الهٌكلٌة  ،الدنف  ،لمرضى السرطان  الهزال مفاهيم البحث الرئيسية:
 .)RCP-TR emit-laeR(تفاعل البولٌمٌراز المتسلسل اللحظً  ،) ANRتسلسل الرنا (
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Chapter 1: Introduction 
 
1.1 Overview 
1.1.1  History, Etymology, and Definition 
Cachexia is known for centuries. The earliest link of cachexia to chronicity of ailment 
dates back 2400 years to the classical Greece and the school of medicine of 
Hippocrates [1]. It was described by Hippocrates as: 
"The flesh is consumed and becomes water,... the abdomen fills with 
water, the feet and legs swell, the shoulders, clavicles, chest, and 
thighs melt away... The illness is fatal." [1].  
Hippocrates, 460-377 BC 
The first time cachexia was used to describe involuntary weight loss in the context of 
chronic illness is unknown. However, "cardiac" cachexia was first documented by 
Charles Mauriac, a French physician, back in 1860 when it was described as a:  
“commonly observed secondary phenomenon in patients affected with 
diseases of the heart... a peculiar state of cachexia which is... 
conventionally designated cardiac cachexia” [2].  
Cachexia was also acknowledged by Herta Müller, a 2009 Nobel Prize winner for 
literature, who wrote in her novel "Atemschaukel", which was translated to English 
"The Hunger Angel"[3] as: 
"…once the flesh has disappeared from the body, carrying the bones 
becomes a burden; it draws you down into the earth”  
Müller, 2009 
Cachexia is a term originating from the Greek " kakós" and "hexis"; meaning "bad 
condition or appearance" [2]. Cachexia or the "Wasting Syndrome" is evident in 
many diseases and conditions such as: cancer, chronic heart failure, chronic kidney 
disease, chronic obstructive pulmonary disease, cystic fibrosis, rheumatoid arthritis, 
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multiple sclerosis, Alzheimer's disease, infectious diseases such as acquired 
immune deficiency syndrome, and tuberculosis, familial amyloid polyneuropathy, 
gadolinium poisoning, mercury poisoning, hormonal deficiency, and many other 
chronic illnesses [4]. 
Definition of cancer cachexia has changed several times in the last few years 
despite the slow-paced understanding of its etiopathogenesis. Up till 2008, cachexia 
had no operational definition that can adequately and reasonably validate it in terms 
of its existence and pathological processes. This had hindered, for years, properly 
designed and conducted clinical and basic sciences research. Thus, many efforts 
were taken to reach a consensus definition for the syndrome [5-7]. However, many 
cachexia definitions share two main themes; weight loss and inflammation [8] with 
many other associated symptoms: anorexia, fatigue, insulin resistance, and 
increased muscle protein breakdown. Cachexia is different from starvation, age-
related loss of muscle mass, primary depression,malabsorption, hyperthyroidism, 
and all other metabolic diseases and conditions. The latest definition of cancer 
cachexia states that it is a: 
"multifactorial syndrome characterized by an ongoing loss of skeletal 
muscle mass (with or without loss of fat mass) that cannot be fully 
reversed by conventional nutritional support and leads to progressive 
functional impairment" [7].  
None of the definitions of cachexia suggested so far are final. However, the most 
recent systemic review indicated that in clinical practice, muscle wasting is assumed 
in relation to weight loss in cancer patients, provided the patients have no fluid 
retention or a large tumor mass [9]. Keeping in mind that this thesis wishes to 
identify mechanisms of early cachexia, we operationally defined early cancer 
cachexia to guide our patients' selection as: cancer patients with documented or 
self-reported weight loss of 5-10% of total body weight in the past 6 months. 
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1.1.2 Epidemiology 
Cachexia is one of the most serious and highly prevalent, however, underestimated 
and under-diagnosed syndrome. Cachexia is a major unmet health challenge. 
Despite of the scarce resources about the extent of cachexia, it is believed that the 
overall prevalence of cachexia is growing worldwide. It is estimated to constitute 
around 1% of the total population in the developed world [4] and a possibly 
comparable number in the rest of the world. Cachexia prevalence is generally high 
and variable amongst different pathological conditions. For example, it ranges from 
5% to 15% in congestive heart failure and chronic obstructive pulmonary disease 
[4], while it reaches 60% to 80% in advanced cancer [4, 10]. Data about prevalence 
of cachexia in the cancer patients varies considerably depending on the cancer type 
and stage, and also differed depending on the criteria used for its diagnosis [11].  
The incidence of cachexia among cancer patients is very high, but it is dependent 
on tumor type and the stage of the disease. For example, the incidence in patients 
with gastric or pancreatic cancer is more than 80%, while it is around 50% in lung, 
prostate or colon cancer patients, and approximately 40% of patients with breast 
cancer or some leukemias [12, 13]. However, tumor type was not found to have a 
direct correlation to extent of cachexia. For example, some lymphomas can weigh 
several kilograms and cause no cachexia, while pancreatic tumors as small as ˂2 
cm3and weighing one or two grams may cause profound cachexia. 
1.1.3 Classification of Cancer Cachexia 
Cancer cachexia is classified to three clinical stages; precachexia, cachexia, and 
refractory cachexia. Each of these stages has distinguishing clinical features agreed 
on via consensus panel of experts in the field [7]. Stages are distinguished primarily 
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on body mass index (BMI) as an indication of body energy stores in addition to the 
general overall condition. In precachexia, patients demonstrate substantial 
involuntary weight loss (i.e. ≤5%) in addition to early clinical and metabolic signs 
(e.g. anorexia). In cachexia stage, weight loss exceeds 5% of stable body weight 
over the past 6 months, or a body mass index (BMI) less than 20 kg/m² and ongoing 
weight loss of more than 2%. On the other hand, refractory cachexia is a stage 
reached at the very advanced cancer when patients are clinically "terminal" (life 
expectancy of less than 3 months) and it is distinguished by the presence of rapidly 
progressive cancer unresponsive to antineoplastic therapy, active catabolism, 
and/or the presence of factors that render active management of weight-loss no 
longer possible or appropriate [7]. In refractory cachexia, patients also demonstrate 
low performance status. While there are three identifiable stages of cachexia, 
patients will not necessarily exhibit the all three phases.   
The risk of developing cachexia, the stage of cachexia, and the rate of progression 
of cachexia varies depending on the cancer type and stage, the presence of 
systemic inflammation, food intake, and response to anticancer therapy [7]. Cancer 
cachexia is further complicated by anticancer treatment (e.g. chemotherapy and 
radiotherapy) which themselves induce anorexia, and malabsorption that exacerbate 
the effects of the cancer itself. Also, obstruction of the gastrointestinal tract by the 
tumor will also cause anorexia, nausea and vomiting and reduction in digestion and 
absorption. All these can even further complicate cachexia.   
1.1.4 Significance of Weight Loss in Cancer Patients 
Cachexia is known since ancient Greek times as a label for 'signummaliominis' 
(indicating end stage and poor quality of life) in various, mostly fatal, diseases. 
Weight loss (the most prominent feature of cachexia) is a positive risk factor for 
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death for cancer patients. Its presence is always associated with high-mortality and 
diminishing quality of life [14]. Mortality rates of patients with cachexia are highest in 
cancer patients. More than 30% of cancer patients die due to cachexia and it 
reaches around 80% in some cancer cases, and more than 50% of patients with 
cancer die with cachexia being present [4, 15]. In cancer patients, death normally 
happens when weight loss exceeds 30% of total body weight [16]. While in 
starvation, weight loss exceeding 40% of body weight usually leads to death [17]. 
Considering cancer as a disease of old age, weight loss is a well-documented factor 
for a significant increasing mortality among elderly patients whether they are 
discharged home [18] or residing at nursing homes [19].  
On the other hand, weight loss as a primary measure of cachexia is important due to 
unavailability of data on body composition. Attainment and accurate measurement 
of baseline data on body composition is clinically hard to perform and isn’t yet 
considered as an acceptable clinical standard. Also, changes in body weight can be 
accurately and easily assessed and followed up.  
On the other hand, however, weight loss is still debated as a mono measure of 
diagnosing the cachectic state. Weight loss alone cannot fully explain the associated 
physical symptoms that accompany cachexia. Nevertheless, the preponderance of 
evidence is in favor for the importance of weight loss as the main clinical 
manifestation of cachexia and that it is highly predictive of morbidity and mortality in 
cachectic patients. 
1.1.5 Diagnosing Cancer Cachexia 
Cancer cachexia is rarely screened and always under-diagnosed due to its 
complexity in nature, and the lack of generally acceptable definition or diagnostic 
guidelines. However, clinically, multiple definitions of cachexia been utilized to 
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examine the presence or absence of cachectic state in cancer patients. Fox et.al. 
(2009) conducted a study to estimate the cachectic state amongst cancer patients 
based on four different cachexia definitions; ICD-9 diagnostic code of 799.4 
(cachexia), ICD-9 diagnosis of cachexia, anorexia, abnormal weight loss, or feeding 
difficulties, prescription for megestrol acetate, oxandrolone, somatropin, or 
dronabinol, and ≥5% weight loss in patients with different malignancies [11]. The 
eye opening findings of the study was the huge discrepancy in cachexia prevalence 
in cancer patients under each of these categories depending upon the employed 
definition. For example, in breast cancer patients, prevalence of cachexia was 8.8%, 
13.9%, 20.5%, and 31.3% for the four categories respectively. That is around 3.6 
fold increase between the first and the forth definition [11]. Thus, unless we 
operationally define cachexia based on more educated insights about its 
etiopathogenicity, developing a specific/sensitive/accurate diagnostic measure/s is 
an unattainable goal.  
The two gold standard measures for diagnosing cachexia should be computed 
tomography and the magnetic resonance imaging. The two measures are expensive 
and not used routinely. However, since cachexia is a time-dependent process, it is 
highly unlikely that these methods could be routinely applied to the clinical diagnosis 
of cachexia, because of the absence of a baseline comparison. 
1.2 Management of Cancer Cachexia 
Patients with cancer cachexia have limited treatment options. Current available 
options basically treat symptoms of cachexia, such as anorexia, and not cachexia 
itself.  
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1.2.1 Nutritional Treatment 
Many attempts were made to reverse cachexia via nutritional management (i.e. 
enteral, parenteral, and nutritional supplements). However, none of these achieve 
improvement in lean body mass [20]. A meta-analysis evaluating the effect of 
enteral nutritional supplementation failed to demonstrate any survival benefit in 
cancer patients but was able to decrease some post operatively risks and to 
reduces the overall hospital stay [21]. Furthermore, parenteral nutrition was found to 
be associated with net negative consequences in cancer patients [22] and does not 
alone affect the overall survival or quality of life [23].  
Supplements tested in cachexia include minerals, vitamins, omega-3fats, protein-
enriched nutrition, and antioxidants [24]. Omega-3fats, have been extensively 
investigated in cachexia and found to have a minimal positive effect on weight, 
appetite and quality of life in advanced cancer patients[25]. Taken together, the 
complex mix of different mediators involved in the pathophysiology of cancer 
cachexia renders nutritional intervention a strategy unlikely to succeed completely, 
although of course overall nutrition needs to be adequate [26]. 
1.2.2 Non-Pharmacological Treatments 
Non-pharmacological treatments include different measures such as: 
counseling/education, psychotherapeutic interventions, and physical training (or 
therapeutic exercise).  Psychotherapeutic interventions such as the creation of a 
pleasant environment for meals, encouraging patients to eat with adequate attention 
to the food preferences of the patient show some promise [27]. The 
pathophysiologic changes in cachexia include: insulin resistance, a decrease in the 
rate of protein synthesis, and a systemic inflammatory response. Physical exercise 
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exerts beneficial documented evidence in increasing insulin sensitivity, protein 
synthesis rate, and suppression of the inflammatory response [28]. However, most 
research has not found a conclusive evidence for its effectiveness [29]. 
1.2.3 Drug Therapy 
Many drugs have undergone clinical trials that attempt to reverse cachexia. 
Thalidomide was used in clinical trial with advanced pancreatic cancer patients and 
found to be well tolerated and effective at attenuating loss of weight, arm muscle 
mass and physical function [30]. Nevertheless, no study has provided information on 
long-term weight gain in a larger trial, or in end stage disease, or in advanced 
cachexia. On the other hand, cannabis extract of tetrahydrocannabinol did not result 
in any differences in appetite or quality of life in patients with cancer cachexia [31]. 
While cannabinoids may increase appetite in selected patients, there is not enough 
evidence to support their use. In a systematic review, megestrol; an appetite 
stimulant, was found to improve appetite and weight gain in cancer cachexia [32], 
but it increased mortality without a significant increase of body-weight [33].  
Short-term treatment with steroids improved appetite and activity in terminally ill 
cancer patients [34] while in longer treatment duration did not result in weight gain 
[35-37]. On the other hand, the long-term use of non-steroidal anti-inflammatory 
drugs showed reduction in the resting energy expenditure and preservation of total 
body fat, while lean body mass was not influenced [38]. Finally, prokinetics did not 
improve the nutritional status of patients with cachexia [39].  
1.2.4 Multimodal Therapy 
Considering the multi-factorial nature of cancer cachexia pathogenesis, treating the 
underlying neoplasm that trigger its initiation is the treatment gold standard. The 
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best way to treat cancer cachexia is to cure the cancer. Anticancer treatment will 
not, per se, alleviate cachexia through targeting the metabolic changes and the 
other documented etiologies. Metabolic changes such as reduced energy intake, in 
turn, can be supported by targeting more than one of the contributing factors despite 
the absence of properly tested combination therapy in cancer cachexia. For 
example, combination of megestrol with tetrahydrocannabinol [40] and 
eicosapentaenoic acid [41] did not provide any benefits compared with megestrol 
alone but was more effective when combined with ibuprofen [42]. Another large 
study comparing medroxyprogesterone, megestrol acetate, eicosapentaenoic acid, 
L-carnitine and thalidomide found that the combination of all drugs was superior to 
any of the other treatment arms with single drug treatment leading to increased lean 
body mass, decreased resting energy expenditure and improved appetite [43]. 
Therefore, multimodal therapy for cancer cachexia should be presented as opposed 
to monotherapy. Also, early palliative care should be initiated to manage the 
individual symptoms associated with refractory cachexia and that research in this 
domain should be promoted. 
1.3 Prevention of Cachexia 
Many intervention been tested for likelihood to prevent cachexia. Relaxation training 
with deep abdominal breathing, autosuggestion, controlled tension and relaxation of 
body parts and voluntary image control are some of these tested interventions. 
Relaxation, for example, was found to have positive effects on body weight and 
performance status in a group of cancer patients [44]. However, this study did not 
separate the cachectic from the non-cachectic patients and its results have not been 
reproduced. 
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1.4 Etiopathogenesis of Cancer Cachexia 
Cancer cachexia is a multifactorial, so far, irreversible syndrome. Symptoms of 
cachexia involve loss of muscle, with or without fat, frequently associated with 
anorexia, inflammation and insulin resistance. Cachexia has its unique pathology 
that sets it unique compared to starvation. Cachexia has a preferential muscle loss 
for an equivalent amount of weight loss compared to starvation [45]. In cachexia, the 
visceral protein compartments are preserved [46]. Muscle loss occurs predominantly 
in skeletal muscles rather than visceral muscle [47]. Even more interestingly, the 
volume of the liver and other viscera may increase in cancer cachexia as opposed 
to the decrease observed in starvation [45]. However, the mechanisms of that 
increase are unknown. As in sepsis, patients with advanced cancer have an 
elevated rate of whole-body tracer flux and depressed non-export (structural) 
hepatic protein synthesis rate [46]. This brings cancer cachexia in proximity to 
sepsis. Yet, cancer cachexia develops slowly and is not associated with the 
tremendous increase in basal metabolism due to the surge of different inflammatory 
cytokines in sepsis [48].  
On the other hand, patients with anorexia have the majority of weight lost from fat 
compared to lung cancer patients, who lose weight from both, total body fat and 
skeletal muscle protein mass [49]. In summary, the changes in body composition 
seen in cachexia resemble those found in infection and injury rather than those in 
starvation. During prolonged starvation, ketone bodies produced by fat metabolism 
in the liver replace glucose as an energy source for the brain, thus preventing loss of 
muscle through glucogenesis from amino acids. However in cachexia, this does not 
occur, probably because the energy demands on the host are sufficiently high to 
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prevent the buildup of acetyl CoA in the liver and its subsequent conversion to 
acetoacetate and  -hydroxybutyrate [50].  
1.4.1 Energy Balance and Energy Expenditure 
Body mass is controlled by the balance between the amount of energy intake and 
energy expenditure. Therefore, a major contributor to the cachexia can be attributed 
to the increased energy expenditure. Since the majority of energy intake is spent on 
the resting energy expenditure (REE), determining the level of REE in cancer patient 
can be the starting point to uncover the etiology of cancer cachexia. The rate of REE 
in cancer patients is strongly determined by the type of tumor. For example, patients 
with lung [38] and pancreatic [51] cancer have an elevated REE, while gastric and 
colon cancer patients have no increase in REE [38]. This can, at least in part, 
explain the higher mortality rates of lung and pancreatic cancer patients. In 
pancreatic cancer patients, for example, the increase in REE is proportional with the 
increase in the acute phase response (APR) [51]. APR proteins have long been 
known to be a measure of underlying tissue injury, infection, or inflammation. In 
APR, the liver redirects protein synthesis from albumin to acute phase proteins 
(APP), such as C-reactive protein (CRP), fibrinogen, serum amyloid A, α-2-
macroglobulin, and andα1-antitrypsin. Elevated levels of APP, in turn, are correlated 
with shorter survival in pancreatic cancer patients [51]. The link between the 
development of an APR and the rate of loss of body mass is also established in lung 
and gastrointestinal cancers [52]. Furthermore, serum levels of interleukin6 (IL-6) 
was found to correlate with level of CRP in patients with non-small cell lung [53]. 
Despite of the above evidence, pancreatic cancer patients were found to have 
reduced total energy expenditure (TEE) due to a reduction in their physical activity 
level (PAL) [54].  
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Recently, research on the link between brown adipose tissue (BAT) and cachexia 
has been brought to the surface. The history of this link goes back to the study 
which examined autopsy samples of peri-adrenal tissue that showed BAT to be 
present in 80% of cachectic cancer patients, compared with only 13% of age 
matched controls [55]. BAT has a well-established role in controlling body 
thermostasis and energy balance despite its scarcity in adult humans. 
Thermogenesis in BAT and its possible link to cachexia was studied in the context of 
REE. Thethermogenic effect of BAT and skeletal muscle is probably due to the 
function of uncoupling proteins (UCP). UCPs are mitochondrial inner membrane 
proteins that can dissipate the proton gradient before it can be used to provide the 
energy for oxidative phosphorylation by decreasing the level of coupling of 
respiration to ADP phosphorylation [56]. There are five types of UCPs: UCP1 found 
only in BAT, UCP2 found in most tissues, UCP3 found only in BAT and skeletal 
muscle, UCP4 found in brain tissue, and UCP5 found in brain, testis and others 
[57].Of these five, UCP1 is considered to be most important, although UCP3 also 
plays an important role in energy balance and lipid metabolism. In a murine model of 
cachexia, mRNA expression levels of UCP1, but not UCP2 and 3, in BAT was 
significantly elevated over controls [58]. However, expression of UCP2 and 3 were 
significantly increased in skeletal muscle [58]. In cachectic cancer patients, UCP3 
expression level in rectus abdominis muscle was five times higher than controls [59]. 
This increased expression level might be the mechanism by which REE is increased 
in skeletal muscles of cachectic patients. Therefore, the increase in REE is not 
merely the main cause of cachexia.  
Another way of which energy balance can be a cause of cachexia is the "futile 
energy cycle". This futile cycle, a phenomenon termed "Warburg effect", is used by 
most cancer cells to generate ATP. Warburg effect utilized glycolysis followed by 
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lactic acid fermentation in the cytosol, rather than by a comparatively low rate of 
glycolysis followed by oxidation of pyruvate in mitochondria in most normal cells as 
the principal method to generate energy [60]. Malignant cells typically have 
glycolytic rates up to 200 times higher than those of their normal tissues of origin 
even with the presence of oxygen.Several reasons are attributed to this 
phenomenon. However, regardless of the possible reasons, the Warburg effect 
results in a net yield of two ATP molecules as opposed to oxidative phosphorylation 
that yields a total of approximately 30-32 ATP molecules. Thus, the conversion of 
glucose into lactic acid is an energy-inefficient process, which means that growth of 
tumors requires 40 times more glucose than if it was fully oxidized through the 
tricarboxylic acid cycle. In order for the lactate to be recycled by liver, a net of 4 ATP 
molecules are needed. Hence, the Warburg effect results in a negative balance of 2 
ATP molecules; which is another energy inefficient process [61]. In weight losing 
colorectal cancer patients, the rates of glucose production and recycling were 
significantly higher than that in controls [62]. This complete futile process account for 
an approximately additional loss of energy in cancer patients of 300 kcal/day [63]. 
Regardless of these evidence, fast progressing cachexia such that evident in 
pancreatic cancer patients, cannot be attributed merely to this futile cycle. 
Pancreatic tumors are relatively small in size and require a long period to develop 
which is disproportional to the degree and intensity of weight loss observed in these 
patients.  
1.4.2 Anorexia and Cachexia 
Anorexia, or loss of appetite, is one of the symptoms of cachexia and is common in 
cancer patients. Cancer patients report early satiety. This may be the result of many 
factors such as: the mechanical obstruction of the gastrointestinal tract which may 
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hinder the passage of food, the functional abnormalities of the gastrointestinal 
mucosa resulting in malabsorption, or chemical triggers that suppresses appetite 
center in the brain. If anorexia, regardless of the cause, is the main reason of weight 
loss in cancer patients, one should expect a direct correlation between reduced food 
intake and the degree of weight loss. Surprisingly, the opposite is true! A large study 
of 297 cancer patients found that weight loss could not be accounted for by a 
diminished dietary intake, since the absolute amounts of energy intake did not differ, 
and the intake per kilogram of body weight was actually higher in the weight-losing 
patients compared with the weight-stable patients [64].  
Also, if anorexia is a direct and essential etiology for cachexia, nutritional 
supplementation to compensate for the deficiency in caloric intake would be 
expected to promptly reverse cachectic state. However, clinical trials showed that 
the wasting process in cancer patients cannot be reversed by all means of 
nutritional supplementation such as dietary counseling [65], total parenteral nutrition 
[66], or appetite stimulants such as cryoheptadine [67], or dronabinol. In addition, 
weight gain due to the total parenteral nutrition was transient and translated into an 
increase in fat and water rather than lean body mass [66]. This effect is not only 
limited to weight loss in cancer patients, but was also observed in patients with 
human immunodeficiency virus [68], and sepsis [69]. However, nutritional 
supplementation in pancreatic cancer patients has some survival advantage despite 
of its inability to reverse body weight loss [70]. These results show that anorexia is 
an important symptom of cachexia but is not the sole suspect for the loss of body 
mass.  
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1.4.3 Cachexia as a Catabolic State 
In the absence of stimuli, adult muscle mass remains constant with relatively equal 
rates of protein synthesis and degradation. However, an imbalance via depression 
in protein synthesis, an increase in protein degradation, or a combination of both 
should occur for cachexia to develop; research evidence is available for all the 
possibilities. For example, one study suggested that cachexia is primarily a result of 
alterations in protein synthesis rather than protein degradation [71]. Other study 
suggested the high protein turnover rates in patients with hepatocellular carcinoma 
to be the result of an elevated rate of protein breakdown, with oxidation of the 
released amino acids [72]. However, the majority of studies suggest that both 
processes are occurring simultaneously. There are three major proteolytic pathways 
responsible for the degradation of proteins in skeletal muscle; the lysosomal system, 
the calcium-activated system, and the ubiquitin-proteasome pathway [73].  
The lysosomal system includes the acid optimal cysteine proteases cathepsins B, H, 
and L as well as the aspartate protease cathepsin D. This system is mainly 
responsible for the degradation of extracellular proteins, cell receptors, endocytosed 
proteins, and phagocytosed bacteria rather than influencing the normal turnover of 
cytosolic proteins [74, 75]. This degradation system is accelerated by glucagon in 
the liver and the lack of insulin or essential amino acids [76]. The second 
degradation system is the ATP-independent, calcium-activated, cytosolic cysteine 
proteases system that are activated by an increase in cytosolic calcium which is 
mainly involved in tissue injury, necrosis, and autolysis. These proteases include 
calpains I and II [77-79]. The third degradation system is the ATP- and ubiquitin-
dependent proteasome pathway.  The function of the ubiquitin-proteasome pathway 
is to degrade defective protein products produced from errors in translation or from 
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oxidative stress [80, 81]. It works in harmony with the calpain system to disassemble 
and degrade muscle myofilaments [82]. The defective protein is targeted by the 
addition of multiple ubiquitin molecules and the subsequent recognition and 
degradation by the 26S proteasome [83]. Polyubiquitination of the protein is a 
process that not only tag proteins for degradation, but also ensures the specificity of 
the process that is normally handled by the proteasome. For polyubiquitination to 
occur, ubiquitin is activated by an activating enzyme (E1) in two steps. Firstly, an 
intermediate is formed by ATP hydrolysis connecting adenosine monophosphate 
(AMP) with the carboxy-terminal carboxyl group of glycine in ubiquitin. Secondly, a 
thioester linkage with a cysteine residue in E is formed [81]. Then, the ubiquitin 
carrier protein (E2) accepts this ubiquitin to its active site at a cysteine residue. This 
is followed by E2 carrier protein recognizing the ubiquitin protein ligase (E3). Then, 
the E3 ligase transfers ubiquitin from the E2 thioester intermediate either to a 
specific ubiquitin binding site or to an isopeptide linkage with some degree of 
substrate specificity [73]. After multiple rounds of E3, ubiquitin ligation creates a 
polyubiquitin chain on the target protein. Once the proteins are marked with a 
polyubiquitin chain, they are degraded into oligopeptides (peptides containing six to 
nine amino acid residues) by the 26S proteasome [84]. These are then degraded by 
the giant protease tripeptidyl peptidase II (TPPII) and various aminopeptidases. 
TPPII cleaves peptides generated by the proteasome into tripeptides [85]. In normal 
situations, this process is not rate-limiting for proteolysis. However, it is important 
because the accumulation of abnormal peptides may be injurious to the cell.  
1.4.3.1 Ubiquitin Proteasome Pathway System and Cachexia 
The ubiquitin proteasome pathway system is responsible for the majority of skeletal 
muscle protein catabolism [73] and has been extensively reviewed [86]. This 
pathway is activated in catabolic states resulting in muscle atrophy. Thus, it more 
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likely accounts for the advanced proteolysis seen in wasting conditions such as 
fasting, sepsis, metabolic acidosis, acute diabetes, weightlessness and cancer 
cachexia [87].  
In vitro studies of atrophying muscles have demonstrated no involvement of the 
lysosomal proteases or calcium-activated proteases systems. Yet, inhibiting ATP 
production decreased the rate of proteolysis to that of control muscles indicating that 
the ATP-dependent ubiquitin proteasome pathway is primarily responsible for 
skeletal muscle degradation [88, 89]. 
In mice bearing the cachexia-inducing MAC16 tumor, both proteasome proteolytic 
activity and TPPII activity increase in parallel with weight loss reaching a maximum 
at 16% weight loss, after which there was a progressive decrease in activity for both 
proteases with increasing weight loss [90]. In other animal models of cancer 
cachexia and in cancer patients, the ubiquitin proteasome pathway found to play the 
predominant role in the degradation of myofibrillar proteins especially in patients 
with ˃10% weight loss [91]. In yoshida ascites hepatoma (YAH)-bearing rats, 
removal of calcium or blocking the calcium-dependent proteolytic system did not 
inhibit muscle protein degradation, while inhibition of the lysosomal function reduced 
proteolysis by 12% in muscles [92]   . Nevertheless, when ATP production was 
inhibited, proteolysis in muscles was similar to that of controls [92]. The same study 
showed a significant increase in ubiquitin mRNA (590-880%), the level of ubiquitin-
conjugated proteins, and of mRNA for multiple proteosome subunits (100-215%) 
[92]. These findings indicate that the ubiquitin pathway is the predominant 
degradation system in animal models of cachexia. 
Normally, the majority of cellular proteins are degraded by the proteasome pathway. 
However, for patients with a low weight loss (i.e. 2.9%), muscle biopsies showed no 
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change in components of the ubiquitin proteasome pathway, but rather an increase 
in the expression of cathepsin B mRNA [93]. Another study also showed an increase 
in lysosomal activity, as measured by cathepsin D and acid phosphatase, in skeletal 
muscle of cancer patients which in part of the subjects appears to correlate with  
weight loss [94]. Myofibrillar protein constitutes half of the total muscle protein and is 
lost at a faster rate than other proteins during atrophy. In a murine model of 
cachexia, myosin heavy chain was selectively targeted by the ubiquitin proteasome 
pathway in the cachectic state, while other core myofibrillar proteins including 
troponin T, tropomyosin (α- and β-forms), and α-sarcomeric actin remain unchanged 
[95].  
With increasing evidence of the involvement of the ubiquitin proteasome pathway in 
regulating the skeletal muscle degradation in cancer cachexia, it is important to 
understand its triggers and how it gets activated.  
1.4.4 Tumor and Host Factors Influencing Muscle Mass in Cachexia 
1.4.4.1 Tumor Necrosis Factor-α 
Animal studies provide a considerable evidence for the importance of tumor 
necrosis factor-α (TNF-α) in triggering muscle wasting in cancer cachexia. 
Transplantation of Chinese hamster ovary cells that is transfected with the human 
TNF-α gene in mice resulted in a syndrome resembling cachexia, with progressive 
wasting, anorexia, and early death [96]. Also, genetically engineered mice deficient 
in the TNF-α receptor protein type I which are transplanted with Lewis lung 
carcinoma showed reduced wasting of skeletal muscle compared with wild-type 
mice, despite the equal levels of serum TNF-α in both groups [97]. In addition, acute 
treatment of rats with recombinant TNF-α enhanced protein degradation and 
decreased protein synthesis in soleus muscle [98]. The mechanism of which TNF-α-
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induced muscle wasting has also been studied. TNF-α has been shown to induce 
oxidative stress and nitric oxide synthase in murine skeletal muscle causing 
decrease in body weight, muscle wasting, and skeletal muscle molecular 
abnormalities, all of which are prevented by treatment with antioxidants or nitric 
oxide synthase inhibitors [99]. 
In humans, recombinant human TNF-α administered to patients as part of an 
antineoplastic regimen, caused a dose-related metabolic effects of enhanced energy 
expenditure with elevated CO2 production, increased protein catabolism, peripheral 
efflux of amino acids, decreased total arterial amino acid levels, an increase in 
plasma cortisol level, elevated serum triglycerides, as well as increased glycerol and 
free fatty acid turnover [100]. These metabolic effects (both; muscle and fat) 
resemble those seen in refractory cancer cachexia, although its role in the human 
condition is questionable. 
1.4.4.2 Interleukin-6 
IL-6 decreased the half-life of long-lived proteins in in vitro studies in murine 
myotubes by increasing the activity of the proteasome, together with cathepsins B 
and L [101]. However, most research on IL-6 in cancer cachexia is in in vivo models 
with variable results. Inhibition of IL-6 secretion and binding to its cellular receptor by 
suramin, reduces the catabolism seen in colon-26 (C26( adenocarcinoma-bearing 
mice [102]. Also, muscle atrophy is seen in IL-6 transgenic mice that overexpress IL-
6, which is completely reversed by IL-6 receptor antibody and is associated with 
increased mRNA levels for cathepsins (B and L) and ubiquitins [103]. On the other 
hand, wasting was not induced by administration of recombinant IL-6 in mice, even 
with repeated administration [104]. In contrast, using an ApcMin/+ mouse, an 
established model of colorectal cancer and cachexia, to determine the role of 
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circulating IL-6 on the development of cachexia. Mice with the highest circulating IL-
6 levels had the most severe cachectic symptoms [105]. Similarly, administration of 
IL-6 to rats acutely activated both total and myofibrillar protein degradation in muscle 
[106]. Unlike TNF-α, however, IL-6 produced no change in the expression of 
ubiquitin when administered intravenously to rats [107]. Thus, further research is 
needed to verify the role of IL-6 in cancer cachexia.  
1.4.4.3 Interleukin-1ß 
The data for the role of interleukin-1ß (IL-1ß) in cancer cachexia is controversial. 
Alike TNF-α, IL-1 can induce body weight loss and anorexia in mice [108]. Also, 
chronic treatment of rats with recombinant IL-1ß resulted in redistribution in body 
protein and a significant decrease in muscle protein content associated with a 
coordinated decrease in muscle mRNA levels of myofibrillar proteins [109].  
1.4.4.4 Interferon-γ 
In mice bearing Lewis lung tumors, administration of anti-interferon-γ (IFN-γ) 
monoclonal antibodies markedly decreased cachexia [110]. Also, nude mice 
inoculated with CHO-IFN-γ cells exhibited severe cachexia that was prevented in 
mice given anti-INF-γ monoclonal antibodies prior to injection of tumor cells [110]. 
Expression of ubiquitin gene in rat skeletal muscle was also up-regulated by IFN-γ in 
a similar manner to TNF-α and IL-1ß [107].  
Studies have investigated individual key players in triggering the main degradation 
pathway in cancer cachexia (i.e. ubiquitin proteasome pathway), but also it looked at 
the effect of combining these elements together. For example, myotubes and mouse 
muscles treated with TNF-α together with IFN-γ resulted in a significant reduction in 
myosin expression through an RNA-dependent mechanism which indicates that 
these two cytokines are complementary in the progression of muscle degradation 
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[95]. Nevertheless, murine colon-26 adenocarcinoma treated with antibodies to IL-6, 
but not TNF-α or IFN-γ, attenuated the development of weight loss and other key 
parameters of cachexia [111]. However, serum levels of cytokines, including IFN-γ, 
TNF-α, IL-1ß, and IL-6 are poorly correlated, so far, with weight loss and cachexia in 
cancer patients [112].  
1.5 Gene Expression Profiling as a mean of Understanding Pathology 
The transcriptome is the total set of RNA molecules (i.e. transcripts) and their 
quantity in a given cell, tissue, organ, or a whole organism [113]. Unlike genome, 
which is relatively static, transcriptome varies from place to place and time to time in 
response to developmental, environmental, or pathological stimuli [114]. 
Understanding the transcriptome is essential for interpreting the functional elements 
of the genome and revealing the molecular constituents of cells and tissues, and 
also for understanding development and disease [113, 114]. One way for the 
characterization of a physiologic and/or pathological condition in a given tissue can 
be determined by its differentially active genes [114]. "Gene expression profiling" is 
a molecular biology technique that measures and reflects on the activity of many to 
all of the expressed genes between two (pairwise comparison) or more sample 
types (i.e. case/s vs. control/s) at a given time.  
After passing the era of "Human Genome Project", it was necessary to bridge the 
gap between gene sequence and function. A novel technology called "DNA 
Microarray" was introduced which enabled simultaneous measurement or a whole 
transcriptome analysis of the activity of virtually all genes in the genome. Whole 
transcriptome analysis can be done in two main methods; the hybridization- or the 
sequence-based approaches. The hybridization-based approach utilizes 
differentially fluorescently labeled cDNA molecules from the desired sample versus 
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its control. The mixed equal quantities of cDNA are then incubated on a microarray 
plats that contain spots with probes targeting the desired genes. Gene activity based 
on microarray technology relies on spots brightness captured through these probes 
that hybridize to the differentially fluorescently labeled groups of samples. The 
intensity of brightness varies from gene to gene and correlates to the transcriptional 
activity of the examined genes. This technology was an enabler in many aspects of 
cancer biology; we can differentiate between tumor and non-tumor, different tumor 
grades, risk of tumor metastasis, etc. It even enabled clinicians make decisions 
about the optimal treatment of cancer patients. However, the technology did not stop 
there! Thus, understanding the transcriptome plays a pivotal role in interpreting the 
functional elements of the genome and revealing the molecular constituents of cells 
and tissues, and also for understanding development and disease.  
The sequence-based approaches uses high-throughput next generation sequencing 
techniques that were developed based on DNA microarray technology. The use of 
next-generation sequencing technology to study the transcriptome at the nucleotide 
level is known as RNA Sequencing (RNA-Seq). RNA-Seq, also called Whole 
Transcriptome Shotgun Sequencing [115], is a technology that uses next-generation 
sequencing capabilities to reveal an overview of RNA expression and quantity from 
a genome at a given moment in time [116].  
Despite being a yet evolving technology that is yet under active development, RNA-
Seq is expected to revolutionize our understanding of science [113]. It is a 
technology that outweighs all its counterparts in its advantages. Yet, a major 
exclusive setback is the bioinformatics challenges in assuring the righteous and in 
managing these tremendous representations of data [113].   
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Chapter 2: Research Aim, Hypothesis, and Specific Objectives 
 
Given the fact that cancer cachexia has been known for such a long time, our 
understanding of the mechanisms of cancer cachexia lag way behind our knowledge 
of other aspects of tumor biology. This is despite the increase of the prevalence and 
significance of the syndrome. Exploratory clinical research into the basic 
etiopathological causes of cancer cachexia is lacking and we don’t currently have 
any approved effective treatment for the involuntary weight loss in cancer patients.  
The main aim of this thesis was to explore early differential changes in gene 
expression in cancer patients with or without cachexia using state-of-the-art whole 
expression profiling technology (RNA-Seq) in order to identify the mechanistic 
pathway/s responsible for early development of cancer-associated cachexia. This 
can bring reliable, representable, and consistent data from the clinic and back to the 
bench with more focused insights to be investigated and verified. 
It is our hypothesis that identification of early changes in gene expression using 
whole transcriptome analysis in cachexia will lead to an improved understanding of 
the triggering mechanism in cancer patients. Also, understanding cancer cachexia 
can be best achieved through studying representative clinical muscle and fat 
samples.  
Our research specific objectives were to: 
1. Collect representative muscle and fat biopsies from cancer patients with 
cachexia and match them with non-cachectic weight-stable cancer controls.  
2. Conduct global gene expression assays from high quality representative muscle 
and fat biopsies from cancer patients with early cachexia and compare them to 
non-cachectic weight-stable cancer controls. 
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3. Identify differential up and downregulated pathways involved in each of the two 
tissues.  
4. Identify and analyze the highly significantly up and downregulated altered genes 
in each of the two tissues.  
5. Verify expression data from clinical and preclinical models of cancer cachexia 
against the global gene expression results.  
6. Identify and analyze the overlapping differentially expressed genes between 
cachectic skeletal muscles and cachectic adipose tissues.  
7. Confirm increased or decreased expression of a selected genes using real-time 
RT-PCR. 
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Chapter 3: Materials and Methods 
3.1 Ethical Approval 
The ethical approval request was submitted to "Al Ain Medical District Human 
Research Ethics Committee (AAMDHREC)" at the College of Medicine and Health 
Sciences (CMHS) in the United Arab Emirates University (UAEU). AAMDHREC is 
accredited by the Federal Wide Assurance (FWA) under the number 00007109. 
Research ethical proposal and protocol obtained under approval number 
AAMDHREC 11/49. Written informed consents were obtained from each subject and 
each subject was also given “Patient Information Sheet” in the language of 
preference (i.e. Arabic or English) as per the committee recommendation.  
3.2 Subjects 
A total of 24 biopsies were obtained; 12 skeletal muscles and 12 visceral adipose 
tissue. Each set of the two tissues contains 6 biopsies from cachectic cancer cases 
and 6 weight-stable controls. All subjects (cachectic and weight-stable) were with 
diagnosed malignancies. All samples were obtained through elective surgeries. 
Inclusion and exclusion criteria were as following:  
Inclusion Criteria: Cancer patients of any race, sex, and age equal or above 21 year-
old with histologically proven malignancy and under active treatment. All cases 
should have documented or self-reported weight-loss (cachexia) that is measured 
by 5-10% involuntary weight loss of the total body mass in the past 3-6 months who 
are undergoing elective abdominal surgery who agreed to sign an informed consent. 
Exclusion criteria: Subjects who are under 21 year-old. Any subject with any 
autoimmune and/or muscular disease, uncontrolled diabetes or thyroid disorder, 
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history of treatment with any anabolic/catabolic agents for the past 6 months, or 
history of physical impairment that affects mobility was excluded.  
Control subjects were matched for age and diagnosis (as possible) and with no 
documented or self-reported weight loss or gain in the past 3-6 months prior to 
surgery (see Figure 1 for study flow diagram). 
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Figure 1: Study Flow Diagram. 
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3.3 Clinical Parameters 
Body weights were measured with participants in light clothing using a beam scale 
(Seca). Heights were measured using a standard wall mounted measure and body 
mass indices (BMI) were calculated. All current available nutritional and 
inflammatory clinical parameters were recorded. History of weight changes from 
patients' records and/or self-reported weights were also recorded.  
3.4 Collection of Muscle and Adipose Tissue Biopsies 
All biopsies were taken at the start of either open or laparoscopic abdominal 
surgeries. Specimens of approximately 0.5-1.0 cm3 from the rectus abdominis 
and/or visceral fat were removed. The biopsies were washed with normal saline 
solution, blotted, and immediately placed in RNALater (AM7021; Applied 
Biosystems, Carlsbad, CA, USA) and kept overnight at 4ºC to allow thorough 
penetration of the tissue. Tissue samples were then frozen at –80ºC until further 
processing.  
3.5 Sample Labeling and Subject Confidentiality 
Collected samples were given identification labeling composing of two letters to 
denote origin (i.e. "M" for muscle, and "F" for fat) and group (i.e. "S" for cachexia 
cases, and "C" for weight-stable controls). Each sample is then followed by a unique 
identification number. To ensure confidentiality, all other subject identifications were 
removed and never communicated in downstream sample processing. For future 
possible reference to subject data, the link of these labeling and actual medical 
record numbers is kept under the access of the leading experimenter and the 
principle investigator only.  
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3.6 Samples Preparation for RNA and Protein Extraction 
Samples of muscle (45-59 mg) adipose tissue (95-173 mg) were homogenized in ice 
in 1.2 ml of trizol Reagent (15596-026, TRIzol® Reagent, Life Technologies, Thermo 
Fisher Scientific, USA) using the polytron homogenizer (POLYTRON® PT 2100 
Homogenizers, Kinematica, Switzerland). Sample homogenizations were done at 
intermittent intervals with samples kept in ice in between to avoid RNA and protein 
degradation. Intermittent homogenization was the best method to ensure complete 
retrieval of RNA and protein from samples that are difficult to homogenize (e.g. 
muscle) or those who have low RNA and protein yield (i.e. fat) [117-119]. 
Homogenization was done in batches of 6 samples or less at 1500-2000 rpm. 
Completion of each batch took 3 hours (fat) and 4-5 hours (muscle) till no clear 
visible homogenate particles were observed. Polytron generator was cleaned in 
between samples in the following sequence; DNase/RNase free distilled water, 70% 
ethanol in DNase/RNase free distilled water, followed by DNase/RNase free distilled 
water. To ensure proper removal of tissue sticking on the generator, a solution of 
1% of sodium dodecyl sulfate in DNase/RNase free distilled water was used every 
1-2 hours and as needed to clean the probe.   
3.6.1 RNA Extraction 
Once a complete tissue homogenization had been achieved, RNA extraction was 
carried out using a combination of the liquid-liquid extraction technique; the acid 
guanidiniumthiocyanate-phenol-chloroform extraction (AGPC) [120, 121], and the 
column-based system. The AGPC method was used to separate the aqueous phase 
(RNA containing phase). This step was preceded with an additional centrifugation 
for fat samples only in order to remove the floating fat layer before the addition of 
the chloroform. The total RNA was then precipitated using ethanol and processing of 
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RNA isolation was completed using the SV Total RNA Isolation System® (Promega, 
Madison, USA) according to manufacturer’s instructions. The concentration and 
purity of the RNA samples were determined by measuring the absorbance at 260 
nm and the ratio of the absorbance at 260/230 and 260/280 nm using 
spectrophotometer (ND-1000 NanoDrop, Thermo Scientific, Wilmington, DE, USA). 
Only ratios ≥ 1.8 were accepted or else, extractions were repeated till the required 
purity was achieved. RNA samples were kept on ice during processing and quality 
check and then stored at -80º C pending further processing. 
3.6.1.1 RNA Concentration 
Sample yields below 20 ng/µl were concentrated using a cold vacuum centrifuge. 
This was followed by another check for RNA concentration and purity using 
spectrophotometer (ND-1000 NanoDrop, Thermo Scientific, Wilmington, DE, USA). 
3.7 Reverse Transcription 
Total RNA was converted into cDNA using a High Capacity cDNA Reverse 
Transcription Kit® (High Capacity cDNA Reverse Transcription Kit; 4374966; 
Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. Total RNA (420ng) was converted into cDNA in a 30μl reaction volume 
using the following reaction (Table 1) and was repeated whenever needed: 
Table 1: Reverse Transcription Reaction. 
Reverse Transcription Master Mix Components  Volume (1x) 
10 x RT Buffer 3.0 µl 
25 x dNTP Mix 1.2 µl 
10 x RT Random Primers 3.0 µl 
Multiscribe™ Reverse Transcriptase  1.0 µl 
RNASE Inhibitor 1.0 µl 
RNase Free H2O = (30 - 9.2 - vol of 420ng 
template) µl 
Total Volume Reaction 30.0 µl 
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The above reaction gives a final cDNA concentration of = 420ng/30µl = 14ng/µl. 
Each cDNA sample were then diluted to 4ng/µl and stored in -20º C. The reverse 
transcription reaction was carried out in a Veriti thermal cycler (Life Technologies, 
Applied Biosystems, USA) using the following parameter values (Table 2):  
 
Table 2: Parameters of the Thermal Cycler for Reverse Transcription. 
 Step 1 Step 2 Step 3 Step 4 
Temp ºC 25 ºC 37 ºC 85 ºC 4 ºC 
Time 10 minutes 120 minutes 5 minutes ∞ 
 
3.8 Real-Time Reverse Transcription Polymerase Chain Reaction  
The expression levels of mRNA were analyzed using target specific TaqMan® gene 
expression assays using real-time reverse transcription polymerase chain reaction 
(RT–PCR) and performed in a 7900HT Fast ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems, USA). The following TaqMan® primers and probes 
kits were purchased from Applied Biosystems (Table 3): 
 
Table 3: List of the TaqMan® Primers for Real-Time RT-PCR. 
Assay ID Gene Symbol 
Assay ID: Hs01098873_m1  Gene Symbol: COL4A2, hCG33042  
Assay ID: Hs00373339_m1  Gene Symbol: NRXN2, hCG1810991  
Assay ID: Hs00394748_m1  Gene Symbol: AGRN  
Assay ID: Hs01062014_m1  Gene Symbol: NOTCH1, hCG1818285  
Assay ID: Hs00373136_m1  Gene Symbol: PTPRR, hCG25410  
Assay ID: Hs00192297_m1  Gene Symbol: NDUFS1, hCG17250 
Assay ID: Hs00174877_m1 Gene Symbol: LEP, hCG33000  
Assay ID: Hs00223332_m1 Gene Symbol: TNMD, hCG20191  
Assay ID: Hs00896336_m1 Gene Symbol: LHCGR, hCG16776  
Assay ID: Hs04187682_g1  Gene Symbol: CXCL11, hCG23841  
Assay ID: Hs02800695_m1, #4326321E Gene Symbol: HPRT1 
Endogenous 
Controls 
Assay ID: Hs02758991_g1, #4326317E Gene Symbol: GAPDH 
Assay ID: Hs01060665_g1, #4326315E Gene Symbol: ACTB 
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The reaction mix of 10µl containing a total cDNA of 4ng/reaction was prepared using 
TaqMan® H Fast Universal PCR Master Mix, No AmpErase H UNG (Life 
Technologies #4352042, Applied Biosystems, USA) as follow (Table 4): 
Table 4: Real-Time RT-PCR Reaction. 
Real Time PCR Master Mix Reaction Volume (1x) 
DNase/RNase free H2O 3.5 µl 
cDNA (stock concentration 4ng/µl) 1 µl 
2 X TaqMan H Fast Universal PCR Master Mix  5 µl 
20 X Gene of Interest (GOI) 0.5 µl 
 
Quantitative real-time PCR assay for the gene of interest was performed in 
duplicates and in a singleplex PCR reaction. The PCR thermal cycling parameters 
were run in fast mode as follow (Table 5): 
 
 
Table 5: Parameters of the Thermal Cycler for Real-Time RT-PCR. 
 Step 1 Step 2 Step 3 Step 4 
Temp ºC 50º C 95 º C 40 cycles of  
95 º C 
60 º C  
Time 2 minutes  20 seconds 1 second 20 seconds 
 
Results were initially analyzed with the ABI Prism 7900HT SDS program v2, 4, all 
remaining calculations and statistical analysis were performed by the SDS RQ 
Manager 1.1,4 software using the 2-∆∆Ct method with a relative quantification 
RQmin/RQmax confidence set at 95%. Three different endogenous controls were 
tested; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), human 
Hypoxanthine phosphoribosyltransferase (Hprt1) rRNA, and human β-actin. Hprt1 
was found to be the best and used to normalize expression results. Other 
expression related guidelines were followed from the MIQE guidelines [122].  
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3.9 Statistical Analysis 
Preliminary statistical analysis of the next generation sequencing was carried out by 
our collaborator in Qatar. Confirmation of changes in gene expression by real-time 
RT-PCR was done using Student's t-test and analysis was done using the 
GraphPad Prism Software (version 5). 
3.10  Bioinformatics Tools 
Much freely available databases and software were used check gene functions, 
expression pattern, protein interaction, and functional pathways. These databases 
and software are: 
 The US National Library of Medicine National Institutes of Health: 
http://www.ncbi.nlm.nih.gov/pubmed 
 UCSC Genome Bioinformatics: http://genome.ucsc.edu/ 
 Ensembl: http://www.ensembl.org/index.html 
 KEGG database: http://www.genome.jp/kegg/kegg1.html 
 String: http://string-db.org/ 
 Biological General Repository for Interaction Datasets: http://thebiogrid.org/ 
 ExPASy Bioinformatics Resource Portal: 
http://www.expasy.org/proteomics/protein-protein_interaction 
3.11 RNA Sequencing 
Muscle and fat RNA samples (600ng) were sent in dry ice to our collaborators in 
Weill Cornel Medical College in Qatar for RNA Sequencing (RNA-Seq). RNA-Seq is 
a revolutionary transcriptomic technique that uses deep-sequencing technologies. 
The technique utilizes a population of RNA that is reversed transcribed into a library 
of cDNA fragments.  
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All samples underwent quality check prior to sequencing by measuring the RNA 
Integrity Number and ensuring that all samples are with a RNA Integrity Number 
value of at least 7. Samples were then reversed transcribed into cDNA. RNA-Seq 
was then performed on the Illumina HiSeq 2500 System. 
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Chapter 4: Results and Discussions – Muscle 
4.1 Demographic and Biochemical Characteristics of Subjects 
4.1.1 Results 
Demographic and biochemical details of patients for muscle cachexia cases (MS) 
and muscle weight-stable controls (MC) are shown in bellow tables. The table 
shows the data after excluding two samples (one of each group) since they were 
outliers from the RNA-Seq data. The cause of these two samples as outliers was 
investigated. Data on the excluded cachexia sample was obtained through patients 
self-report of weight changes in the past six months with the complete absence of 
baseline data in patient's record. The patient was a referral to the hospital from a 
different city just to be operated. On the other hand, further investigation of the 
excluded control sample in patient's extended electronic records in different health 
institutions found to have obvious fluctuation of patients weight in between the two 
time points that our study has initially selected patients on. All samples were then 
analyzed based on weight, BMI, some nutritional parameters, inflammatory markers, 
and other related demographics.  
Table 6 shows subjects' oncological diagnoses for muscle biopsies. All patients 
were with histologically confirmed malignancies. Age and gender distribution were 
not significantly different between cachexia muscle cases (MS) and weight-stable 
muscle controls (MC) (Table 7). All biochemical nutritional parameters (i.e. 
hemoglobin, total protein, albumin, urea, and creatinine) and inflammatory markers 
(i.e. WBC and CRP) were not significantly different between both groups (Table 7). 
Baseline weights and BMIs in the cachexia group did not differ significantly from the 
control. The time range between current (at time of biopsy) and baseline weights 
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(preceding date of biopsy) was 3-6 months. Mean weight loss from baseline in the 
cachexia group was 4.6 kg which is 6.5% of baseline body weight (i.e. 3-6 months 
before the date of sample collection). Amount and percentage of weight loss was 
significantly different from controls that had stable weights; P-value of 0.0014 and 
0.0003, respectively. 
 
Table 6: Subjects' Diagnoses for Skeletal Muscle Biopsies. 
Cachectic Muscle Cases (MS)  Weight-stable Muscle Controls (MC) 
MS1: Malignant Neoplasm of Rectum MC1: Malignant Neoplasm of Rectum 
MS2: Malignant Neoplasm of Stomach MC2: Malignant Neoplasm of Rectum 
MS3: Malignant Neoplasm of Rectum MC3: Malignant Neoplasm of Colon 
MS4:Malignant Neoplasm of Duodenum MC5: Malignant Neoplasm of Connective 
and Soft Tissue 
MS6: Malignant Neoplasm of Pancreas MC8: Malignant Neoplasm of Colon 
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Table 7: Demographic Data for Cachectic Muscle Cases and Weight-Stable Muscle 
Controls. 
Gender (M/F)  
MS: 4/1; MC: 3/2 
MS: 
N=5 
MC: 
N=5 
Mean  SEM Median Range P-Value  
Characteristics 
Age Cach. 
Cont. 
61.40 
53.40 
7.461 
6.447 
67.00 
59.00 
44-83 
36-66 
0.4406 
Hemoglobin  Cach. 
Cont. 
114.0 
114.6 
4.669 
8.583 
111.0 
122.0 
103-125 
90-135 
0.9525 
Creatinine Cach. 
Cont. 
65.75 
61.60 
10.23 
3.385 
69.00 
63.00 
41-84 
52-72 
0.6837 
Urea Cach. 
Cont. 
6.650 
3.480 
1.735 
0.3980 
6.300 
3.900 
2.9-11.1 
1.9-4.0 
0.0863 
Total protein Cach. 
Cont. 
52.75 
51.60 
4.535 
3.516 
49.50 
49.00 
46-66 
42-63 
0.8441 
Albumin  Cach. 
Cont. 
27.50 
30.00 
4.349 
2.280 
25.00 
29.00 
20-40 
23-37 
0.6047 
WBC Cach. 
Cont. 
8.900 
8.640 
1.307 
1.613 
9.000 
9.600 
6.0-13.3 
4.4-12.1 
0.9034 
CRP Cach. 
Cont. 
12.50 
14.67 
7.331 
2.333 
7.500 
14.00 
1-34 
11-19 
0.8172 
Baseline BMI  Cach. 
Cont. 
23.58 
29.86 
2.378 
1.765 
23.02 
30.46 
15.57-92.92; 
25.26-35.38 
0.0667 
 
Current BMI  Cach. 
Cont. 
21.95 
29.79 
2.030 
1.811 
21.98 
30.46 
14.81-26.44; 
24.91-35.38 
*0.0205 
 
Baseline weights  Cach. 
Cont. 
67.92 
81.20 
5.738 
2.653 
73.00 
84.00 
45.00-74.60; 
73.00-87.00 
0.0689  
Current weights  Cach. 
Cont. 
63.38 
81.00 
5.213 
2.811 
67.90 
84.00 
42.80-71.20; 
72.00-87.00 
*0.0177 
 
Amount of weight 
loss 
Cach. 
Cont. 
4.540 
0.2000 
0.8818 
0.2000 
4.000 
0.0000 
2.200-7.000 
0.0000-1.000 
**0.0014 
% of weight loss Cach. 
Cont. 
6.552 
0.2740 
0.9994 
0.2740 
5.479 
0.0000 
4.558-9.589 
0.0000-1.370 
***0.0003 
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Table 8 compares weight and BMI changes between current and baseline within 
each group (paired t-test). The cachectic muscle cases (MS) had a significant 
difference between current and baseline data while weight-stable controls (MC) had 
no significant change. 
 
Table 8: Paired t-Tests for Weight and BMI Changes for Muscle Biopsies. 
Characteristics N=MS/MC; 
5/5 
Mean  SEM Median Range P-Value  
Weight MS 
(cachectic) 
Baseline 
Current 
67.92 
63.38 
5.738 
5.213 
73.00 
67.90 
45.00-74.60; 
42.80-71.20 
** 0.0068 
 
BMI MS  
(cachectic) 
Baseline 
Current 
23.58 
21.95 
2.378 
2.030 
23.02 
21.98 
15.57-29.24; 
14.81-26.44 
* 0.0140 
Weight MC 
(weight-stable) 
Baseline 
Current 
81.20 
81.00 
2.653 
2.811 
84.00 
84.00 
73.00-87.00 
72.00-87.00 
0.3739 
BMI MC 
(weight-stable) 
Baseline 
Current 
29.86 
29.79 
1.765 
1.811 
30.46 
30.46 
25.26-35.38 
24.91-35.38 
0.3739 
 
4.1.2 Discussion 
In the above demographic analysis, patients included in the study were chosen 
meticulously to be at the early stages of cachexia (i.e. 5 - < 10% weight loss). 
Consensus definition had identified early cachexia as weight loss >5% or BMI 
<20kg/m2 and weight loss >2% or sarcopenia and weight loss >2% with often 
reduced food intake or systemic inflammation [7]. Our subjects had a mean 
percentage of weight loss of 6.5% (range 4.6-9.6 %). Since systemic inflammation 
measured via serum CRP may or may not be present in patients with cachexia [7], 
our subjects were included regardless of their CRP values (range 1-34, Table 6). 
However, the CRP values between cachectic cases (MS) and weight-stable controls 
(FC) were ensured to be not statistically significant; P= 0.325 in muscle.  
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Nutritional and nutrition-related biochemical markers were all ensured to be 
comparable in both groups to objectively exclude the possibility of malnutrition as 
the primary cause of weight loss.  
4.2 Heat Map of RNA Sequencing Data 
4.2.1 Results 
Figure2shows the heat map of differentially regulated genes between cachectic 
muscle cases (MS) and weight-stable controls (MC). The figure shows a complete 
and clear cut separation between both groups. The heat map shows a total of 238 
significantly upregulated genes and 235 downregulated genes (P-value < 0.05; and 
FDR < 0.5).  
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Figure 2: Heat Map Representation of the Differentially Expressed Genes in Skeletal 
Muscle Tissue. 
Gene expression is shown for the cachectic muscle cases (MS; purple bars; upper 
panel) and weight-stable controls (MC; green bar; lower panel). Colors represent 
scaled and centered expression values; red represents higher expression, blue 
represents lower expression. 
 
4.2.2  Discussion 
The heat-map provides a graphical visualization of the matrix dataset by 
representing individual values with different colors. This necessity stems from the 
increasing data volumes generated by scientific studies. Effective data visualization 
enables understanding data at both broad and detailed levels. Recent progress in 
high-throughput techniques, such as RNA-Seq, has increased the demand for the 
visualization of multi-dimensional in addition to the numeric data [123]. This simple 
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hierarchical cluster analysis revealed a clear visual distinction of gene expression 
signature between cachexia muscle cases (MS) from those with weight-stable 
controls (MC).  
4.3 Analysis of Differentially Expressed KEGG Pathways 
4.3.1 Introduction to Pathways Analysis 
Even for the simplest biological function, single-gene expression analysis has its 
own limitations for understanding the biological mechanism of a disease/syndrome. 
Complicated biological and pathological processes are a function of hundreds of 
differentially expressed genes. These genes never work independently. Whole 
genome expression analysis draws attention for discovering the hidden links 
disregarded by the single-gene analysis.  
The introduction of high throughput technology, like microarray, enabled 
simultaneous quantification of thousands of genes to the full genome expression. 
However, “next generation sequencing” is much more powerful than microarray in 
identifying a more quantitative expression of genes of the whole transcriptome from 
cells or tissues. 
4.3.1.1 Why Pathways Analysis? 
Pathways analysis has emerged as one of the most important methods to gain 
insight into the underlying biology of differentially expressed genes. It is a logical 
next step in any high-throughput experimentation. Basing the massive quantity of 
data generated through full genome expression assays on pathways analysis 
reduces the complexity of single gene analysis. Also, high-throughput experiments 
do not produce biological findings. Since gene products do not work alone, but in an 
intricate network of interactions, pathways analysis helps interpret the data in the 
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context of biological processes; pathways and networks. Thus, it gives a global 
perspective on the data and the problem in hand.  
Pathways analysis also provides in-depth and contextualized findings to help 
understand the mechanisms of disease/conditions in question. It helps in 
identification of genes and proteins associated with the etiology of a specific 
disease. Also, it helps to understand how to intervene therapeutically in disease 
processes by prediction of drug targets. It aids in data integration from diverse 
biological information and hence the discovery of the function of unknown genes.  
Many pathways analysis approaches and resulting software/tools are available. 
These tools have evolved in, so far, three generations of algorithms of increasing 
complexity and hence, comprehensiveness [124].  "KEGG pathway analysis" is one 
of the third generation tools that is widely used [124]. Tools in the first and the 
second generations consider only the number of genes in a pathway or gene 
coexpression to identify significantly altered pathways. Thus, they always produce 
the same results no matter how they are analyzed [124]. However, the third 
generation pathways analysis utilizes additional information available from these 
knowledge bases [124]. It is important to understand this concept during data 
analysis since variations in statistical significance is highly likely [125]. For example, 
statistical significance of cytokine-cytokine receptor interaction pathway calculated 
by three different methods resulted in P-values of 8.08×10-6, 0.72, and 6.19×10-2 
[125]. This huge difference should be always considered during data analysis. 
However, the real value of pathway analysis is to generate hypothesis, inferences, 
and explore the overall picture of a complex unknown 
diseases/conditions/syndromes.  
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4.3.1.2 KEGG Pathways 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is a project that 
was initiated back in 1995 under the then ongoing Japanese Human Genome 
Program [126]. It is a collection of databases (seventeen main databases) that are 
broadly categorized into 4 broad categories that deals with genomes, biological 
pathways, diseases, drugs, and chemical substances. In our study, our collaborator 
in Qatar has initially utilized it to generate a computer representation from our 
molecular-level information (RNA Sequencing results) to explore differentially 
involved pathways in cachexia pathogenesis [126, 127]. The outcome of this 
analysis is the "KEGG pathway mapping", whereby the gene content in the genome 
is compared with the "KEGG PATHWAY" database to examine which pathways and 
associated functions are likely to be differentially encoded in the genome. 
Several pathways were found to be differentially expressed; up- or downregulated, 
when expression data was analyzed using KEGG pathways analysis. Each of these 
pathways has several genes that are significantly altered and will be discussed 
below. 
4.3.2 Upregulated KEGG Pathways in Cachectic Skeletal Muscle 
4.3.2.1 Results 
Four KEGG pathways are differentially upregulated in cachectic muscles cases vs. 
weight-stable control muscles; notch signaling pathway, cell adhesion molecules 
(CAMs), acute myeloid leukemia, extracellular matrix (ECM)-receptor interaction. 
These pathways have 4, 6, 4, and 4 significantly upregulated genes respectively 
(Table 9).Figure 2shows the individual genes in each pathway and the overall 
statistical significance for each of these pathways. Table 10 shows a summary of 
the full gene name, fold change, and P-value for individual genes in each pathway.  
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Table 9: Differentially Upregulated KEGG pathways in Cachectic Skeletal Muscle. 
KEGG 
Pathway  
Gene Gene Gene Gene Gene Gene P-
value 
FDR 
Notch 
signaling 
pathway 
NOTCH1 NOTCH4 MFNG DTX2   0.021 0.87 
Cell 
Adhesion 
molecules 
F11R CLDN11 ESAM HLA-A HLA-C NRXN
2 
0.025 0.70 
Acute 
myeloid 
leukemia 
RARA STAT5A TCF7L2 RELA   0.036 0.70 
ECM-
receptor 
interaction 
AGRN COL4A2 HSPG2 VWF   0.088 0.90 
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Table 10: Data of Individual Genes in the Upregulated KEGG Pathways in Cachectic 
Skeletal Muscle. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-
Value 
Muscle-Up /  Notch Signaling Pathway  
MFNG MFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
2.99 0.0022 
NOTCH1 Notch homolog 1, translocation-associated (Drosophila) 5.69 0.0143 
NOTCH4 Notch homolog 4 (Drosophila) 3.69 0.0040 
DTX2 deltex homolog 2 (Drosophila) 3.70 0.0155 
Muscle-Up /  Cell adhesion molecules (CAMs)  
F11R F11 receptor 2.59 0.0160 
CLDN11 claudin 11 6.76 0.0158 
ESAM endothelial cell adhesion molecule 3.39 0.0004 
HLA-A major histocompatibility complex, class I, A 2.92 0.0162 
HLA-C major histocompatibility complex, class I, C; major 
histocompatibility complex, class I, B 
3.56 0.0173 
NRXN2 neurexin 2 11.83 0.0148 
Muscle-Up / Acute myeloid leukemia  
RARA retinoic acid receptor, alpha 3.06 0.0134 
STAT5A signal transducer and activator of transcription 5A 3.33 0.0150 
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 2.36 0.0169 
RELA v-relreticuloendotheliosis viral oncogene homolog A 
(avian) 
2.29 0.0069 
Muscle-Up / ECM-receptor interaction  
AGRN Agrin 2.75 0.0161 
COL4A2 collagen, type IV, alpha 2 8.54 0.0184 
HSPG2 heparan sulfate proteoglycan 2 7.79 0.0189 
VWF von Willebrand factor 3.22 0.0167 
 
4.3.2.2 Discussion 
Notch Signaling Pathway 
Notch signaling is an evolutionarily conserved intercellular pathway that regulates 
interactions between physically adjacent cells and is a well-documented pathway in 
skeletal muscle development and regeneration [128]. Normally, Notch pathway in 
skeletal muscles regulates proliferation and commitment of activated satellite cells to 
myogenic lineage. Also, activation of Notch signaling is a prerequisite for the 
expansion of postnatal satellite cells and to prevent the premature differentiation of 
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myogenic progenitor cells precursors in injured myofibers into mature muscle [129, 
130]. These two processes ensure muscular homeostasis. Muscle injury, which is 
the early cachexia in our case, is known to activate Notch pathway.  Two known 
notch receptors NOTCH1 and NOTCH4 were upregulated. In addition, two known 
activators of the pathway [131, 132] were upregulated; MFNG, which encodes for 
manic fringe (a protein family that also includes the radical and lunatic fringe) which 
fucosylates and thereby modulates notch, and DTX2, which encodes for deltex-1 an 
E3 ubiquitin ligase which is positive regulator of downstream, were upregulated 
[133, 134].  
Cell adhesion molecules and ECM-receptor interaction pathways  
It is well-know that further activation of Notch pathway require more cell-cell 
contacts [135]. Thus, no wonder that two other supportive pathways; cell adhesion 
molecules (CAM), and extracellular matrix-receptor interaction, were also 
upregulated with multiple genes involved at different levels.  
On a different note, elements in the extracellular matrix-receptor interaction pathway 
were also correlated to documented literature in muscle wasting. For example, agrin 
(AGRN) fragments are under investigation as a possible biomarker for sarcopenia 
[136] and was also found to be upregulated in cachectic muscles. Also, expression 
of collagen type 4 alpha 1 (COL4A1, from original data) and collagen type 4 alpha 2 
(COL4A2) genes; which are components of the myocyte basal lamina [137], are 
significantly upregulated. The matrix metalloproteinase genes (MMP2 and MMP9) 
code for abundant gelatinases in muscle that hydrolyze fibrillar collagens [138]. The 
two genes which are normally expressed in quiescent satellite cells [139]. MMP2 is 
activated by MMP14 at the sarcolemma [138]. MMP2, its activator; MMP14 and 
MMP9 are massively upregulated (but not statistically significant) in the cachectic 
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muscles. This signature molecular changes in our cachectic muscles reflects the 
quiescent state of the satellite cells which are, possibly, at its borderline activation 
once the degrading forces for the type IV collagens (i.e. COL4A1 and 2) exceeds 
cellular degradation resistance threshold.   
Acute myeloid leukemia pathway 
Another upregulated pathway in cachectic muscles is the acute myeloid leukemia. 
One gene is of a particular and a justified importance in the cachexia context; the 
transcription factor 7-like 2 (TCF7L2) gene. This gene was found in a genome-wide 
association scans to be the most important locus predisposing and consistently 
involved in type 2 diabetes [140]. Insulin resistance is an important common feature 
between cancer cachexia and type 2 diabetes and patients with cancer cachexia 
have profound insulin resistance [141, 142].  
A certain polymorphism that increases TCF7L2 gene expression is associated to 
type 2 diabetes [140] and it could be that the same gene involved in muscles 
contributing to insulin resistance in cachectic patients. Not only TCF7L2, but also 
another gene in the same pathway; the signal transducer and activator of 
transcription 5A (STAT5A) gene, plays an important role in insulin resistance. 
STAT5A is a physiological substrate of the insulin receptor that is independent of 
JAK [143]. Insulin activates STAT5A (along other stats) [143]. Prolonged insulin 
exposure in skeletal muscle cells increases STAT5 expression which may play an 
important role in the manifestation and/or progression of insulin resistance in 
muscles [144]. RELA, which is a member of the NFkappaB family, forms a 
heterodimer with p65-c-Rel to from a transcriptional activator. Expression of RELA 
gene, on the other hand, was increased in human and mouse model of Huntington's 
disease [145].   
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4.3.3 Downregulated KEGG Pathways in Cachectic Skeletal Muscle 
4.3.3.1 Results 
Eleven KEGG pathways are differentially downregulated in cachectic muscles cases 
vs. weight-stable muscles. Several of these pathways share many of the same 
genes (Table 11). We decided to collectively call these pathways (i.e. hypertrophic 
cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular 
cardiomyopathy, and cardiac muscle contraction); the cardiac muscle contraction 
and cardiac myopathy pathway. Also, via studying the nature of the genes involved 
in the insulin signaling pathway, we decided to call it glycogen metabolism pathway. 
Table 11 shows the individual genes in each pathway and the overall statistical 
significance for each of these pathways. Table 12 shows a summary of the full gene 
name, fold change, and P-value for individual genes in each pathway. 
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Table 11: Differentially Downregulated KEGG Pathways in Cachectic Skeletal 
Muscle. 
KEGG 
Pathway 
Gene Gene Gene Gene Gene Gene Gene Gene 
P-
value 
FDR 
Hypertrophic 
cardio-
myopathy 
ATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD TTN TPM2 PRKAB2 0.0001 
0.01
2 
Dilated cardio-
myopathy 
ATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD TTN TPM2  0.001 
0.06
3 
Arrhythmo-
genic  right 
ventricular 
cardio-
myopathy 
ATP2A2 CACNA2D1 CACNA2D3 ITGB6 SGCD   CTNNA3 0.003 
0.06
4 
Cardiac muscle 
contraction 
ATP2A2 CACNA2D1 CACNA2D3    TPM2 ATP1B4 0.02 
0.07
8 
Insulin signaling 
pathway 
PHKA1 PHKB  PPP1R3A PPP1R3B PPP1R3C  PRKAB2 0.002 0.33 
Valine, leucine 
and isoleucine 
degradation 
AUH ACADM ACADSB DLD     0.02 0.29 
Parkinson’s 
disease 
 NDUFB5 NDUFS1 ATP5B PINK1 PARK2 UBE2G1  0.028 0.33 
Calcium 
signaling 
pathway 
ATP2A2 CAMK2G  PHKA1 PHKB PLCB1 PPP3CB PHKG1 0.029 0.31 
Long-term 
potentiation 
 CAMK2G  RPS6KA3  PLCB1 PPP3CB  0.062 0.51 
MAPK signaling 
pathway 
EGF CACNA2D1 CACNA2D3 RPS6KA3 SOS2 PTPRR PPP3CB MEF2C 0.064 0.48 
Alzheimer’s 
disease 
ATP2A2 NDUFB5 NDUFS1 ATP5B SOS2 PLCB1 PPP3CB  0.066 0.46 
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Table 12: Data of Individual Genes in the Downregulated KEGG Pathways in 
Cachectic Skeletal Muscle. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-
Value 
Muscle-Down / Hypertrophic cardiomyopathy (HCM)  
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
-2.36 0.0096 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
-3.37 0.0018 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
-3.65 0.0052 
ITGB6 integrin, beta 6 -5.09 0.0002 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
-2.64 0.0001 
SGCD sarcoglycan, delta (35kDa dystrophin-associated 
glycoprotein) 
-2.53 0.0137 
TTN Titin -2.09 0.0135 
TPM2 tropomyosin 2 (beta) -2.44 0.0019 
Muscle-Down /  Dilated cardiomyopathy  
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
-2.36 0.0096 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
-3.37 0.0018 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
-3.65 0.0052 
ITGB6 integrin, beta 6 -5.09 0.0002 
SGCD sarcoglycan, delta (35kDa dystrophin-associated 
glycoprotein) 
-2.53 0.0137 
TTN Titin -2.09 0.0135 
TPM2 tropomyosin 2 (beta) -2.44 0.0019 
Muscle-Down /  Insulin signaling pathway  
PHKA1 phosphorylase kinase, alpha 1 pseudogene 1; 
phosphorylase kinase, alpha 1 (muscle) 
-2.21 0.0185 
PHKB phosphorylase kinase, beta -2.46 0.0016 
PHKG1 phosphorylase kinase, gamma 1 (muscle) -2.14 0.0142 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
-2.64 0.0001 
PPP1R3A protein phosphatase 1, regulatory (inhibitor) subunit 
3A 
-2.52 0.0099 
PPP1R3B protein phosphatase 1, regulatory (inhibitor) subunit 
3B 
-2.97 0.0040 
PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 
3C 
-2.53 0.0081 
SOS2 son of sevenless homolog 2 (Drosophila) -2.39 0.0005 
Muscle-Down /  Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
-2.36 0.0096 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
-3.37 0.0018 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
-3.65 0.0052 
CTNNA3 catenin (cadherin-associated protein), alpha 3 -4.38 0.0007 
ITGB6 integrin, beta 6 -5.09 0.0002 
SGCD sarcoglycan, delta (35kDa dystrophin-associated -2.53 0.0137 
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glycoprotein) 
Muscle-Down /  Cardiac muscle contraction  
ATP1B4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide -2.87 0.0126 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
-2.36 0.0096 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
-3.37 0.0018 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
-3.65 0.0052 
TPM2 tropomyosin 2 (beta) -2.44 0.0019 
Muscle-Down /  Valine, leucine and isoleucine degradation  
AUH AU RNA binding protein/enoyl-Coenzyme A 
hydratase 
-2.16 0.0007 
ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain 
-3.64 0.0004 
ACADSB acyl-Coenzyme A dehydrogenase, short/branched 
chain 
-2.20 0.0055 
DLD dihydrolipoamide dehydrogenase -2.09 0.0026 
Muscle-Down / Parkinson's disease  
  ATP5B ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide  
-2.10 0.0012 
  Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 5, 16kDa  
-2.04 0.0009 
  NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q reductase)  
-2.34 0.0005 
  Pink1 PTEN induced putative kinase 1  -2.16 0.0153 
  park2 Parkinson disease (autosomal recessive, juvenile) 2, 
parkin  
-3.26 0.0012 
  ube2g1 ubiquitin-conjugating enzyme E2G 1 (UBC7 
homolog, yeast)  
-2.01 0.0063 
Muscle-Down / Calcium signaling pathway  
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 
-2.36 0.0096 
CAMK2G calcium/calmodulin-dependent protein kinase II 
gamma 
-2.09 0.0068 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -2.06 0.0057 
PHKA1 phosphorylase kinase, alpha 1 pseudogene 1; 
phosphorylase kinase, alpha 1 (muscle) 
-2.21 0.0185 
PHKB phosphorylase kinase, beta -2.46 0.0016 
PHKG1 phosphorylase kinase, gamma 1 (muscle) -2.14 0.0142 
PPP3CB protein phosphatase 3 (formerly 2B), catalytic 
subunit, beta isoform 
-2.06 0.0139 
Muscle-Down /  Long-term potentiation  
CAMK2G calcium/calmodulin-dependent protein kinase II 
gamma 
-2.09 0.0068 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -2.06 0.0057 
PPP3CB protein phosphatase 3 (formerly 2B), catalytic 
subunit, beta isoform 
-2.06 0.0139 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 -2.02 0.0001 
Muscle-Down /  MAPK signaling pathway  
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
-3.37 0.0018 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 
-3.65 0.0052 
EGF epidermal growth factor (beta-urogastrone) -2.41 0.0008 
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MEF2C myocyte enhancer factor 2C -2.12 0.0163 
PPP3CB protein phosphatase 3 (formerly 2B), catalytic 
subunit, beta isoform 
-2.06 0.0139 
PTPRR protein tyrosine phosphatase, receptor type, R -7.61 0.0177 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 -2.02 0.0001 
SOS2 son of sevenless homolog 2 (Drosophila) -2.39 0.0005 
Muscle-Down / Alzheimer's disease  
ATP5B ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide  
-2.10 0.0012 
 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2  
-2.36 0.0096 
 Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 5, 16kDa  
-2.04 0.0009 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q reductase)  
-2.34 0.0005 
 PLCB1 phospholipase C, beta 1 (phosphoinositide-specific)  -2.06 0.0057 
 PPP3CB protein phosphatase 3 (formerly 2B), catalytic 
subunit, beta isoform  
-2.06 0.0139 
 
4.3.3.2 Discussion 
Cardiac Muscle Contraction and Cardiac Myopathy Pathway  
Expression of two L-type voltage-gated calcium channel (VGCC) subunits genes are 
downregulated in the "cardiac muscle contraction and cardiac myopathy" pathway; 
CACNA2D1 and CACNA2D3. VGCCs are multi-subunit membrane proteins that 
regulate calcium influx into excitable cells (i.e. cardiac, smooth, and skeletal muscle 
cells) [146]. Specific subunits are expressed differentially in different tissue types. 
CACNA2D1 and CACNA2D3 are α2δ genes that form two linked subunits; α2 and δ 
(which are both the product of the same gene) that interacts the most with the α1 
subunit. Co-expression of the α2δ enhances the level of expression of the α1 
subunit and causes an increase in current amplitude, faster activation and 
inactivation kinetics and a hyperpolarizing shift in the voltage dependence of 
inactivation.  
Other downregulated genes in the same pathway are the ATP2A2 and TPM2.These 
two genes previously reported as a short-term response gene in muscle in response 
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to atrophy induction [147]. ATP2A2 encodes one of the SERCA Ca2+-ATPases, 
which are intracellular pumps located in the sarcoplasmic reticulum of muscle cells 
which function is coupled with the calcium transient from the cytosol to the 
sarcoplasmic reticulum lumen, and is involved in calcium sequestration associated 
with muscular excitation and contraction. TPM2 is a skeletal muscle contractile gene 
that is reported to cause muscle weakness when mutated [148, 149]. PRKAB2, on 
the other hand, is the regulatory non-catalytic beta subunit gene for the AMP-
activated protein kinase (AMPK). PRKAB2 is a positive regulator of the AMPK that is 
highly expressed in skeletal muscle [150]. AMPK is an important energy-sensing 
enzyme that monitors cellular energy status in response to cellular metabolic 
stresses. PRKAB2 is also reported to be  downregulated in a mouse model of 
severe cachexia [151].  These two genes (TPM2 and PRKAB2) might contribute to 
the muscular fatigability and decreased mobility that are evident signs of cachexia.   
The SGCD gene is one of four known components of the sarcoglycan complex, 
which is a family of transmembrane proteins and a subcomplex of the dystrophin-
glycoprotein complex (DGC). DGC is responsible for connecting the muscle fibre 
cytoskeleton to the extracellular matrix, preventing muscular damage. Mutations in 
this gene have been associated with autosomal recessive limb-girdle muscular 
dystrophy which is characterized by progressive muscle wasting [152].  
Titin (TTN) is the third most abundant sarcomeric protein in muscle; an adult human, 
80 kg weight, have approximately 0.5 kg of titin [153]. Mutation in TTN gene is 
known to cause tibial muscular dystrophy which is characterized by weakness and 
atrophy that is usually confined to the tibialis anterior muscle [154]. One of the main 
functions of titin is to support the contractile elements and maintain muscular 
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elasticity [154]. Titin also plays a key role in multiple signaling pathways, being a 
binding site for multiple ligands for a large number of other muscle proteins [154].  
The integrin beta 6 (ITGB6) gene is highly expressed in skeletal muscle [155]. It is 
downregulated in mouse models of cachexia [156]. Integrins are a group of 
transmemebrane receptors that have two different chains, the alpha and beta 
subunits that form obligate heterodimers. In mammals, there are eighteen α and 
eight β subunits [157]. This downregulation of ITGB6 is of unique interest in the 
context of cachexia because our data shows upregulation in almost every single 
subunit in all integrins (though not statistically significant in any) except for the 
ITGB6.  
CTNNA3 is one of three alpha-catenin genes [158].  Alpha-T-catenin belongs to the 
family of cell–cell adhesion molecules and is believed to act as a link between 
cadherins and actin-containing filaments of the cytoskeleton resulting in strong cell–
cell adhesion [158]. It is expressed in cardiomyocytes, skeletal muscle, testis and 
brain [158]. In silico analysis revealed that the alpha-T-catenin promoter contains 
several binding sites for cardiac and muscle-specific transcription factors [158]. The 
two known promoters for CTNNA3 are either unexpressed (GATA4) or significantly 
downregulated (MEF2C) in our cachectic muscle samples (data from original file) 
[158]. 
Glycogen Metabolism Pathway  
Another downregulated pathway is the insulin signaling pathway which we rather 
call "Glycogen metabolism Pathway" due to the function of the genes involved. 
Three phosphorylase kinase genes (PHKA1, PHKB, and PHKG1) and three protein 
phosphatase 1 (PP1) genes (PPP1R3A, PPP1R3B, and PPP1R3C) are 
downregulated. Phosphorylase kinases are a serine/threonine-specific protein 
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kinase which activates glycogen phosphorylase to release glucose-1-phosphate 
from glycogen [159]. Protein phosphatases 1, on the other hand, are a class of 
protein serine/threonine phosphatases that inactivate the active (phosphorylated) 
form of phosphorylase and also activate the inactive form of glycogen synthase 
[160]. These two groups of proteins play a crucial role in the regulation of glycogen 
metabolism. In muscle cells, to power activity instantly when energy is in demand, 
glycogenolysis is needed to hydrolyze the stores of glycogen to glucose by the 
sequential removal of glucose monomers. This provided a prompt energy supply for 
immediate activity in muscle cells [159]. Phosphorylase kinase stimulates glycogen 
hydrolysis into free glucose by phosphorylating glycogen phosphorylase and 
stabilizing its active conformation[159]. This is the rate-limiting step in 
glycogenolysis [159]. Phosphorylase "a" in its active R state has PP1 bound tightly 
preventing any phosphatase activity of PP1 and maintains the active phosphorylated 
configuration resulting in a cascade of events that generate the required energy. 
These changes in gene expression are likely to be involved in the known reduction 
in glycogen turnover in patients with cancer cachexia, which in turn leads to muscle 
weakness and rapid fatigue [161]. PRKAB2is a 5'-AMP-activated protein kinase 
subunit beta-2 that encodes for the regulatory subunit of the AMP-activated protein 
kinase (AMPK). AMPK is an important energy-sensing enzyme that monitors cellular 
energy status. This subunit may be a positive regulator of AMPK activity that is 
highly expressed in skeletal muscle [162]. PRKAB2 knockout mice had reduced 
maximal and endurance exercise capacity during treadmill running which was also 
associated with also reduced levels of muscle and liver glycogen [162].  
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Calcium Signaling Pathway and Long Term Potentiation 
CAMK2G encodes for calcium/calmodulin-dependent protein kinase type II gamma, 
which is involved in sarcoplsamic reticulum Ca2+ transport in skeletal muscle [163]. 
In slow-twitch muscles, is involved in regulation of sarcoplasmic reticulum Ca2+ 
transport and in fast-twitch muscle participates in the control of Ca2+ release from the 
sarcoplasmic reticulum through phosphorylation of the ryanodine receptor-coupling 
factor triadin. In neurons, may participate in the promotion of dendritic spine and 
synapse formation and maintenance of synaptic plasticity which enables long-term 
potentiation (LTP).   
PLCB1 encodes for phospholipase C, beta 1 which catalyzes the formation of 
inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-
bisphosphatephosphatidylinositol 4,5-bisphosphate. This is an important part of the 
calcium signaling second messenger system that is crucial for muscle cell growth 
and differentiation [164].  
Parkinson’s Disease and Alzheimer’s Disease 
Three genes are downregulated in Parkinson's and Alzheimer's diseases; NDUFS1, 
NDUFB5, and ATP5B. Both NDUFS1 and NDUFB5 encode subunits of proteins in 
the Complex I. Complex I or NADH: ubiquinone oxidoreductase, is the first enzyme 
of the mitochondrial electron transport chain that initiate cellular respiration or 
oxidative phosphorylation in the mitochondria in the inner mitochondrial 
membrane.ATP5B is a subunit of the ATP synthase. It catalyzes ATP synthesis 
through using the proton motive force created by the electron transport chain across 
the inner membrane as a source of energy in the process of oxidative 
phosphorylation.  
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It is clear that common genes in the Parkinson's and Alzheimer's diseases might 
sound at the face value to be irrelevant in the context of cancer cachexia. However, 
these are genes at the core requirements for cellular respiration, and hence energy 
generation in muscle cells and can clearly contribute to the poor mobility and 
fatigability in cachectic patients.   
4.4 Analysis of Highly Significantly Altered Genes in Cachectic Muscles 
From our experience, data generated via high throughput gene expression 
technology is more likely to be reproduced via other confirmatory gene expression 
methods such as quantitative RT-PCR only when it has the highest statistical 
significance levels. Thus, we decided to data-mine our expression data and isolate 
selected genes with more than two-fold change, highest P-value, and lowest 
possible FDR. In muscle, 30 genes showed highly significant change in expression 
(5 upregulated and 25 downregulated: P<0.0005 - P<0.00001, FDR 0.2).  
4.4.1 Highly Significantly Upregulated Genes 
4.4.1.1 Results 
Table 13 shows the 5 highly significantly upregulated genes in cachectic muscle. 
(P<0.0005 - P<0.00001, FDR 0.2). They include 2 involved with calcium signaling 
and 2 with cell matrix interactions, and one transcriptional regulator. Table 13 
categorizes individual gene function into respective functional domain. It also shows 
the full gene name, fold change, and the P-value. 
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Table 13: Highly Significantly Upregulated Genes in Cachectic Skeletal Muscle. 
Gene 
Symbol  
Gene Full Name Fold 
change 
P-Value 
Signaling 
PLCXD1 phosphatidylinositol-specific phospholipase C, X domain 
containing 1 
4.60 <0.00001 
PITPNM2 phosphatidylinositol transfer protein, membrane-
associated 2 
3.82 0.00005 
Cell Matrix interaction 
ESAM endothelial cell adhesion molecule 3.39 0.0004 
PXN Paxillin 2.16 <0.00001 
Transcription 
MLLT1 myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 1 
2.36 < 0.0003 
 
4.4.1.2 Discussion 
Calcium Signaling Genes 
Two genes which are suggested to be involved in signaling are significantly 
upregulated in cachectic muscles; PLCXD1 and PITPNM2. PLCXD1 codes for 
phosphatidylinositol-specific phospholipase C, X domain containing 1. 
Phospholipase C (PLC) is a group of enzymes with differences in domain structure, 
that cleave the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl 
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG remains bound to the 
membrane, and IP3 is released as a soluble structure into the cytosol to bind to IP3 
receptors, particularly calcium channels in the smooth endoplasmic reticulum. This 
causes the cytosolic concentration of calcium to increase, causing a cascade of 
intracellular changes and activity [165, 166]. In turn, calcium and DAG together work 
to activate protein kinase C, which goes on to phosphorylate other molecules, 
leading to altered cellular activity [165]. Phospholipases are ubiquitously expressed 
and have diverse biological functions [166]. In tumor cells, PLCXD1 suppress 
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growth when transfected in melanoma cell line [167]. There are no further functional 
studies characterizing this gene, however, like other phospholipases, it undoubtedly 
plays an important role in cellular signaling specifically through calcium release, 
which is important in modulating many muscle-related functions.  
The second upregulated gene is PITPNM2 which codes for phosphatidylinositol 
transfer protein (PITP) membrane-associated 2 protein. PITP proteins are 
ubiquitous cytosolic domain involved in transport of phospholipids from their site of 
synthesis in the endoplasmic reticulum and Golgi to other cell membranes. 
PITPNM2 is not functionally characterized yet. However, PITPα, a member of the 
PITP family that was also upregulated in our study, was identified as an essential 
component in ensuring substrate supply to phospholipase C by dictating the rate of 
inositol trisphosphate production by promoting the synthesis of PIP2 [168]. 
Thus, these two genes could be functioning through IP3/DAG pathway. Thus, 
PITPNM2 might be promoting PIP2 synthesis and making it readily available for PLC 
(in our case is PLCXD1) which in turn cleaves the PIP2 into PIP3 and DAG. Both of 
which work as key second messengers, which via multiple cascades of events, 
causes Ca2+ transient into the cytosol. Calcium, in turn, participates in the cascade 
by activating proteins.  
Cell Matrix Interaction 
Two cell matric interaction genes were markedly upregulated in cachectic muscles; 
ESAM and PXN. ESAM encodes is an endothelial cell-selective adhesion molecule. 
Though ESAM has never been studied, per se, in skeletal muscle, it has been 
studied in the context of coronary vascular disease (CVD) and kidney disease [169]. 
Skeletal muscle vasculature is of considerable importance. Around 20% of cardiac 
output is directed toward skeletal muscle vasculature during rest and more than 
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80% of cardiac output can be directed to contracting muscles. Increased expression 
of ESAM may indicate early endothelial dysfunction that precedes kidney function 
decline among individuals with established CVD [169]. Also, induced endothelial 
dysfunction in skeletal muscle arterioles compromise glucose utilization and 
facilitates the development of hypertension in diabetes [170]. Muscular vasculature 
is of a great importance to muscle development, maintenance, and function. The 
dysfunctional vascular endothelium associated with higher ESAM in CVD and 
kidney disease may indicate the importance of ESAM in healthy muscular 
vasculature. Thus, higher ESAM in the muscle of cachectic patients may have a 
deleterious effect in vasculature compromising blood flow and/or glucose utilization.  
Paxillin (encoded by PXN) is a signal transduction, adaptor, cytoskeletal, 
extracellular matrix (focal adhesion) protein involved in actin-membrane attachment 
[171]. The C-terminal region of paxillin contains four LIM domains that target paxillin 
to focal adhesions. It is presumed through a direct association with the cytoplasmic 
tail of beta-integrin [171]. The N-terminal region of paxillin is rich in protein–protein 
interaction sites [171].  
One might wonder why two cell matrix interaction proteins are upregulated in 
muscles of patients with early cachexia. However, muscle hypertrophy (not 
hyperplasia) in both cardiac and skeletal muscle is an adaptation to regular, 
increasing workloads that exceed the preexisting capacity of the muscle fibers. Thus 
hypertrophy allows cardiac muscle to pump blood more effectively, while skeletal 
muscle becomes more efficient at transmitting forces through its tendonous 
attachments to bones [172]. Paxillin has been associated with the regulation of 
cytoskeletal organization, focal adhesion formation, cell migration and cell motility 
[173]. Paxillin is also localized to the myotendinous and neuromuscular junctions of 
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skeletal muscle [174]. While expression of non-phosphorylatable paxillin mutants in 
canine tracheal smooth muscle inhibits tension development [173]. 
Wasted patients are usually weaker. That said, normal/regular activities can be 
envisioned as progressive overload causing intermittent levels of stress to skeletal 
muscle. Thus, as an adaptation to wasting, paxillin may be attempting but failing to 
promote hypertrophy in this situation. Muscular hypertrophy means its ability to 
adapt by increasing the size and amount of contractile proteins (cell matrix 
interaction proteins), which comprise the myofibrils within each muscle fiber, leading 
to an increase in the size of the individual muscle fibers and their consequent force 
production [172]. That is similar to previously reported evidence of the increased in 
paxillin expression along other proteins upon the increased mechanical load per unit 
of cross-sectional area during short period of an increasing load [175]. 
Transcriptional Regulation 
Transcriptional regulation is a complicated series of mechanisms used by cells to 
increase or decrease the expression of specific gene products. These sophisticated 
programs of gene expression serve several purposes of which developmental and 
adaptive responses are just a few. Transcriptional regulation is a versatile and 
adaptable mechanism allowing the cell to express proteins when needed. For these 
reasons, upregulation of genes involved in transcriptional regulation is expected in 
the context of wasting muscle. Whether cachectic muscles die via apoptosis or 
necrosis, attempt to regenerate or differentiate, or just change in its morphogenic 
features, regulation of transcription is definitely needed.  
MLLT1 gene, or myeloid/lymphoid or mixed-lineage leukemia translocated to 1, 
codes for a transcriptional regulator that is highly significantly upregulated in 
cachectic muscle. MLLT1 has never been studied in the context of cachexia nor 
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muscular transcriptional regulation. However, evidence suggests an important 
developmental role of this gene. MLLT1 has nuclear localization signal, and 
expressed widely in variant tissues suggesting its role as a coactivator activating 
individual lineage developmental programs [176]. MLLT1 has been shown to be 
required for early embryonic development in the mouse, as knock-out embryos are 
non-viable [176]. Also, an enhanced MLLT1 expression plays a role in testicular 
germ cell tumors [177]. Thus, MLLT1 gene could be an activator for gene 
expression of multiple genes that can either explain the pathology of wasting and/or 
illustrate an early compensatory role to resist wasting. Identifying which of these 
roles MLLT1 plays would require further investigation.  
4.4.2 Highly Significantly Downregulated Genes 
4.4.2.1 Results 
Table 14 shows the 5 highly significantly downregulated genes in cachectic muscle. 
(P<0.0005 - P<0.00001, FDR 0.2). Analysis of the 25 downregulated genes involved 
include 7 that are involved with metabolism (5 of which are mitochondrial); 4 with 
signaling; 4 with ubiquitination; and 3 with intracellular trafficking. There was marked 
downregulation of multiple genes involved in glycogen metabolism which correlates 
with the lack of glycogen, muscle weakness, and fatigue; characteristic of cachexia. 
Table 14, also categorizes individual gene function into respective functional 
domain. It also shows the full gene name, fold change, and the P-value.   
 
 
 
 
   63 
 
 
 
 
 
Table 14: Highly Significantly Downregulated Genes in Cachectic Skeletal Muscle. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-Value 
Mitochondrial Metabolism  
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit -2.33 <0.0003 
ALDH5A1 aldehyde dehydrogenase 5 family, member A1 -4.16 <0.00001 
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain -3.64 <0.0004 
NARS2 asparaginyl-tRNAsynthetase 2, mitochondrial 
(putative) 
-2.05 0.0003 
NNT nicotinamide nucleotide transhydrogenase -2.62 0.00003 
Metabolism 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
-2.64 0.0001 
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-
glucanotransferase 
-3.51 0.0002 
Signaling 
PLCL1 phospholipase C-like 1 -3.64 <0.00008 
NXPE3 neurexophilin and PC-esterase domain family, 
member 3 
-2.90 <0.00005 
ZFYVE9 zinc finger, FYVE domain containing 9 -2.07 0.0002 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 -2.02 <0.00008 
ZNF41 zinc finger protein 41 -2.12 0.0003 
Muscle Contraction 
PPP1R12B protein phosphatase 1, regulatory subunit 12B -2.10 0.00005 
Cell Matrix Interaction 
ITGB6 integrin, beta 6 -5.09 0.0002 
Ubiquitination 
WWP1 WW domain containing E3 ubiquitin protein ligase 1 -3.37 0.00001 
ZYG11B zyg-11 family member B, cell cycle regulator -3.01 0.00007 
FBXL17 F-box and leucine-rich repeat protein 17 -2.38 0.00005 
DCAF6 DDB1 and CUL4 associated factor 6 -2.59 0.0004 
Intacellular Trafficking 
RAB9B RAB9B, member RAS oncogene family -3.10 <0.00009 
RAB10 RAB10, member RAS oncogene family -2.18 0.00006 
CLASP2 cytoplasmic linker associated protein 2 -2.30 0.0004 
Apolipoproteins 
VLDLR very low density lipoprotein receptor -2.9 <0.00005 
APOOL apolipoprotein O-like -2.06 <0.0003 
Uncharachterized 
C1orf192 chromosome 1 open reading frame 192  -3.87 <0.0004 
 
 
   64 
 
 
 
 
 
4.4.2.2 Discussion 
Mitochondrial Metabolism 
SUCLA2 (succinyl-CoA ligase [ADP-forming] mitochondrial) encodes for ADP-
forming succinyl-CoA synthetase, a mitochondrial matrix enzyme which catalyzes 
the reversible synthesis of succinyl-CoA from succinate and CoA [178]. It plays a 
key role as one of the catalysts involved in the citric acid cycle, a central pathway in 
cellular metabolism [165]. Decreased SUCLA2 activity due to mutation was found in 
muscle mitochondria of patients with encephalomyopathy and mtDNA depletion 
[179].Myopathy is a disease of dysfunctional muscle fibers resulting in muscular 
weakness. 
ALDH5A1 codes for succinate-semialdehyde dehydrogenase, mitochondrial, an 
enzyme that belongs to the aldehyde dehydrogenase family of proteins [180]. 
ALDH5A1 deficiency results in muscle hypotonia and developmental delay [181, 
182]. Hypotonia is a state of low muscle tone (the amount of tension or resistance to 
stretch in a muscle), often involving reduced muscle strength. Mice with a 
homozygous knockout of ALDH5A1 exhibit symptoms including reduced body 
weight  [183]. 
ACADM encodes for an acyl-coenzyme a dehydrogenase that is important for 
hydrolyzing medium-chain fatty acids to produce energy, especially during periods 
of fasting [184]. Fatty acid oxidation spares glucose during fasting and is also 
required for amino acid metabolism, which is essential for the maintenance of 
adequate glucose production [185]. With a deficiency of this enzyme, medium-chain 
fatty acids cannot be hydrolysed then these fatty acids are not converted into 
energy, leading to weakness, lethargy, and low blood sugar [186]. Training 
increases fatty acid oxidation and skeletal muscle oxidative capacity by increasing 
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expression of ACADM which results in increased use fatty acids to enhance skeletal 
muscle oxidative capacity [187].  
NARS2 codes for asparaginyl-tRNA synthetase 2 [188]. This class-II synthetase is 
specific for alanine, asparagine, aspartic acid, glycine, histidine, lysine, 
phenylalanine, proline, serine, and threonine [189]. NARS2 mutations cause severe 
myopathy characterized by proximal muscle weakness, severe amyotrophy 
(progressive wasting of muscle tissues), excessive fatigability, dysarthria, paresis of 
facial muscles, and ptosis [190]. Skeletal muscle biopsies show atrophic fibers, 
ragged-red fibers, and enlarged mitochondria [190]. Other NARS2 mutations cause 
Leigh Syndrome, which results in hypotonia (low muscle tone and strength), 
dystonia (involuntary, sustained muscle contraction), and ataxia (lack of control over 
movement). Mutations in mitochondrial seryl-tRNAsynthetase, another member of 
the class II amino-acyl tRNA family, cause severe cachexia [191]. 
NNT codes for nicotinamide nucleotide transhydrogenase, an integral protein of the 
inner mitochondrial membrane. Under physiological conditions, this enzyme uses 
energy from the mitochondrial proton gradient to produce high concentrations of 
NADPH. The resulting NADPH is used for biosynthesis and in free radical 
detoxification [192].  
Metabolism 
As mentioned above PRKAB2 is the regulatory non-catalytic beta subunit gene for 
the AMP-activated protein kinase (AMPK). PRKAB2 is a positive regulator of the 
AMPK that is highly expressed in skeletal muscle [150]. AMPK is an important 
energy-sensing enzyme that monitors cellular energy status. PRKAB2 is also 
reported to be downregulated in a mouse model of severe cachexia [151].  PRKAB2 
knockout mice had reduced maximal and endurance exercise capacity during 
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treadmill running which was also associated with also reduced levels of muscle and 
liver glycogen [162]. Thus, PRKAB2 might contribute to the muscular fatigability and 
the decreased mobility that are evident signs of cachexia.   
AGL codes for the glycogen debranching enzyme which facilitates the hydrolysis of 
glycogen in through glucosyltransferase and glucosidase activity [193]. Mutation in 
AGL causes one of the glycogen storage diseases (type III) and results in peripheral 
muscular impairment which can vary from minimal to severe [194] as well as muscle 
weakness [195].  
Signaling 
PLCL1 codes for phospholipase C-Like 1, one of several phosphoinositide 
phospholipase C enzymes that play an important role in signal transduction [196]. 
These enzymes participate in phosphatidylinositol 4,5-bisphosphate (PIP2) 
metabolism in a calcium-dependent manner. All members in this family are capable 
of catalyzing the hydrolysis of PIP2 into two important second messenger molecules 
(DAG and IP3), which go on to alter multiple cellular responses such as proliferation, 
differentiation, apoptosis, cytoskeleton remodeling, vesicular trafficking, ion channel 
conductance, endocrine function and neurotransmission.  
However, it is not the only member in the PLC family that is downregulated. PLCB1 
is also downregulated in multiple muscle downregulated KEGG pathways (Table 
12). This is important since calcium signaling is important for muscle contraction and 
thus, it affects muscle contraction and eventually causes weakness. NXPE3 codes 
for neurexophilin and PC-esterase domain family, member 3 which is another 
uncharacterized gene [197].  
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ZFYVE9 encodes a zinc finger FYVE domain-containing protein 9 or SARA (SMAD 
anchor for receptor activation) [198]. SARA contains a double zinc finger (FYVE 
domain). SARA is an anchoring protein involved in transforming growth factor beta 
(TGF-β) signaling. It binds to the R-SMADs SMAD2 and SMAD3 [199].It facilitates 
the phosphorylation of the R-SMAD, which subsequently dissociates form SARA 
and the receptor and binds a co-SMAD where they enter the nucleus as 
transcription factors. All SMADs are downstream to myostatin (and TGF-β and all of 
its related proteins), which is believed to be activated in wasting muscle. However, 
our data shows significantly downregulatedmyostatin in cachectic muscles (as will 
be explained in details later). Thus, a downregulated ZFYVE9 may be further 
evidence of an adaptive response to myostatin signaling in cachexia. 
RPS6KA3 codes for the ribosomal protein S6 kinase which is a member of the RSK 
(ribosomal S6 kinase) family of serine/threonine kinases. This kinase 
phosphorylates various substrates, including members of the mitogen-activated 
kinase (MAPK) signaling pathway (which one of the downregulated KEGG pathways 
in cachectic muscles as above) [200]. The activity of this enzyme has been 
implicated in controlling cell growth and differentiation. In muscle cells, it mediates 
cellular differentiation through regulation of NFAT3 [201]. Mutations in this gene are 
associated with Coffin-Lowry syndrome [202], which is characterized by growth and 
psychomotor retardation, hypotonia, and progressive skeletal changes [203]. Also, 
RPS6KA3 knockout mice have altered extracellular signal-regulated kinase 
signaling and glycogen metabolism in skeletal muscle, 10% reduction in weight, and 
are 14% shorter than wild-type littermates [204]. A study of patients with Coffin-
Lowry syndrome showed episodes of sudden, non-epileptic collapse with atonia, 
described as a form of cataplexy (Cataplexy comprises an abrupt, complete, or 
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partial loss of voluntary muscle tone and is usually seen in response to strong 
emotion) [205]. 
ZNF41 encodes for zinc finger protein 41, a member of zinc finger family of 
transcription factors [206]. So far, little is known about ZNF41. However, having one 
of the highest expressions of ZNF41 in skeletal muscle [207] is an indicator of its 
transcriptional importance. 
Muscle Contraction 
PPP1R3A codes for the regulatory subunit and myosin binding subunits of myosin 
light chain phosphatase (MLCP), which is abundantly expressed in skeletal and 
cardiac muscle [208]. This gene plays an important regulatory role in muscle 
contraction. 
Ubiquitination 
Ubiquitination (also known as ubiquitylation) is an enzymatic, post-translational 
modification (PTM) process in which ubiquitin protein is attached to a substrate 
protein, targeting the protein for degradation. This results in the addition of one 
(monoubiquitination) or multiple (polyubiquitination) ubiquitin molecules to the 
substrate protein [209]. The ubiquitination system functions in a wide variety of 
cellular processes.  
WWP1 codes for a NEDD4-like E3 ubiquitin-protein ligase, which belongs to a family 
of E3 ubiquitin-ligases that regulate key trafficking decisions, including targeting of 
proteins to proteosomes or lysosomes. Interestingly, studies aimed at understanding 
chicken muscular dystrophy showed mutations in WWP1 in dystrophic chicken 
[210]. Another study on chickens treated with dexamethasone (which causes 
wasting) found that WWP1 expression was dependent on the duration of 
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dexamethasone treatment; short-term resulted in decreased WWP1 expression, 
while long-term increased WWP1 expression [211]. Detection of highly significant 
downregulation of WWP1 in cachectic muscles in our patients suggests an adaptive 
response to the early cachexia.  
ZYG11B codes for zyg-11 family member B, a cell cycle regulator protein. It 
probably acts as target recruitment subunit in the E3 ubiquitin ligase complex 
ZYG11B-CUL2-Elongin BC [212]. One study showed that erythropoietin (EPO) 
functional knock-out mice have lower ZYG11B expression in skeletal muscle 
compared to controls [213]. The EPO receptor is highly expressed in muscle and 
may suggest important role of EPO in stimulating skeletal muscle regeneration 
[213].  
FBXL17 codes for the F-box and leucine-rich repeat protein 17, a member of the F-
box protein family. Complexes, formed by the presence of F-box proteins act as 
protein-ubiquitin ligases [214]. There is no further information regarding this gene.  
Intacellular Trafficking 
RAB9B codes for a member of sub-family of the RAS small guanosine triphosphate 
(GTP)-binding proteins that regulate membrane trafficking. The encoded protein 
may be involved in endosome-to-Golgi transport [215]. Diseases associated with 
RAB9B include pelizaeus-merzbacher disease which has early onset hypotonia. 
With progressive disease, even more severe muscular involvement is evident.  
RAB10 codes for another member in the RAS oncogene family [216]. RAB10 has 
the highest expression in heart and skeletal muscle [217]. It is involved in the insulin 
signaling cascade that causes intracellular vesicles containing glucose transporter-4 
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(GLUT4) to translocate to and fuse with the plasma membrane and enhance 
glucose uptake [218, 219].  
CLASP2 codes for cytoplasmic linker associated protein 2, a microtubule plus-end 
tracking protein that promotes the stabilization of dynamic microtubules. It is also 
required for the polarization of the cytoplasmic microtubule arrays in migrating cells 
towards the leading edge of the cell. Like RAB10, CLASP2 has a role in insulin 
signaling and glucose uptake in myocytes and adipocytes [220]. CLASP2 
colocalizes with the glucose transporter GLUT4 at the plasma membrane within 
areas of insulin-mediated cortical actin remodeling [220]. CLASP2 knockdown 
inhibits insulin-stimulated GLUT4 translocation and glucose transport [220].  
This downregulation of this pathway undoubtedly contributes to the insulin 
resistance and muscle fatigue in cachectic patients.  
On the other hand, a hallmark of the neuromuscular junction (NMJ) is the high 
density of acetylcholine receptors (AChRs) in the postsynaptic muscle membrane 
[221, 222]. CLASP2 mediates microtubule capturing at the synaptic membrane for 
the maintenance of a normal neuromuscular phenotype [222, 223]. The absence of 
CLASP2 impairs the maintenance of the neuromuscular junction with a decreased 
subsynaptic membrane in muscles, and a decrease of synaptic AChRs [224]. The 
significant downregulation of CLASP2 in cachectic muscles will alter the vitality of 
the NMJ and it turn cause impairment of muscle excitability [224]. Even more 
interestingly, the regulation of CLASP2 strictly controlled by agrin (AGRN) [223], 
which is itself downregulated in the KEGG pathways as discussed above.  
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Apolipoproteins 
VLDLR is a very-low-density-lipoprotein receptor; a transmembrane lipoprotein 
receptor of the low-density-lipoprotein (LDL) receptor family. VLDLR is widely and 
highly expressed in heart, muscle, and adipose tissues, which are active in fatty acid 
metabolism [225], so the receptor targets lipoproteins to these tissues [226]. 
Although the mechanism of VLDLR function in muscle is not fully understood, the 
defective clearance of triglyceride-rich lipoproteins leads to impaired energy 
metabolism, reduced exercise capacity, cachexia, and malnutrition syndrome in 
patients with advanced chronic kidney disease [227]. Also, reduced levels of 
lipoprotein lipase and VLDLR contribute to cachexia and reduced exercise capacity 
[227]. Mutations of this gene causes type I lissencephaly; a condition of which one 
of the symptoms is hypotonia [228].  
APOOL encodes an apolipoprotein O-like protein. The apoliprotein 0-like domain is 
found in the protein component of circulating lipoprotein complexes. Apolipoprotein 
O is a cardiolipin-binding component of the Mitofilin/MINOS protein complex 
determining cristae morphology in mitochondria (the folds in the inner membrane of 
a mitochondrion) [229]. Downregulation of APOOL impairs mitochondrial respiration 
and causes major alterations in cristae morphology; which are only altered under 
pathological conditions [229]. The important paralog; APOO [229]. APOO transgenic 
mouse fed a high-fat diet exhibited depressed ventricular function with reduced 
fractional shortening and ejection fraction, and the myocardial sections revealed 
mitochondrial degenerative changes [230]. Hence, APOO represents a link between 
impaired mitochondrial function and cardiomyopathy onset causing impaired 
contractility [230]. Furthermore, APOO enhances mitochondrial uncoupling and 
respiration, both of which were reduced by targeted knockdown of APOO [230]. If 
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that is the case in cardiac muscle, then APOOL downregulation in our cachectic 
muscle could be an early sign of impairment in skeletal muscle contractility as a 
result of damaged mitochondria.  
4.5 Anticipated Results from Previous Studies 
Preclinical studies have a few produced findings in multiple settings that attempt to 
explain the pathogenesis of cancer cachexia. Without exception, these findings so 
far have failed to explain cachexia in the clinical setting. This section aims to look at 
some of the prominent findings from clinical and preclinical models of cancer 
cachexia in order to see its reproducibility in our sequencing data.  
4.5.1 Preclinical Findings 
4.5.1.1 Atrophy-Specific Ubiquitin Ligases  
It is long believed that cachexia is a result of a negative nitrogen balance caused by 
decreased protein synthesis combined with increased protein degradation. The 
ubiquitin proteasome pathway is the main protein degradation pathway involved. 
Two genes were repeatedly found to be downregulated in preclinical models of 
cachexia; FBXO32 (atrogin-1/MAFbx) and TRIM63 (MURF1).  
FBXO32 codes for F-box only protein 32 [231], while TRIM63 codes for E3 ubiquitin-
protein ligase also known as MURF1. These are two atrophy-specific ubiquitin 
ligases that are two of the several key regulators of the ubiquitin proteasome 
degradation pathway. Both of the genes mediate sarcomeric breakdown and inhibit 
protein synthesis [232]. FBXO32 expression was significantly upregulated in 
atrophying muscles in cachectic rats and mice secondary to fasting, diabetes, renal 
failure or experimental cancer [231]. This upregulation was also confirmed in vitro in 
a murine skeletal muscle cell line [233]. Both MuRF1 and MAFbx were substantially 
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upregulated in rat skeletal muscle after immobilization, denervation, hind limb 
suspension or treatment with interleukin-1 or dexamethasone; conditions that are all 
associated with a significant loss of muscle mass [234].  
In our data of cachectic muscle, nether of the two genes were found to be 
upregulated. Indeed, in contrast, FBXO32 was even found to be significantly 
downregulated. Similarly, the two major microarray experiments documenting gene 
expression changes in human muscle biopsies of cachectic patients also found no 
change in the expression level of either of these two genes, which were long 
believed to be key players in the pathogenesis of cachexia [235, 236]. The 
downregulation of FBXO32 was not a surprise since the downregulation of the 
ubiquitin pathway was also evident with 4 other highly significantly downregulated 
genes (as discussed earlier). Downregulation of this protein degradation pathway 
may be a compensatory mechanism to defend against wasting in the cachectic 
subjects.  
Myostatin (MSTN) and its associated receptor activin (ACVR2B) have recently 
stolen the limelight as a possible cause of cachexia. MSTN or growth and 
differentiation factor 8 (GDF8) is a TGF-β family member. Mutations in the MSTN 
gene causes muscular hypertrophy in animals [237] as well as humans [238]. On 
the other hand, overexpression of MSTN caused pronounced muscular atrophy 
[239].  
MSTN which is mainly synthesized in skeletal muscle cells works by activating 
ACVR2B receptor that in turn, recruits an Alk family kinase resulting in activation of 
a SMAD2 and SMAD3 transcription factor complex and leading to activation of 
muscle loss signals that are as yet not fully understood [240]. For that, many 
attempts have been tried to block this signals in atrophying muscle. For example, 
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blocking the ACVR2B receptor in mice can reverse cachexia and muscle wasting 
[241].  
Neither the present study nor the previous clinical expression studies have shown 
any upregulation in MSTN, its receptor, or any downstream elements. In contrast, 
our data shows significant downregulation in both, MSTN and ACVR2B, which again 
may reflect the bodies' complicated response to try to prevent wasting. Based on the 
previous animal studies, several clinical trials are currently investigating the outcome 
of blocking MSTN with monoclonal antibodies or inhibiting elements of its 
downstream signaling. We believe that because the receptor and downstream 
elements are downregulated that these trials are desined to failure. However, it 
might give some reversal to the syndrome in unique settings. It should be noted that 
some cancers appear themselves to produce MSTN [242].  If this is found to be a 
general phenomenon then downregulation of muscle MSTN and its receptor may be 
considered adaptive responses to protect the muscle from tumor-derived MSTN. 
A very interesting finding from our data is the significant overexpression of GDF15. 
GDF15 is a growth and development factor 15 (NAG-1; MIC-1). It belongs to the 
transforming growth factor beta superfamily [243] that has a role in regulating 
inflammatory and apoptotic pathways in injured tissues and during disease 
processes [244]. In advanced cancer, high serum levels of GDF15 can lead to 
cachexia via central regulation of appetite [245]. In mice, cachexia induced by 
GDF15 overexpression can be reversed by anti-GDF15 monoclonal antibodies 
[245]. Our data shows a very interesting significantly upregulated GDF15 in 
cachectic muscle (12.9 fold change; P-value 0.028). This level of change is reported 
for the first time within the muscle, indicating its probable role in cachexia 
pathogenesis that warrants further investigation.  
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4.5.2 Previous Clinical Findings 
4.5.2.1 Inflammatory Cytokines and Tumor Specific Factors 
The proteolysis-inducing factor (PIF) was isolated from urine using monoclonal 
antibody in murine cachexia model [246] as well as human subjects with pancreatic 
cancer [247]. PIF is believed to possess an ability to degrade skeletal muscle. 
Although PIF has been linked with weight loss in patients, other groups have failed 
in reproducing the above finding; hence PIF was not redetected [248]. Despite our 
knowledge that PIF was originally captured in subjects' urine, we were still 
interested in checking its expression within the cachectic muscles. PIF (DCD; 
dermicidin) was not detected in our sequencing data. It should be noted that if the 
tumor itself is the source of PIF, we would not have expected to detect it in the 
muscle tissue; so we cannot discount its existence at this time. 
Many inflammatory cytokines have long been implicated in muscle wasting. Those 
include tumor necrosis factor-alpha (TNF), interleukin-6 (IL6), and interferon-gamma 
(IFNG). Preclinical studies showed significant contribution of each of these cytokines 
in the development of cachexia [96, 110, 111]. Unlike TNF and  IFNG which were 
not found to correlate to weight loss in human [112], circulating levels of IL-6 have 
been shown to correlate with weight loss in cancer patients [249]. In the present 
study, the expression levels of these three cytokines in cachectic muscle were not 
statistically significant (Table 15). However, for IL6 and IFNG expression was 
higher, but not significant. It is possible that expression of these cytokines is 
increased in some but not all cachectic patients.   
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Table 15: Inflammatory Cytokines and Tumor Specific Factors. 
Gene Full Name Gene Fold Change P-Value 
Tumor necrosis factors-alpha TNF 1.12 0.8997 
Interleukin-6 IL6 6.96 0.2241 
Interferon-gamma IFNG 5.47 0.1819 
Dermcidin/proteolysis-inducing factor DCD/PIF Not expressed 
 
 
4.5.3 Results from Previous Genome Wide Expression Analysis 
Stephens et al. (2010) were the first group to look at genome wide expression 
profiling in muscle biopsies obtained from weight losing cancer patients compared to 
weight stable non-cancer controls [235]. Using muscle biopsies from the rectus 
abdominis, eight genes were found to be differentially expressed by the microarray 
that were also confirmed by RT-PCR. Changes in expression of these eight genes 
were then rechecked in two different groups of muscles (diaphragm and vastus 
lateralis) from a different center. Only two genes were reproducible from the 8 
genes; TIE1 and CAMK2B. Both genes are "endurance exercise"-activated genes. 
Overexpression of such two genes may signal muscles attempt to maintain its 
viability through activation of pathways usually active during moderate endurance 
activity [235]. We looked at the expression level of all the genes that was found to 
be significant in the previous microarray study 1 (Table 16). Only TIE1 was found to 
be significantly upregulated in the present study, in-line with what was previously 
reported. How HTIE1 functions is still unknown, however it is an exercise activated 
gene, usually upregulated in response to prolonged training [250].  
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Table 16: Results of Significantly Altered Genes in Previous Microarray Study 1. 
Gene Full Name Gene Fold Change P-Value 
Adenomatosis polyposis coli down-regulated 1 APCDD1 3.50 0.1063 
Calcium/calmodulin-dependent protein kinase 
II beta 
CAMK2B 1.00 0.9963 
Eukaryotic translation initiation factor 3, subunit 
I 
EIF3I -1.11 0.5461 
Hepatocyte growth factor-regulated tyrosine 
kinase substrate 
HGS 2.67 0.0936 
NudC nuclear distribution protein NUDC -1.16 0.5105 
Polymerase (RNA) mitochondrial (DNA 
directed) 
POLRMT 1.25 0.7541 
Tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 
TIE1 4.50 0.0218 
Tuberous sclerosis 2 TSC2 1.81 0.031 
Serum/glucocorticoid regulated kinase 1 SGK1 4.52 0.3278 
 
In 2012, the same group of investigators of the above study reattempted another 
microarray-based, genome-wide expression analysis of quadriceps muscle biopsies 
in single biopsies from healthy controls and in paired biopsies (pre-resection 
baseline and 8 month post-resection follow-up) from cachectic cancer patients [236]. 
They detected 10 genes where expression was significantly changed (Table 17). 
Table 17: Results of Significantly Altered Genes in Previous Microarray Study 2. 
Gene Full Name Gene Fold Change P-Value 
Cartilage oligomeric matrix protein COMP Not expressed 
Adiponectin, C1Q and collagen domain 
containing 
ADIPOQ 6.98 0.3605 
Matrix metallopeptidase 3 MMP3 Not expressed 
Phosphoenolpyruvatecarboxykinase 1 
(soluble) 
PCK1 15.29 0.2891 
Angiopoietin-like 7 ANGPTL7 1.75 0.3664 
Heat shock protein 90kDa alpha (cytosolic), 
class B member 1 
HSP90AB1 -1.29 0.2028 
Solute carrier family 25 (mitochondrial iron 
transporter), member 37 
SLC25A37 -1.24 0.229 
Prospero homeobox 1 PROX1 -1.4 0.4232 
Regulator of calcineurin 1 RCAN1 2.41 0.3536 
Histidine triad nucleotide binding protein 3 HINT3 -2.45 0.0061 
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Of the genes studied, the only significantly changed gene that is common with the 
present study is the HINT3. HINT3 is a histidine triad nucleotide binding protein 3 
[251]. It is an uncharacterized gene. However, it has been recently found to be 
expressed in skeletal muscle in the chimpanzee [252]. 
4.6 Verified Results Using Real-Time Reverse Transcription PCR 
Despite of the high reliance of the quantitative capability of the RNA sequencing 
results, it is important to verify part of the expression results using a different 
method. A cherry-picked selection of genes that are of a high significance and high 
fold-change were picked. Confirming the difference of high fold-change expression 
data can allow us to check and verify them later-on at protein level. Four 
upregulated genes; COL4A2, NRXN2, NOTCH1, and AGRN, and two 
downregulated genes; NDUFS1, and PTPRR were chosen.  
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4.6.1 Results 
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Figure 3: Upregulation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in Cachectic Skeletal Muscle. 
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Figure 4: Downregulation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in Cachectic Skeletal Muscle. 
 
All chosen genes that were previously shown to be upregulated/downregulated were 
reproducible via real-time RT-PCR (Figure 3 and 4).  
 4.6.2 Discussion 
Expressions of four upregulated genes that are statistically significant were 
confirmed via real-time RT-PCR.  
AGRN (Agrin) and COL4A2 (collagen type 4 alpha 2) (section 4.3.2.2) are elements 
in the extracellular matrix-receptor interaction. AGRN fragments are under 
investigation as a possible biomarker for sarcopenia [136] and was also found to be 
upregulated in cachectic muscles. Also, COL4A2 is a component of the myocyte 
basal lamina [137].  
 
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However, the other two genes; NOTCH1 receptor (section 4.3.2.2), an activators of 
the notch pathway [131, 132], and NRXN2 (a cell adhesion molecules) are two 
poorly characterized genes in skeletal muscle and their confirmed upregulation 
warrant further research. 
The confirmed downregulated genes were the NDUFS1 and the PTPRR. The 
NDUFS1 is upregulated in the Parkinson's and Alzheimer's diseases (section 
4.3.3.2). NDUFS1 encodes subunit of proteins in the Complex I. Complex I or 
NADH: ubiquinone oxidoreductase, is the first enzyme of the mitochondrial electron 
transport chain that initiate cellular respiration or oxidative phosphorylation in the 
mitochondria in the inner mitochondrial membrane.ATP5B is a subunit of the ATP 
synthase. It catalyzes ATP synthesis through using the proton motive force created 
by the electron transport chain across the inner membrane as a source of energy in 
the process of oxidative phosphorylation.  
PTPRR is a protein tyrosine phosphatase, receptor type, R. PTPRR gene is a 
MAPK signaling pathwaygenethat is uncharacterized in the skeletal muscle and is 
correlated for the first time to cachexia.  
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Chapter 5: Results and Discussions – Adipose Tissue 
 
5.1 Demographic and Biochemical Characteristics of Subjects 
5.1.1 Results 
Demographic and biochemical details of patients for fat cachexia samples (FS) and 
fat weight-stable controls (FC) are shown in bellow tables. The tables show data for 
6 samples in each group. Samples were analyzed based on weight, BMI, some 
nutritional parameters, inflammatory markers and other related demographics.  
Table 18 shows subjects oncological diagnoses for visceral adipose tissue biopsies. 
All patients were with histologically confirmed malignancies. Age and gender 
distribution were not significantly different between cachexia fat cases (FS) and 
weight-stable controls (FC) (Table 19). All biochemical nutritional parameters (i.e. 
hemoglobin, total protein, albumin, urea, and creatinine) and inflammatory markers 
(i.e. WBC and CRP) were not significantly different between both groups (Table 19). 
Baseline weights and BMIs in the cachexia group did not differ significantly from the 
control.  The time range between current (at time of biopsy) and baseline weights 
(preceding date of biopsy) was 3-6 months. Mean weight loss from baseline in the 
cachexia group was 4.6 kg which is 6.5% of baseline body weight (i.e. 3-6 months 
before the date of sample collection). Amount and percentage of weight loss was 
significantly different from controls that had relatively stable weights; P-value of 
0.0001 and < 0.0001, respectively.  
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Table 18: Subjects' Diagnoses for Adipose Tissue Biopsies. 
Cachexia Fat Cases  (FS) Weight-stable Fat Controls (FC) 
FS1: Malignant Neoplasm of Rectum FC3: Malignant Neoplasm of Colon 
FS2: Malignant Neoplasm of Stomach FC5: Malignant Neoplasm of Colon 
FS3: Malignant Neoplasm of Rectum FC6: Malignant Neoplasm of Connective 
and Soft Tissue 
FS4:Malignant Neoplasm of Duodenum FC7: Malignant Neoplasm of Rectum 
FS5: Malignant Neoplasm of Colon FC9: Malignant Neoplasm of Rectum 
FS6: Malignant Neoplasm of Pancreas FC10: Malignant Neoplasm of Colon 
 
 
Table 19: Demographic Data for Adipose Cachectic Cases and Weight-Stable 
Adipose Controls. 
Gender (M/F) 
FS: 4/2; FC: 4/2 
FS: 
N=6 
FC: 
N=6 
Mean  SEM Median Range P-Value  
Characteristics 
Age Cach. 
Cont. 
58.67 
55.50 
6.677 
4.387 
56.00 
58.00 
44-83 
41-66 
0.7002 
Hemoglobin  Cach. 
Cont. 
115.5 
118.2 
4.0978.
356 
117.0 
121.0 
103-125 
90-143 
0.7803 
Creatinine Cach. 
Cont. 
64.40 
66.83 
8.035 
6.300 
59.00 
64.50 
41-84 
49-94 
0.8142 
Urea Cach. 
Cont. 
5.940 
4.100 
1.520 
0.5013 
5.300 
3.800 
2.9-11.1 
3.0-6.5 
0.2451 
Total protein  Cach. 
Cont. 
52.20 
61.50 
3.555 
5.620 
50.00 
64.00 
46-66 
42-79 
0.2163 
Albumin Cach. 
Cont. 
27.80 
35.33 
3.382 
2.929 
26.00 
37.00 
20-40 
23-44 
0.1248 
WBC Cach. 
Cont. 
9.633 
7.100 
1.295 
1.186 
9.350 
5.900 
6.0-13.3 
4.4-12.1 
0.1797 
CRP Cach. 
Cont. 
11.00 
18.40 
5.874 
5.810 
7.000 
19.00 
1-34 
1-34 
0.3966 
Baseline BMI  Cach. 
Cont. 
24.79 
28.41 
2.290 
0.8553 
25.27 
28.66 
15.57-30.86; 
9..96-31.23 
0.1692 
 
Current BMI  Cach. 
Cont. 
23.12 
28.37 
2.027 
0.9097 
23.61 
28.58 
14.81-28.96; 
24.91-31.23 
* 0.0397 
 
Baseline 
weights  
Cach. 
Cont. 
70.10 
78.07 
5.168 
2.843 
73.50 
75.50 
45.00-81.00; 
71.40-89.00 
0.2066  
 
Current weights  Cach. 
Cont. 
65.48 
77.93 
4.748 
2.883 
68.45 
75.30 
42.80-76.00; 
72.00-89.00 
*0.0489 
 
Amount of WT 
loss 
Cach. 
Cont. 
4.617 
0.133 
0.7241 
0.2171 
4.500 
0.0000 
2.200-7.000 
(-0.6000)-1.000 
*** 0.0001 
% of WT Loss Cach. 
Cont. 
6.489 
0.178 
0.8185 
0.2991 
5.826 
0.0000 
4.558-9.589 
(-0.8403)- 1.370 
***< 0.0001 
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Table 20 compares weight and BMI changes between current and baseline within 
each group (paired t-test). The cachectic fat cases (FS) had a significant difference 
between current and baseline data while weight-stable fat controls (FC) had no 
significant change. 
Table 20: Paired t-Tests for Weight and BMI Change for Adipose Biopsies. 
Characteristics FS/FC: N=6/6 Mean  SEM Median Range P-Value  
Weight FS  
(cachectic) 
Baseline 
Current 
70.10 
65.48 
5.168 
4.748 
73.50 
68.45 
45.00-81.00 
42.80-76.00 
**0.00.2 
BMI FS  
(cachectic) 
Baseline 
Current 
24.79 
23.12 
2.290 
2.027 
25.27 
23.61 
15.57-30.86 
14.81-28.96 
**0.0035 
 
Weight FC 
(weight-stable) 
Baseline 
Current 
78.07 
77.93 
2.843 
2.883 
75.50 
75.30 
71.40-89.00 
72.00-89.00 
0.5659 
BMI FC 
(weight-stable) 
Baseline 
Current 
28.41 
28.37 
0.8553  
0.9097 
28.66  
28.58 
25.26-31.23  
24.91-31.23 
0.6247 
 
5.1.2 Discussion 
Similar to the discussion in section 4.1.2, in the above demographic analysis, 
patients included in the study were chosen meticulously to be at the early stages of 
cachexia (i.e. 5 - < 10% weight loss). Our subjects had a mean percentage of weight 
loss of 6.5% (range 4.6-9.6 %). Since systemic inflammation measured via serum 
CRP may or may not be present in patients with cachexia [7], our subjects were 
included regardless of their CRP values (range 1-34, Table 19). However, the CRP 
values between cachectic cases (FS) and weight-stable controls (FC) were ensured 
to be not statistically significant; P= 0.325 in muscle.   
Nutritional and nutrition-related biochemical markers were all ensured to be 
comparable in both groups to objectively exclude the possibility of malnutrition as 
the primary cause of weight loss.  
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5.2  Heat Map of RNA Sequencing Data 
 5.2.1 Results 
Figure 5shows the heat map of differentially regulated genes between cachectic fat 
cases (FS) and weight-stable fat controls (FC). The figure shows separation 
between both groups but not as clear cut as that seen in skeletal muscle. The heat 
map shows a total of 365 significantly upregulated genes and 93 downregulated 
genes (P-value < 0.05; and FDR < 0.5). 
 
 
Figure 5: Heat Map Representation of the Differentially Expressed Genes in Adipose 
Tissue. 
Gene expression is shown for the cachectic fat cases (FS; purple bars; lower panel) 
and weight-stable fat controls (FC; green bar; upper panel). Colors represent scaled 
and centered expression values: red represents higher expression, blue represents 
lower expression. 
   86 
 
 
 
 
 
5.2.2 Discussion 
This simple hierarchical cluster analysis revealed a clear visual distinction of gene 
expression signature between cachexia fat cases (FS) from those with weight-stable 
fat controls (FC).  
5.3 Analysis of Differentially Expressed KEGG pathways 
5.3.1 Upregulated KEGG Pathways in Cachectic Adipose Tissue 
5.3.1.1 Results 
Five KEGG pathways are differentially upregulated in cachectic fats cases vs. 
weight-stable control fats; Prion diseases, steroid biosynthesis, cytokine-cytokine 
receptor interaction, systemic lupus erythematosus (SLE), and N-Glycan 
biosynthesis. These pathways have 5, 3, 11, 6, and 4 significantly upregulated 
genes respectively (Table 21). Table 21 shows the individual genes in each pathway 
and the overall statistical significance for each of these pathways. The level of 
statistical significance for the prion disease pathway is an order of magnitude 
greater than that for the other pathways. Thus, it was the only discussed pathway as 
below. However, Table 22 shows a summary of the full gene name, fold change, 
and P-value for individual genes in each pathway.  
Table 21: Differentially Upregulated KEGG Pathways in Cachectic Adipose Tissue. 
KEGG Pathway Gene Gene Gene Gene Gene Gene P-
value 
FDR 
Prion diseases BAX C1QC C6 LOC407835 NCAM2  0.0065 0.56 
Steroid biosynthesis EPB SQLE SOAT1    0.051 0.96 
Cytokine-cytokine 
receptor interaction 
CCR1 CCR5 CXCL10 CXCL11 IL1R1 IL20RA 0.056 0.91 
IL23A MET TGFB1 TNFRSF11A TNFRSF8  
Systemic lupus 
erythematosus 
FCGR1A C1QC C6 HIST1H3I HLA-
DMA 
SNRPB 0.062 0.87 
N-Glycan 
biosynthesis 
ALG1 DPM2 MAN1B1 RPN1   0.077 0.87 
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Table 22: Data of Individual Genes in the Upregulated KEGG Pathways in Cachectic 
Adipose Tissue. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-
Value 
Fat-Up / Prion diseases  
BAX BCL2-associated X protein 2.30 0.0272 
C1QC complement component 1, q subcomponent, C 
chain 
3.24 0.0239 
C6 complement component 6 2.26 0.0473 
LOC407835 mitogen-activated protein kinase kinase 2 
pseudogene 
3.65 0.0246 
NCAM2 neural cell adhesion molecule 2 2.27 0.0406 
Fat-Up /  Steroid biosynthesis  
EBP emopamil binding protein (sterol isomerase) 2.34 0.0266 
SQLE squaleneepoxidase 2.45 0.0161 
SOAT1 sterol O-acyltransferase 1 2.22 0.0222 
Fat-Up /  Cytokine-cytokine receptor interaction  
CCR1 chemokine (C-C motif) receptor 1 2.48 0.0234 
CCR5 chemokine (C-C motif) receptor 5 2.10 0.0293 
CXCL10 chemokine (C-X-C motif) ligand 10 4.31 0.0364 
CXCL11 chemokine (C-X-C motif) ligand 11 5.84 0.0076 
IL1R1 interleukin 1 receptor, type I 2.04 0.0339 
IL20RA interleukin 20 receptor, alpha 5.71 0.0094 
IL23A interleukin 23, alpha subunit p19 2.98 0.0389 
MET met proto-oncogene (hepatocyte growth factor 
receptor) 
2.08 0.0307 
TGFB1 transforming growth factor, beta 1 2.40 0.0235 
TNFRSF11A tumor necrosis factor receptor superfamily, member 
11a, NFKB activator 
3.35 0.0087 
TNFRSF8 tumor necrosis factor receptor superfamily, member 
8 
2.96 0.0302 
Fat-Up /   Systemic lupus erythematosus (SLE) 
FCGR1A Fc fragment of IgG, high affinity Ic, receptor (CD64); 
Fc fragment of IgG, high affinity Ia, receptor (CD64) 
4.26 0.0118 
C1QC complement component 1, q subcomponent, C 
chain 
3.24 0.0239 
C6 complement component 6 2.26 0.0473 
HIST1H3I histone cluster 1, H3j; histone cluster 1, H3i; histone 
cluster 1, H3h; histone cluster 1, H3g; histone 
cluster 1, H3f; histone cluster 1, H3e; histone cluster 
1, H3d; histone cluster 1, H3c; histone cluster 1, 
H3b; histone cluster 1, H3a; histone cluster 1, H2ad; 
histone cluster 2, H3a; histone cluster 2, H3c; 
histone cluster 2, H3d 
4.14 0.0345 
HLA-DMA major histocompatibility complex, class II, DM alpha 2.03 0.0036 
SNRPB small nuclear ribonucleoprotein polypeptides B and 
B1 
2.01 0.0205 
Fat-Up /   N-Glycan biosynthesis 
ALG1 asparagine-linked glycosylation 1, beta-1,4-
mannosyltransferase homolog (S. cerevisiae) 
2.24 0.0107 
DPM2 dolichyl-phosphate mannosyltransferase 
polypeptide 2, regulatory subunit 
2.52 0.0212 
MAN1B1 mannosidase, alpha, class 1B, member 1 2.14 0.0460 
RPN1 ribophorin I 2.02 0.0176 
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5.3.1.2 Discussion 
Prion Diseases 
BAX is a pro-apoptotic member of the Bcl-2 gene family. Apoptosis regulator BAX 
promotes apoptosis by binding to and antagonizing the Bcl-2 protein [253]. Activated 
BAX results in the release of cytochrome c and other pro-apoptotic factors from the 
mitochondria, often referred to as mitochondrial outer membrane permeabilization, 
leading to activation of caspases [254].   
C6 gene codes for complement component 6 protein that is involved in the 
complement system. It is part of the membrane attack complex which can insert into 
the cell membrane and cause cell lysis to clear pathogens from an organism via a 
number of small proteins. The system is stimulated by one of several triggers 
causing release of proteases that cleave specific proteins to release cytokines and 
initiate an amplifying cascade of further cleavages. Thus results in massive 
amplification of the response and activation of the cell-killing membrane attack 
complex. Activation of BAX and C6 in adipose cells of cachectic patients could 
reflect their same functional properties prior to wasting of adipose tissue. NCAM2 
encodes for one of three neural cell adhesion molecule (NCAM), also called CD56, 
is expressed on the surface of neurons, glia, skeletal muscle and natural killer cells.  
5.3.2 Downregulated KEGG Pathways in Cachectic Adipose Tissue 
5.3.2.1 Results 
One KEGG pathway is differentially downregulatedin cachectic fat cases vs. weight-
stable fat controls; the neuroactive ligand-receptor interaction. This pathway has 6 
significantly downregulated genes and overall has a very high level of statistical 
significance (Table 23). Table 23 shows the individual genes in the pathway. Table 
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24 shows a summary of the full gene name, fold change, and P-value for individual 
genes in the neuroactive ligand-receptor interaction pathway. 
Table 23: Differentially Downregulated KEGG Pathway in Cachectic Adipose Tissue. 
KEGG Pathway Gene Gene Gene Gene Gene Gene P-value FDR 
Neuroactive receptor 
ligand interaction 
GABRG1 GRIA4 LEP LHCGR NMUR1 NPY1R 0.002 0.068 
 
Table 24: Data of Individual Genes in the Downregulated KEGG Pathway in 
Cachectic Adipose Tissue. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-
Value 
Fat-Down /  Neuroactive ligand-receptor interaction 
GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 -3.26 0.0249 
GRIA4 glutamate receptor, ionotrophic, AMPA 4 -3.10 0.0172 
LEP Leptin -3.50 0.0032 
LHCGR luteinizing hormone/choriogonadotropin receptor -3.90 0.0028 
NMUR1 neuromedin U receptor 1 -2.69 0.0133 
NPY1R neuropeptide Y receptor Y1 -3.47 0.0242 
 
5.3.2.2 Discussion 
Neuroactive Ligand-Receptor Interaction Pathway 
LEP encodes for leptin, a "satiety hormone" that signals energy sufficiency and 
thereby inhibits hunger. Leptin discovery was a breakthrough in 1994. It is secreted 
from adipocytes in proportion to fat stores and acts on receptors in the 
hypothalamus to regulate appetite [255]. Leptin suppresses feeding and decreases 
adiposity in part by release of αMSH and cocaine and amphetamine related 
transcript that directly suppress appetite, in part by inhibiting hypothalamic NPY 
synthesis and release, since NPY stimulates appetite, and partly by inhibiting 
release of agouti-related peptide that acts by blocking the action of αMSH at its 
receptor [256]. The regulation of appetite is a complex process involving multiple 
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hormones [257]. Hypothalamus is the main appetite regulator in the body that 
senses external multiple hormonal stimuli. 
Leptin decreases food intake by affecting the balance between orexigenic and 
anorexigenic hypothalamic pathways [258]. Low leptin increases appetite and body 
weight. Crosstalk between leptin and inflammatory signaling known to be activated 
may be responsible for this paradox [258]. Many studies looked at the serum level of 
leptin in cancer patients. Cachectic esophageal cancer patients had decreased 
circulating leptin [259-262].  
Interestingly, in vitro and in vivo, insulin plays a major transcriptional activation that 
stimulates leptin circulation level [263]. However, patients with cachexia do usually 
have high insulin resistance which does not elevate, at least in our study, the 
adipocyte production of leptin. This downregulation of leptin production in adipocyte 
does not seem to increase appetite in cancer patient. This reflects that the 
deregulation of appetite and weight in cachectic patient is a complex process.   
Leptin levels are low, as expected, signaling that there are NOT sufficient energy 
stores in fat. However, this is not reflected in the expected increase in appetite! 
Paradoxically, NPY expression in the ARC is decreased (you would expect it to be 
increased in the absence of leptin signaling) and that of POMC (source of αMSH) 
increased (you would expect it to be decreased in absence of leptin). There is 
speculation that this is a response to GAD15 in the hypothalamus and GAD15 
expression was significantly increased in cachectic muscle in the present study 
[258]. 
Leptin level are negatively correlated with the degree of cachexia [259]. Although 
regulation of fat stores is deemed to be the primary function of leptin, obese 
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individuals have a decreased sensitivity to leptin occurs, resulting in an inability to 
detect satiety despite high energy stores [264].  
LHCGR codes for the luteinizing hormone/choriogonadotropin receptor protein. 
LHCGR is abundantly expressed in preadipocytes and mature adipocytes [265]. It is 
studied the most in the gonads. In the ovary, the LHCGR is required for follicular 
maturation and ovulation, as well as luteal function upon hormonal stimulation [266]. 
Low levels of the receptor are repeatedly linked to infertility.   
While the function of this receptor is uncharacterized in adipose tissue, we do 
believe there is a strong correlation between the downregulation of that receptor and 
the depletion of fat stores. Female athletes one of the commonest examples of 
infertility caused by depletion of fat stores which both could be possibly due, at least 
in part, to the downregulation of the receptor in gonads and adipose tissue.  
NPY1R codes for the Neuropeptide Y receptor type 1 protein. NPY, the 
neuropeptide Y, is a neurotransmitter involved in food intake and body weight 
regulation [267] and prevention of lipolysis [268] via Y1 and Y5 receptors. Y1 
receptors are coded by NPY1R which is increased in adipose tissue samples of 
obese patients and in turn signals for inhibition of lipolysis [269].  Additionally, 
NPY1R expression in visceral adipose tissue is positively correlated with body 
weight, BMI, and insulin levels [267]. Downregulation of the gene in cachectic 
adipose tissue neutralizes its "lipolysis inhibition" signal which may contribute to 
adipose wasting.  
NMUR1 codes forneuromedin-U (NMU) receptor 1. NMU overexpressing tumors in 
mice resulted in lowering of body weight and cachexia [270]. NMUR1 in human is 
highly expressed in intestinal adipose tissue [271]. 
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Intracerebroventricular administration of NMU markedly suppresses food intake in 
rats [272]. The downregulation of NMUR1 could be a compensatory mechanism to 
oppose the possible outcome of receptor stimulation with is documented to lead to 
cachexia in mice.  
GABRG1 encodes for gamma-aminobutyric acid receptor subunit gamma-1 protein 
which is a subunit of the GABAA receptor. GABAA receptors are located 
synaptically as well as presynaptically and are activated by gamma-aminobutyric 
acid (GABA) [273]. GABA is a neuroinhibitory transmitter in the brain [273]. Oral 
GABA given activates peripheral GABA receptors and this improves glucose 
tolerance, improves insulin sensitivity, and prevents obesity without altering calorie 
intake in mice [274]. Thus, the downregulation in cachectic adipose tissue could play 
a role in insulin resistance seen in cachectic cancer patients and could be a 
compensatory measure trying to stimulate weight gain.  
GRIA4 encodes for glutamate receptor 4. It is a member of a family of L-glutamate-
gated ion channels that mediate fast synaptic excitatory neurotransmission. 
Glutamate receptors are protein complexes known to be the main excitatory 
neurotransmitter receptors in the mammalian brain [275]. The regulation of 
glutamate receptors is influenced by leptin levels [276] which is also downregulated 
in cachectic adipose tissues.   
Surprisingly, five out of the six above genes are receptors. The sixth gene is leptin, 
which also functions to downregulate one of receptors (i.e. GRIA4) is also 
downregulated. Most of these receptors are well studied and characterized in the 
brain, while this is the first time they are reported, as far of our knowledge, to be 
collectively downregulated in human adipose tissue.   
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5.4 Analysis of Highly Significantly Altered Genes in Cachectic Adipose 
Tissues 
In visceral fat, 16 genes showed highly significant change in expression (10 
upregulated and 6 downregulated: P<0.001-0.0002, FDR 0.5).  
5.4.1 Highly Significantly Upregulated Genes 
5.4.1.1 Results 
Table 25 shows the 10 highly significantly upregulated genes in cachectic fat 
(P<0.001-0.0002; DFR 0.5). They include 2 involved with transcriptional regulation, 
2 transporters, on in each of the development, angiogenesis inhibitor, metabolism, 
and signaling, and 2 uncharacterized.  
Table 24 categorizes individual gene into respective functional domain. It also 
shows the full gene name, fold change, and P-value.  
Table 25: Highly Significantly Upregulated Genes in Cachectic Adipose Tissue. 
Gene 
Symbol  
Gene Full Name Fold 
Change 
P-
Value 
Transcription regulation 
RPP40 RibonucleaseP protein subunit p40 3.49 0.001 
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 2.49 <0.001 
Transporters 
SLC19A1 Solute carrier family 19 (folate transporter), member 1 2.34 0.001 
STEAP3 Metalloreductase STEAP3 2.57 0.0002 
Development 
IFRD2 interferon-related developmental regulator 2 2.25 0.001 
Angiogenesis Inhibitor 
BAI2 Brain-specific angiogenesis inhibitor 2 4.43 0.0008 
Metabolism 
PUSL1 pseudouridylate synthase-like 1 2.37 0.001 
Signaling  
LYPD1 Ly6/PLAUR domain-containing protein 1 5.54 0.001 
Un-characterized 
CCDC94 Coiled-coil domain containing 94 2.51 0.0003 
C15orf57 chromosome 15 open reading frame 57 2.49 0.001 
   94 
 
 
 
 
 
5.4.1.2 Discussion 
Transcription Regulation 
RPP40 encodes for ribonuclease P protein subunit p40, which generates mature 
tRNA molecules by cleaving the 5'-end of the leader sequence of precursor tRNA. 
RNase P is a ribozyme; a unique form of RNase that functions as a catalyst in the 
same way that a protein enzymes work [277] and is required for normal and efficient 
transcription of various small noncoding RNAs, such as tRNA, 5S rRNA, SRP RNA 
and U6 snRNA genes [278, 279]. However the RNase P in human mitochondria is a 
protein with no RNA component. Moreover, the enzyme is composed of a tRNA 
methyltransferase, a short-chain dehydrogenase/reductase-family member, and a 
protein of hitherto unknown functional and evolutionary origin, possibly representing 
the enzyme's metallonuclease moiety [280]. 
IGF2BP2 encodes insulin-like growth factor 2 mRNA-binding protein 2, a member of 
the IGF-II mRNA-binding protein family [281]. It functions by binding to the 5' UTR of 
the insulin-like growth factor 2 mRNA and regulates its translation by modulating the 
rate and location at which it encounters the translational apparatus and shields it 
from endonuclease attacks or microRNA-mediated degradation [281]. An important 
paralog of this gene is IGF2BP3 [281]. There is a strong association between 
IGF2BP2 insulin resistance and type 2 diabetes mellitus, however, the exact 
mechanisms has not been determined [282-285]. 
On the other hand, adipose tissue plays a role in secreting a variety of factors which 
are involved in the modulation of adipose mass [286]. Adipose tissue development 
and metabolism are regulated by growth hormone (GH) and the insulin-like growth 
factor (IGF) system [286]. GH plays an anti-insulin effect; however, the mechanism 
by which GH antagonizes insulin stimulation of lipogenesis is unknown [286]. 
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IGF2BP2 downregulates the expression of IGF2; a growth factor that plays a pivotal 
role in controlling adipogenesis [287]. Therefore, IGF2BP2 may contribute to type 2 
diabetes through alterations in adipose tissue [287]. Also, a more than two-fold 
increase in IGF2BP2 expression level was observed in the adipose tissue of diabetic 
patients compared to controls [288]. Similarly, an altered expression of IGF2BP2 in 
adipocytes of subjects with type 2 diabetes compared with healthy people was also 
detected [289]. Thus, an increase in the IGF2BP2 in the adipose tissue of cachectic 
subject in our study is no surprise since it alters adipogenesis and promotes insulin 
resistance.  
Transporters 
SLC19A1 encodes for solute carrier family 19 (folate transporter), member 1 protein. 
It facilitates intracellular uptake of reduced folate to maintain intracellular 
concentrations of folate. Despite of the plethora of studies on SLC19A1, the majority 
of these investigated it in terms of polymorphic effects on drug dosing (i.e. the 
antimetabolite; methotrexate). Thus, studies investigating the role of this transporter 
in adipose tissues are lacking. However, SLC19A1 has three protein kinase C (PKC) 
phosphorylation sites [290]. Effect of PKC is cell type specific. In adipose tissue, 
PKC transduces the effects of adrenergic agonists (specifically agonists of the β3 
receptor). β3-adrenergic agonists stimulate brown adipose tissue thermogenesis 
[291]. In white adipose tissues; however, β3-adrenergic agonists increase energy 
expenditure and lipolysis, which in turn promote lipid mobilization [291]. These 
effects causes adipose tissue wasting and decreased fat stores [291] which are all 
key manifestations in the cachectic patients. β3-Adrenergic agonists also enhance 
glucose disposal to provide energy for the maintenance of metabolic activity and 
muscle function under limited energy availability [291]. Other adrenoreceptors have 
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other effects on lipid and glucose metabolism; α1-adrenoceptors and β2-
adrenoceptors are linked to glycogenolysis and gluconeogenesis in adipose tissue; 
while β1-adrenoceptors and β3-adrenoceptorsare linked to lipolysis in adipose 
tissue [292].  
STEAP3 codes for six-transmembrane epithelial antigen of prostate STEAP family 
member 3, a metalloreductase that is capable of converting iron from an insoluble 
ferric (Fe3+) to a soluble ferrous (Fe2+) form. This family comprises STEAP1-4; all of 
which share metalloreductases activity [293]. They participate in a wide range of 
biologic processes, such as molecular trafficking in the endocytic and exocytic 
pathways and control of cell proliferation and apoptosis [293]. STEAP3 is also 
known as tumor-suppressor activated pathway-6 (TSAP6) or dudulin-2. Mutations in 
STEAP3 result in an autosomal recessive trait characterized by an inefficient supply 
of iron to erythrocytes, leading to anemia and iron overload [294].  
STEAP3 is upregulated in white adipose tissue of rats fed high fat diet and 
significantly downregulated in rats treated with capsaicin (a potential anti-obesity 
drug) [295]. This indicate that STEAP3 increases when fat supply is abundant and 
not during times of energy deficit. It is possible that STEAP3 increases as a 
compensatory mechanism to signal resistance to fat loss and/or to stimulate energy 
storage that mimic the state of abundance under the forces or triggers of wasting.  
On the other hand, one anti-obesity strategy is to block adipocyte differentiation, 
preventing fat storage and the secretion of adipokines [296]. STEAP3 is upregulated 
in differentiating adipocytes [296]. This suggests that the adipose tissue in cachexia 
is undergoing an early-onset protective mechanism by inducing adipocyte 
differentiation in an attempt to prevent further lipolysis and wasting.  
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Development 
IFRD2 codes for interferon-related developmental regulator 2. Very little is known, 
so far, about I the FRD2 gene. However another member of this gene family, IFRD1 
is expressed in skeletal and cardiac muscle. It is also expressed in differentiating 
myoblasts in vitro [297]. IFRD1 knockout mice have delayed muscular regeneration 
after muscle crush damage [298]. In contrast, upregulation of IFRD1 in injured 
muscle potentiates muscle regeneration [299].  
IFRD1 was also recently studied in white adipose tissue in obese mice, where its 
expression is increased [300]. It is also upregulated under stressful stimuli such as 
hypoxia [300], where it prevents the inhibition of adipogenesis [300]. This effect is 
abrogated by knockdown of IFRD1 by shRNA which inhibits adipogenesis. These 
findings suggest that IFRD1 may play a role in adipogenesis under conditions of 
hypoxia and obesity.  
The uniqueness of importance of IFRD1 in muscle regeneration and adipogenesis, 
suggests a similar mechanism of action for IFRD2, which may be more specific for 
adipose tissue. Furthermore, since IFRD1 potentiates the regenerative process, 
IFRD2 might be activated in cachectic adipose tissue as a defense mechanism to 
reduce the loss of adipocytes due to wasting.  
Metabolism 
PUSL1 encodes for pseudouridylate synthase-like 1, an uncharacterized 
metabolism protein with pseudouridine synthase activity. Pseudouridylate synthase 
is an enzyme that catalyzes the conversion of uracil and D-ribose 5-phosphate to 
pseudouridine 5'-phosphate and H2O. This enzyme belongs to the family of lyases 
that participate in pyrimidine metabolism; an indicator for the rate of DNA turnover 
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[301]. Despite not knowing exactly how the PUSL1 enzyme functions in adipose 
tissue, what we know so far about pyrimidine metabolism is extremely exciting. All 
pyrimidine nucleotides are synthesized de novo, mainly in the liver. Pseudouridine is 
an intermediate in the pyrimidine synthesis pathway. Pseudouridylate synthase 
activity allows E. coli to grow in the presence of pseudouridine, with growth 
paralleling measured enzymic activity [302]. More excitingly, pseudouridylate 
synthase is a catabolite repressible enzyme [303]. Catabolite repression, usually 
observed in bacteria and other microorganisms, is the inhibition of synthesis of 
enzymes involved in catabolism of carbon sources other than the preferred one 
[304].  
The above data can be correlated to cachectic patients whose adipose tissues is 
trying to repress catabolism and as a compensatory mechanism, rather trying to 
build up the key building blocks of adipogenesis (i.e. ribonucleic acid material or 
pyrimidines). With pyrimidines being mostly synthesized in the liver; it is not 
surprising that unlike the atrophying livers of patients losing weight due to starvation, 
the livers of patients with cachexia become significantly enlarged, probably due to 
overload.  
Signaling 
LYPD1 encodes for Ly6/PLAUR domain-containing protein 1. However, the 
understanding of this protein in the context of cachexia is hard since very little, if 
any, is known about it.  LYPD1 partial silencing results in a highly significant 
increase in overall anchorage-independent growth in HeLaHF cells. LYPD1 
overexpression reduced cell survival and anchorage-independent growth and 
induced higher levels of apoptosis in soft agar [305].  
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LYPD1 is associated with bannayan-riley-ruvalcaba syndrome, a rare overgrowth 
syndrome [306]. One of the predominant features of the syndrome is the occurrence 
of multiple subcutaneous lipomas [306, 307].  
Angiogenesis Inhibitor 
BAI2 encodes for brain-specific angiogenesis inhibitor 2, a member of the adhesion-
G-protein coupled receptors (adhesion-GPCRs) family of receptors [308]. BAI2 and 
BAI3 are similar to BAI1, have similar tissue specificities and structure and may also 
play a role in angiogenesis [309]. BAI2 is dominantly expressed in the brain [310]. 
However, its functions are still unclear but it is suggested that BAI2 is a functional 
GPCR regulated by proteolytic processing and activates the NFAT pathway [310]. It 
is known that the nuclear factor of activated T cell (NFAT) group of transcription 
factors contributes to glucose and insulin homeostasis [311]. Expression of NFATc2 
and NFATc4 is induced upon adipogenesis and in obese mice, while ablation of 
both NFATc2 and NFATc4 increases insulin sensitivity [311].  
If BAI2 upregulation is confirmed to activate the NFAT pathway, this suggests that 
such activation signals induced adipogenesis as an adaptive response to the 
wasting triggers in cachexia. Also, upregulation of this pathway could explain, at 
least in part, by the increased insulin resistance in these patients. 
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5.4.2 Highly Significantly Downregulated Genes in Cachectic Adipose 
Tissues 
5.4.2.1 Results 
Table 26: Highly Significantly Downregulated Genes in Cachectic Adipose Tissue. 
Gene Symbol  Gene Full Name Fold Change P-Value 
Metabolism 
CES1 Liver carboxylesterase 1 -5.65 0.0006 
NQO1 NAD(P)H dehydrogenase [quinone] 1 -3.82 <0.0006 
Transcription Factor 
AFF3 AF4/FMR2 family member 3 -2.30 0.00003 
Angiogenesis Inhibitor 
TNMD Tenomodulin -15.46 <0.0007 
Uncharacterized 
LOC100996634 Transmembrane protein FLJ37396 -15.24 0.0001 
TRIM16L Tripartite motif containing 16-like -2.98 <0.0002 
 
5.4.2.2 Discussion 
Metabolism 
CES1 codes for the liver carboxylesterase 1 enzyme. CES1 is present in most 
tissues with higher levels in the liver [312], and is highly regulated in adult adipose 
tissue [313], with higher levels in obese subjects and lower levels during weight loss 
[314]. This enzyme hydrolyzes long-chain fatty acid esters and thioesters. CES1 is 
an inducible serine esterase that hydrolyses many drugs (to activate or inactivate 
them) and a nutrients, as well as cholesterol esters, etc. CES1 could be an 
important player in metabolism of triglycerides and cholesterol in adipocytes [315]. 
Thus, CES1 is suggested to play a major role in the trafficking of lipids and lipid 
metabolism in hepatocytes and its upregulation mediates adipocyte lipolysis through 
the hydrolysis of cholesteryl esters and triglycerides [313]. Studies correlated 
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increased expression to be a measure of adiposity and insulin resistance (well here 
we have decreased adiposity but insulin resistance.  
Expression level of CES1 in adipose tissue was positively associated with body 
mass index, homeostasis model assessment-insulin resistance, and level of fasting 
glucose, insulin, and triglycerides [315]. In murine adipocytes, CES3 was identified 
as a gene that increased lipid storage [316]. All of which are measures and/or 
triggers of adiposity.  
In vitro and in vivo studies suggested that inhibition of CES1 could help treat type 2 
diabetes [316]. In murine models of diabetes, a CES3 inhibitor protected animals 
from weight gain, decreased liver lipid accumulation and increased insulin sensitivity 
[316]. CES1 activity was upregulated in adipose tissue from patients with type 2 
diabetes, compared with that in lean controls [316], and also upregulated in obese 
children [313]. 
Hence, the highly significantly downregulated CES1 in the adipose tissue of our 
cachectic patients reflects the actual weight losing state of our patients, and explain 
the compensatory state of adipose tissue to resist lipolysis and the state of insulin 
resistance.  
NQO1 codes for an NAD(P)H dehydrogenase [quinone] 1 enzyme which is a 
member of  family of enzymes that prevents the one electron reduction and 
detoxification of quinones and their derivatives that results in the production of 
radical species [317]. NQO1 has a high expression in human adipose tissue, 
particularly in large adipocytes and is reduced by weight loss (similar to CES1) and 
also correlates with adiposity [318].  
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NQO1 regulates the ubiquitin-independent p53 degradation pathway through 
stabilization of p53. NQO1 downregulation reduces p53 stability, leading to 
resistance to some drugs including chemotherapeutics. One important and exciting 
correlation is the increased hematotoxicity in benzene-exposed workers in China 
with a certain NQP1 genotype isolated from bone marrow that showed failure to 
express NQO1 [319]. NQO1 null mice exhibited increased toxicity when 
administered menadione [320]. However, these mice exhibit significantly lower 
levels of abdominal adipose tissue, lower blood levels of glucose, no change in 
insulin, and higher levels of triglycerides, b-hydroxy butyrate, pyruvate, lactate, and 
glucagon and insulin resistant as compared with wild-type mice [317]. Also, the liver 
glycogen reserve was found to be decreased [317]. All of which data suggest that 
the loss of NQO1 causes alteration in the intracellular redox activities leading to 
reduction in pyridine nucleotide synthesis and reduced glucose and fatty acid 
metabolism resulting in a significant reduction in the amount of abdominal adipose 
tissue [317]. In addition, the loss of NQO1 leads to the alteration in lipid deposition 
due to the decrease in gluconeogenesis and fatty acid metabolism [321]. 
NQO1 mutations are also found to be associated with tardive dyskinesia (TD) an 
incurable form of dyskinesia; a disorder resulting in involuntary, repetitive, and 
tardive (slow or belated onset) body movements [322]. 
Transcription Factor 
AFF3 is an AF4/FMR2 family member 3 that encodes a tissue-restricted nuclear 
transcriptional activator [323] that functions in lymphoid development and 
oncogenesis [324, 325]. AFF3 is associated with kidney disease in diabetics with 
type 1 [326] but not type 2 diabetics [327].    
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Angiogenesis Inhibitor 
TNMD codes for tenomodulin; a novel chondromodulin-I related gene. 
Chondromodulin-I is a cartilage-specific glycoprotein that functions to stimulate 
chondrocyte growth and to inhibit tube formation of endothelial cells [328]. The 
TNMD transcript is found in hypovascular tissues such as tendons and ligaments 
and that is believed to be an angiogenesis inhibitor [329]. TNMD is also expressed 
in both the adipocyte and stromal vascular fraction of adipose tissue [330]. 
TNMD expression is decreased in the adipose tissue of subjects who have lost 
weight and its expression level is strongly correlated with body mass index [330]. 
Expression remained was also consistently remained downregulated after weight 
loss of subjects on a low-calorie diet and after weight maintenance [331]. TNMD is 
associated the risk of developing diabetes [332], although this association is not yet 
well-understood. However, genetic variation of the TNMD gene is associated with 
serum levels of systemic immune mediators which have a well-established 
connection to obesity, metabolic syndrome, and type 2 diabetes [333].  
The potential mechanisms that links TNMD with the pathogenesis of obesity, 
diabetes, and metabolic syndromes are yet to be confirmed [330]. However, in the 
context of our weight losing cachectic patients, TNMD downregulation is perhaps 
expected. However, the 15-fold downregulation is massive given the small degree 
(5-10%) weight loss. Thus, we believe this dramatic downregulation is important 
given the effect of weight loss, insulin resistance, and the metabolic syndrome of 
cachexia.  
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5.5 Anticipated Results from Previous Studies 
5.5.1 Preclinical Findings 
Adipose depletion in cachexia is a function of lipolysis [334]. Adipose tissue atrophy 
starts with the excessive hydrolysis of triglycerides to free fatty acids and glycerol 
that is then mobilized and released in the circulation. The key enzymes catalyzing 
this reaction are the hormone sensitive lipase (LIPE) and adipose triglyceride lipase 
(PNPLA2) [335]. Preclinical studies showed that inhibition of lipolysis through 
genetic ablation of LIPE or PNPLA2 ameliorates certain features of murine model of 
cancer cachexia [336]. Expressions of neither LIPE nor PNPLA2 were significantly 
altered in the present study. However, a different lipid mobilizing factor; zinc-α 
glycoprotein 1(AZGP1), has been previously shown to be involved in cachexia as a 
clinical finding [337]. Expression of AZGP1 was also increased in the present study 
but with only borderline significance (Fold change 2.79, P-value 0.0576).  
Parathyroid hormone-related protein (PTHLH) is a causative factor of hypercalcemia 
in malignancy. A recent suggested hypothesis to cancer cachexia is that there is 
adipose tissue "browning" that results in an increased in energy expenditure leading 
and greater thermogenesis [338]. In murine model cancer cachexia, PTHLH induced 
the expression of genes involved in thermogenesis in adipose tissues while blocking 
PTHLH blocked adipose tissue browning [339]. The present study revealed no 
change in expression of either PTHLH or its associated receptor, PTH1R suggesting 
that tissue browning theory that mediates thermogenesis and consequently an 
increase in energy expenditure is not the one of the contributing factors in human 
subjects.   
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5.5.2 Clinical Findings 
In recent years, adipose tissue is been recognized to have major endocrine 
functions [340]. Several pro-inflammatory cytokines and hormones are believed to 
be produced in cancer cachexia patients, at least in part by the adipose tissue. 
Cytokines (TNF, IL6, and IFNG) and hormones (such as leptin) have been 
investigated in the context of cancer cachexia. Leptin is the "satiety hormone" made 
by adipose cells that helps in the regulation of energy balance by suppressing 
appetite [255]. In obese individuals, however, the body has a decreased sensitivity 
to leptin resulting in an inability to detect satiety despite of the high energy stores 
[264]. Clinical studies found that leptin levels are significantly lower in cachectic 
patients [259, 261, 341] while higher levels of IL6 were associated with future 
development of cachexia [341].  
The present study shows a significant reduction in leptin expression as expected 
(Fold change -3.50, P-value 0.0032). This suggests that leptin does not play an 
important role in cancer cachexia development but rather an indicator for depleting 
adipose stores in these patients. On the other hand, expression of IL6 was elevated 
but not statistically significant. However, it is possible that IL6 expression is 
increased in some but not all cachectic cancer patients.  
5.6 Verified Results Using Real-Time Reverse Transcription PCR 
Despite of the high reliance of the quantitative capability of the RNA sequencing 
results, it is important to verify part of the expression results using a different 
method. A cherry-picked selection of genes that are of a high significance and high 
fold-change were picked. Confirming the difference of high fold-change expression 
data can allow us to check and verify them later-on at protein level. One upregulated 
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gene; CXCL11, and three downregulated genes; TNMD, LEP, and LHCGR were 
confirmed.   
 5.6.1 Results 
  
 
Figure 6: Upregulation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in Cachectic Adipose Tissue. 
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Figure 7: Downregulation of Expression of Selected Genes Confirmed by Real-Time 
RT-PCR in Cachectic Adipose Tissue. 
All chosen genes that were previously shown to be upregulated/downregulated were 
reproducible via real-time RT-PCR (Figure 6 and 7).  
 5.6.2 Discussion 
Expressions of one upregulated gene; CXCL11 that is statistically significant was 
confirmed via real-time RT-PCR.  
CXCL11 codes for chemokine (C-X-C motif) ligand 11 protein (Table 22). It is a 
small cytokine that belongs to the CXC chemokine family that is also called 
interferon-inducible T-cell alpha chemoattractant (I-TAC) and Interferon-gamma-
inducible protein 9 (IP-9)[342]. Normally, expression of CXCL11 in mice adipose 
tissue was found to be consistently very low [343]. Adipose tissue macrophages 
(ATM), which are tissue resident macrophages, are present in adipose tissue. It was 
found that these ATMs are transiently recruited to adipose tissue at times of acute 
weight loss [344, 345]. ATM was found to have a high level expression of CXCL11 
[346]. So far, the right justification of elevated levels of CXCL11 in adipose tissue is 
 
 
 
 
 
 
   108 
 
 
 
 
 
not reached. However, we know that their expression level is normally 
downregulated. 
The confirmed downregulated genes were TNMD, LEP, and LHCGR. The TNMD 
(section 5.4.2.2) is an angiogeneic inhibitor gene that codes for tenomodulin; a novel 
chondromodulin-I related gene. TNMD is expressed in both the adipocyte and 
stromal vascular fraction of adipose tissue [330]. TNMD expression is decreased in 
the adipose tissue of subjects who have lost weight and its expression level is 
strongly correlated with body mass index [330]. Expression remained was also 
consistently remained downregulated after weight loss of subjects on a low-calorie 
diet and after weight maintenance [331]. TNMD is associated the risk of developing 
diabetes [332], although this association is not yet well-understood. However, 
genetic variation of the TNMD gene is associated with serum levels of systemic 
immune mediators which have a well-established connection to obesity, metabolic 
syndrome, and type 2 diabetes [333].  
The potential mechanisms that links TNMD with the pathogenesis of obesity, 
diabetes, and metabolic syndromes are yet to be confirmed [330]. However, in the 
context of our weight losing cachectic patients, TNMD downregulation is perhaps 
expected. However, the 15-fold downregulation is massive given the small degree 
(5-10%) weight loss. Thus, we believe this dramatic downregulation is important 
given the effect of weight loss, insulin resistance, and the metabolic syndrome of 
cachexia.  
LEP (as discussed in section 5.3.2.2) encodes for leptin, a "satiety hormone" that 
signals energy sufficiency and thereby inhibits hunger. Leptin discovery was a 
breakthrough in 1994. It is secreted from adipocytes in proportion to fat stores and 
acts on receptors in the hypothalamus to regulate appetite [255]. Leptin suppresses 
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feeding and decreases adiposity in part by release of αMSH and cocaine and 
amphetamine related transcript that directly suppress appetite, in part by inhibiting 
hypothalamic NPY synthesis and release, since NPY stimulates appetite, and partly 
by inhibiting release of agouti-related peptide that acts by blocking the action of 
αMSH at its receptor [256]. The regulation of appetite is a complex process involving 
multiple hormones [257]. Hypothalamus is the main appetite regulator in the body 
that senses external multiple hormonal stimuli. 
Leptin decreases food intake by affecting the balance between orexigenic and 
anorexigenic hypothalamic pathways [258]. Low leptin increases appetite and body 
weight. Crosstalk between leptin and inflammatory signaling known to be activated 
may be responsible for this paradox [258]. Many studies looked at the serum level of 
leptin in cancer patients. Cachectic esophageal cancer patients had decreased 
circulating leptin [259-262].  
Interestingly, in vitro and in vivo, insulin plays a major transcriptional activation that 
stimulates leptin circulation level [263]. However, patients with cachexia do usually 
have high insulin resistance which does not elevate, at least in our study, the 
adipocyte production of leptin. This downregulation of leptin production in adipocyte 
does not seem to increase appetite in cancer patient. This reflects that the 
deregulation of appetite and weight in cachectic patient is a complex process.   
Leptin levels are low, as expected, signaling that there are NOT sufficient energy 
stores in fat. However, this is not reflected in the expected increase in appetite! 
Paradoxically, NPY expression in the ARC is decreased (you would expect it to be 
increased in the absence of leptin signaling) and that of POMC (source of αMSH) 
increased (you would expect it to be decreased in absence of leptin). There is 
speculation that this is a response to GAD15 in the hypothalamus and GAD15 
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expression was significantly increased in cachectic muscle in the present study 
[258]. 
Leptin level are negatively correlated with the degree of cachexia [259]. Although 
regulation of fat stores is deemed to be the primary function of leptin, obese 
individuals have a decreased sensitivity to leptin occurs, resulting in an inability to 
detect satiety despite high energy stores [264].  
LHCGR (as discussed in section 5.3.2.2) codes for the luteinizing 
hormone/choriogonadotropin receptor protein. LHCGR is abundantly expressed in 
preadipocytes and mature adipocytes [265]. It is studied the most in the gonads. In 
the ovary, the LHCGR is required for follicular maturation and ovulation, as well as 
luteal function upon hormonal stimulation [266]. Low levels of the receptor are 
repeatedly linked to infertility.   
While the function of this receptor is uncharacterized in adipose tissue, we do 
believe there is a strong correlation between the downregulation of that receptor and 
the depletion of fat stores. Female athletes one of the commonest examples of 
infertility caused by depletion of fat stores which both could be possibly due, at least 
in part, to the downregulation of the receptor in gonads and adipose tissue.  
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Chapter 6: Overlapping Genes in Skeletal Muscle and Adipose Tissue 
 
This chapter aims at looking at the significantly altered gene expressions that are 
commonly altered in both; muscle and adipose tissues.  
6.1 Upregulated Genes 
6.1.1 Results 
Table 27: Upregulated Overlapping Genes. 
Gene 
Symbol 
Gene Full Name Muscle Fat 
Fold 
change 
P-Value Fold 
change 
P-
Value 
ASS1 Argininosuccinate Synthase 1 3.70 0.0064 2.14 0.0323 
CLCN2 Chloride Channel, Voltage-
Sensitive 2 
9.48 0.0163 2.29 0.0239 
PGAP3 Post-GPI Attachment To Proteins 
3 
2.80 0.0032 2.12 0.0066 
RPS10 Ribosomal Protein S10 4.58 0.0045 2.18 0.0256 
SLC36A1 Solute Carrier Family 36 
(Proton/Amino Acid Symporter), 
Member 1 
4.00 0.0039 2.07 0.0323 
TGM2 Transglutaminase 2 2.20 0.0114 2.42 0.0244 
 
6.1.2 Discussion 
ASS1 is an argininosuccinate synthase enzyme that catalyzes the penultimate step 
of the arginine biosynthetic pathway. Arginine is classified as a semi-essential or 
conditionally essential amino acid, depending on the developmental stage and 
health status of the individual [347]. Arginine biosynthesis is only needed in 
unhealthy individuals because there are not getting enough nutritional supply. It 
serves many important roles such as cell division, wound healing, ammonia 
metabolism, immune function, and the release of hormones [347, 348]. The direct 
correlation of argininosuccinate synthase function in skeletal and adipose tissues in 
cachectic individuals is unknown. It can be stipulated that in both tissues (when 
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combined, they constitute the majority of human body mass), cachexia is a huge 
insult requiring healing and repair (probably), and definitely replacement. 
On the other hand, mutations in the ASS1 gene cause type I citrullinemia because 
of alteration of an important step of the urea cycle [349]. Individuals with type I 
citrullinemia develop symptoms when alteration in the enzyme causes ammonia 
build up in the body. Hyperammonemia is significantly higher in terminally ill cancer 
patients [350]. Symptoms of hyperammonemia in type I citrullinemia includes lack of 
energy (lethargy), poor feeding, vomiting, and others. All of which are seen in 
cachexia. Skeletal muscle plays a role in ammonia detoxification. Ammonia is also 
known to stimulate the hypothalamic satiety centers which suppress appetite and 
lead to cachexia [351]. Generally, L-arginine reduces adiposity, increase muscle 
mass, and improve the metabolic profile in animals and humans [352]. All of which 
are important adaptive requirement in cachectic patients.  
CLCN2 codes for chloride channel protein 2 that is one of 13 members in the 
chloride channel superfamily of poorly understood ion channels that are implicated 
in many cellular processes. Chloride channels in skeletal muscle play a role in 
setting and restoring the resting membrane potential, thus preventing muscle 
stiffness or myotonia [353]. Mutations in the human skeletal muscle chloride channel 
are associated with dominant and recessive congenital myotonia [353]. While such a 
role is clearly correlated to muscle regulation, the reason of the upregulation in 
adipose tissue is yet to be understood.  
PGAP3 codes for post-GPI attachment to proteins 3 that encodes a 
glycophosphatidylinositol (GPI)-specific phospholipase A2 that is expressed in the 
Golgi apparatus. The enzyme is involved in fatty acid GPI remodeling that is critical 
for proper association between GPI-anchored proteins and lipid rafts [354]. In 
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muscle, mutation in PGAP3 causes muscular hypotonia [354]. PGAP3 is 
responsible for the modification of the fatty acid residues on the GPI anchor in a 
maturation process that occurs in the endoplasmic reticulum and Golgi [354].  
RPS10 is another important gene in the cachectic organs that is likely to be involved 
in the adaptive responses to the forces of wasting. RPS10 codes for the 40S 
ribosomal protein S10 that is one of the two subunits making the ribosomes; the 
organelles that catalyze protein synthesis [355]. Also, RPS10 expressed sequence 
tags were isolated from the skeletal muscle of neonatal healthy and splay leg piglets 
[356]. It belongs to the S10E family of ribosomal proteins. RPS10 expression was 
reduced in brown adipose tissue of hibernating arctic ground squirrels compared to 
mice [357]. Hibernation is an energy-saving strategy adopted by a wide range of 
mammals to survive highly seasonal or unpredictable environments.  
SLC36A1 codes for a solute carrier family 36 (a proton-coupled amino acid 
transporter (PAT1) protein, that mediates symport of protons and small neutral 
amino acids. This carrier has a role in absorption of amino acids from luminal protein 
digestion of the brush border membrane driving transport of amino acids into the 
cytosol (presumably in the gut during absorption) [358]. These amino acids, in turn, 
activate mTORC1, and subsequently stimulate protein synthesis and consequently 
skeletal muscle growth [359]. SLC36A1 expression was increased following 
resistance exercise in young and older men [359]. Also, following a single bout of 
high-intensity resistance exercise, SLC36A1 expression increased amongst many 
other skeletal muscle amino acid transporters in both healthy men and women, 
independent of age [360]. SLC36A1 is yet to be characterized in adipose tissue.  
TGM2 codes for tissue transglutaminase, a calcium dependent enzyme of the 
protein-glutamine γ-glutamyltransferases family [361]. It cross-links proteins 
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between a lysine residue and a glutamine residue, creating an inter- or 
intramolecular bond that is highly resistant to proteolysis [362]. What proteins get 
cross-linked and the consequence of that cross-linking in the context of cachexia is 
yet to be investigated. TGM2 −/− and F13a1−/− double null mice showed no loss of 
bone mass and maintained normal bone mineral density to 12 months age. Bone 
marrow adipocity showed large increases in both fat percent (+70.7%) and 
adipocyte numbers (+65%) suggesting that TG2 and FXIIIA might regulate an 
osteoblast-adipocyte switch via fibronectin matrix stabilization [363, 364].  
TGM2 is downregulated in bone marrow in response to age as it was found to 
enhance cell growth and survival through anti-apoptosis signaling which is usually 
downregulated during aging [365]. TGM2 was one of several genes that have higher 
expression in human brown adipose tissues compared to white adipose tissues 
[366]. 
6.2 Downregulated Genes 
6.2.1 Results 
Table 28: Downregulated Overlapping Genes. 
Gene 
Symbol 
Gene Full Name Muscle Fat 
Fold 
change 
P-
Value 
Fold 
change 
P-
Value 
AC007246.3 Antisense. Uncharacterized 
LOC728730 
-2.98 0.0166 -2.23 0.019 
GPLD1 Glycosylphosphatidylinositol 
Specific Phospholipase D1 
-6.27 0.0172 -2.22 0.012 
GSTT1 Glutathione S-Transferase Theta 1 -2.73 0.0108 -3.40 0.046 
LOC283731 Uncharacterized LOC283731 -13.65 0.0006 -4.04 0.045 
PPP1R9A Protein Phosphatase 1, Regulatory 
Subunit 9A 
-2.62 0.0052 -2.04 0.022 
SYNM Synemin, Intermediate Filament 
Protein 
-2.26 0.0126 -2.26 0.035 
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6.2.2 Discussion 
GPLD1 codes for phosphatidylinositol-glycan-specific phospholipase D1 
enzyme[367]. Many proteins at the extracellular plasma membranes are attached 
via a glycosylphosphatidylinositol (GPI) anchor. GPLD1 is a GPI degrading enzyme 
that hydrolyzes the inositol phosphate linkage in proteins anchored by GPI thereby 
allowing release of the attached protein [368]. In vitro, GPLD1 overexpression is 
associated with increased expression of de novo lipogenesis genes [369]. Also, 
insulin resistance in human subjects was found to be associated with increased 
serum levels of GPLD1 which is also involved in lipid metabolism (triglyceride 
metabolism) [370]. It could be, therefore, a gene that is downregulated in cachectic 
muscle and adipose tissue as a compensation for the presence of insulin resistance. 
Despite this evidence, the role of the gene in muscle has not yet been investigated.  
GSTT1 codes for glutathione S-transferase theta-1, that is a member of a 
superfamily of enzymes that catalyze the conjugation of reduced glutathione. 
Glutathione exists in both reduced (GSH) and oxidized (GSSG) states. In healthy 
states, the majority of glutathione are in the reduced form (GSH). The ratio of 
oxidized-to-reduced (GSSG-to-GSH) is considered indicative of oxidative stress 
[371]. GSTT1 functions on the reduced glutathione. GSTT1 is expressed in both, 
muscle [372] and adipose tissue [373]. 
Fat deposition was investigated in fat vs. lean chicken. GSTT1 was found to be one 
of the differentially upregulated genes in adipose tissue of fat chicken [374].  
GSTT1 was found to co-vary with NNAT expression in murine fed high fat diet white 
adipose tissue [373]. NNAT is an acute diet-responsive gene in white adipose tissue 
and hypothalamus; it may play an important role in metabolism, adipogenesis, and 
resolution of oxidative stress and inflammation in response to dietary excess [373]. 
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Thus, this decreased expression of GSTT1 in the skeletal muscle and adipose 
tissues of cachectic subject could reflect reduced cellular ability to manage free 
radicals and consequently altering cellular functions.  
PPP1R9A codes for protein phosphatase 1, regulatory subunit 9A. The PPP1R9A 
protein is involved in actin cytoskeleton dynamics and in synaptic formation and 
function [375, 376]. PPP1R9A is also imprinted mainly in skeletal muscle [376]. It is 
found to be highly concentrated in the synapses of developed neurons [377]. It is 
suggested that downregulation of PPP1R9A and other genes is an evidence that 
deficiencies in cytoskeletal dynamics play a role in Huntington's disease 
pathogenesis [378]. PPP1R9A was one of many expressed genes that were stably 
retained in H9-hESCs cell line throughout differentiation [379]. 
SYNM (synemin or desmuslin) codes for an intermediate filament (IF) protein [380]. 
IFs function by integrating mechanical stress and maintain structural integrity in 
eukaryotic cells. Diseases involving Ifs have defects in the organization of the 
contractile apparatus of skeletal and cardiac muscle [381]. SYNM was mainly 
studied in the sarcomere of skeletal myocytes [380]. It localizes at the Z-disk and 
has been shown to act as a mechanical linker, transmitting force laterally throughout 
the tissue, especially between the contractile myofibrils and extracellular matrix 
[380]. Synemin is expressed mainly in heart and skeletal muscle [380]. 
Synemin knockout mice have a mild skeletal muscle phenotype, characterized by 
decreased fiber size and increased sarcolemmal deformability and susceptibility to 
injury [381]. On the other hand, abnormal accumulations of synemin and desmin in 
muscle fibres was seen in multiple myopathies [382]. Other study on synemin 
knockout mice showed a higher hypertrophic capacity with increased maximal force 
and fatigue resistance following mechanical overload, compared with control mice 
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[383]. Molecularly, this increased remodeling capacity was accompanied by the 
decreased expression of myostatin and atrogin expression, and increased follistatin 
expression [383]. 
Knockdown of synemin expression with siRNAs within mammalian cells resulted in 
significantly compromised cell adhesion and cell motility, suggesting a possible role 
of synemin as a focal adhesion molecule that is essential for cell adhesion and 
migration [384].  
Synemin upregulation or downregulation has marked effects on skeletal muscle. In 
cachectic patients, the downregulation of expression of this gene may have put the 
muscle under higher susceptibility for injury while decreasing the fiber size and 
contributing to the wasting phenotype. However, so far, no data is available about 
the role of synemin in adipose tissue.  
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Chapter 7: Overall Discussion 
 
Cancer cachexia is a multifactorial syndrome that is responsible for at least one-third 
of cancer-related death worldwide and contributes to the death of many others. 
More than 80% of cancer patients are cachectic towards the end of life. Despite 
intensive research, the mechanisms of cancer cachexia are still poorly understood 
and its multi-faceted etiopathogenesis has never been thoroughly reflected on in a 
single set of experiments. In vitro and in vivo experimentation, so far, has not led to 
any leap in our understanding of cachexia, since no model is able to recapitulate the 
whole spectrum of the cancer cachexia syndrome. In addition, the few conducted 
clinical studies using microarray had neither given us good insight, nor were 
reproducible.   
It is our believe that identification of early changes in gene expression in cachexia 
target tissues (muscle and adipose tissue) will lead to an improved understanding of 
the mechanisms that trigger this important problem in cancer patients. Next 
generation sequencing is the state-of-the-art technique to generate high throughput, 
high quality results. This technique has proven to be much more powerful and 
discriminatory than microarray and is now considered to be the state-of-the-art. 
The decisions to include all of the cachectic and non-cachectic cancer patients was 
made solely based on body weight changes in the past 3-6 months and by 
meticulous exclusion of samples that might have reflected any etiogenesis that 
could contribute/aggravate cachexia (i.e. malnutrition, muscular/endocrine/other 
metabolic diseases, etc.). The cachectic and the weight-stable group showed no 
significant differences in any of the measured biochemical parameters. The 
Glasgow prognostic score, which is suggested to be a measure for diagnosing and a 
guide for treatment of cachexia, failed to distinguish a signature difference in the 
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cachectic group. It contrast it revealed more advance scores in non-cachectic 
controls. However, our small sample size cannot fully refute the possibility of that 
measure to predict cachexia if applied on a larger scale of samples. Yet, we believe 
it may not be the method of choice for looking at early stages of cachexia.  
7.1 Changes in Gene Expression in Skeletal Muscle 
Genes whose expression changed in cachectic muscles reflect of a large spectrum 
of genes encoding skeletal muscle structural proteins, proteins in the muscle 
contractile machinery, energy metabolism, and others. 
Several skeletal muscle proteins in the basement membrane were upregulated, 
namely agrin, perlecan, collagen, laminin, and neurexin (Figure 8). Agrin is required 
for the organization of the cytoskeleton and amelioration of function in diseased 
muscle [385]; perlecan is important in maintaining muscular integrity [386]; collagen 
and laminin are upregulated during endurance training [387]. On the other hand, 
many genes encoding transmembrane and intracellular muscular structural proteins 
were downreguated, such asintegrins, sarcospan, elements of sarcoglycan complex, 
myotilin, desmin, titin, and α-catinin. Collectively, the functions of the upregulated 
genes in the basement membrane of myocyte reflect a defensive adaptive protective 
response to maintain muscular homeostasis which is possibly triggered by the down 
regulation of essential interacellular proteins.  
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Figure 8: Skeletal Muscle Extracellular Matrix and Structural Muscle Proteins. 
Items circled in red are upregulated; items circled in blue are downregulated. 
Amended from [388].  
 
 
Collagen 
Agrin Perlecan 
Integrins 
Sarcospan 
Titin 
α-Catenin 
Neurexin 
   121 
 
 
 
 
 
In addition, integrins, titin [389], and tropomysin [390], which were also 
downregulated, are essential component in the contractile machinery (Figure 9). 
Normally, an action potential causes skeletal muscle to depolarize opening the 
voltage-gated L-type calcium channels (two subunits of which are downreguated). 
This increases intracellular calcium causing it to bind to calmodulin, which in turn 
activates myosin light chain kinase (MLCK) (both of which are downregulated). 
MLCK then phosphorylates the regulatory light chains of the myosin heads leading 
to a cascade of events that causes muscle contraction (Figure 10). Both, the 
signaling cascade and the structural response machinery are altered in the muscle 
of our cachectic patients. Another interesting change in expression was seen in 
genes involved in the cytoskeleton and myofibers. This indicates that morphological 
changes can be also evident in cachectic muscles before/during the cachectic 
changes. Expressions of genes implicated in cellular trafficking were also affected.  
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Tropomysin 
Figure 9: Muscular Contractile Machinery. 
Items circled in blue are downregulated. Amended from  
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Figure 10: Molecular Signaling in Muscular contraction. 
Items circled in blue are downregulated. Amended from  
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Glycogen is an immediate reserve source of energy for skeletal muscle. Many 
disorders of glycogen metabolism (as mentioned above) result in muscular 
phenotypes. Many genes encoding proteins or protein subunits that are necessary 
components in the machinery needed for glycogen metabolism were downregulated 
in the cachectic muscles (Figure 11). The involved genes are necessary for either 
the initiation or progression of glycogenesis (e.g. PGM1; encoding phosphomutase, 
protein hosphatase; PPP1R3A, PPP1R3B, and PPP1R3C; necessary for activation 
of glycogen synthase, and AGL; encoding glycogen branching enzyme), or 
glycogenolysis (Phosphorylase kinase; PHKA1, PHKB, PHKG1; necessary for 
activation of glycogen phosphorylase) (Figure 11). Athletes experiencing a 
phenomenon called "hitting the wall", which is caused by depletion of glycogen 
stores [393], often experience sudden fatigue and loss of energy [394];two 
symptoms repeatedly reported by cachectic patients. Such alteration in the glycogen 
turnover in cachectic patients limits energy availability and redirects muscle cells to 
energy from other sources, such as fat and protein catabolism.  
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Figure 11: Glycogen Metabolism. 
Items circled in blue are downregulated. Amended from [395]. 
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Aerobic cellular respiration is responsible for the most efficient energy production in 
cells[396]. Interestingly in our findings, the machinery responsible for that process 
was found to be downregulation at many levels. Normally, aerobic respiration is 
initiated by glycolysis leading to the production of pyruvate. Pyruvate is then 
converted into acetyl-CoA via a 3-step sequence of enzymatic activities mediated by 
"pyruvate dehydrogenase complex". Dihydrolipoyl dehydrogenase (E3) enzyme that 
is responsible for the last step of the process was found to be downregulated. 
Acetyl-CoA should then be used in the "citric acid cycle"  to generating 
NADH(nicotinamide adenine dinucleotide) [159]. Three enzymes (dihydrolipoyl 
succinyltransferase, succinyl-CoA synthetase, and succinate dehydrogenase) in this 
multistep process were found to be downregulated. NADH can finally enters the 
oxidative phosphorylation via the electron transport pathway [159], which is itself 
has several downregulated genes in its 5 different complexes (Complex I: NDUFB5 
and NDUFS1; complex II: SDHC; complex III: CYCS and UQCRC2; complex IV: 
COX20; and complex V: ATP5B).  
Our evidence of the disrupted aerobic cellular respiration and the clinical evidence of 
an increased lactate production in muscle of cachectic patients [397], is suggestive 
of the possible domination of the anaerobic respiration. This process occurs in 
animal cells under hypoxic (or partially anaerobic) conditions in oxygen starved 
muscles. In cachectic patients, hypoxic conditions might not be the direct cause for 
such switch but rather the slowed aerobic respiration process with increasing 
demands of muscles for energy production. In many tissues, this is a cellular last 
resort for energy that most animal tissue cannot tolerate for an extended period of 
time. It is an energy wasting process that requires lactate to be recycled back into 
glucose by the liver. The production of lactate via glycolysis as a source of energy 
and the followed recycling results in a net loss of 4 ATP molecules which could be 
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the direct cause of cachexia due to an increasing demand of tissue catabolism to 
meet the required demand of energy (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Liver Lactate Recycling and Net ATP Production. 
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The pentose-phosphate pathway is a parallel pathway to glycolysis [398]. The 
reaction sequences of central metabolism, glycolysis and the pentose phosphate 
pathway provide essential precursors for nucleic acids, amino acids and lipids [398]. 
The upregulation of this pathway (Figure 13) is one finding in this study that reflects 
adaptation or compensatory muscular changes. We also found upregulation of 
genes involved in skeletal muscle proliferation, differentiation, and regeneration. We 
believe that increased expression of these genes reflects a compensatory 
mechanism that is attempting to maintain muscular homeostasis. These above 
mechanisms require adequate and strong cell-cell contacts which were evident with 
the upregulation of many cell adhesion molecules and extracellular matrix pathway 
genes. 
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Figure 13: Pentose Phosphate Pathway. 
Items circled in red are upregulated. Amended from  
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Symptoms of cachexia were also reflected in changes in gene expression. 
Weakness and easily fatigability may also be explained by changes in expression of 
multiple genes implicated in maintenance of muscular tone, and contractile 
machinery. In addition, many of the downregulated genes have a documented 
evidence of genetically inherited muscular ailments which are known to affect 
muscular tonicity and contractile ability. Also, expression of multiple genes that are 
implicated in insulin resistance, a key feature of cachexia, were significantly altered.  
The major degradation machinery (the ubiquitination pathway) was surprisingly 
downregulated with reduction in expression of multiple genes and at various 
different levels. The ubiquitin system has been repeatedly implicated in the 
preclinical models as the major mechanisms leading to wasting in many in vitro and 
in vivo experiments. All clinical studies have failed to reproduce any upregulation of 
this degradation system in human skeletal muscle biopsies. However, amongst 
other ground breaking changes in the signature of the cachexia, the present study is 
the first to show that the pathway is actually significantly downregulated, perhaps in 
compensation for the wasting triggers. This gave us a reassurance and evidence 
that our samples represent true early cachectic changes that are subject to bodily 
defensive compensatory mechanisms attempting to maintain homeostasis. 
None of the inflammatory or tumor specific factors were significantly altered. For 
example, no transcripts for the dermicidin gene, which contains the sequence that 
codes for the backbone peptide of proteolysis-inducing factor, were detected. 
Although of course their expression in the tumors themselves may well be altered. 
Furthermore, the genes encoding inflammatory cytokines and their major receptors 
were not found to be significantly altered. In contrast, inflammation is a direct cause 
for cachexia in conditions such as sepsis, severe trauma, or burns. But cancer 
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cachexia has a slower progression phenotype and may be mediated by 
inflammatory cytokines, at least in part, in its advanced stages. 
The myostatin pathway is at the top of the research agenda for cachexia 
researchers. Many animal studies strongly correlated its upregulation to the 
pathogenesis of wasting. However, expression of myostatin in our study was 
significantly decreased as was its receptor, possibly reflecting end organ adaptation 
to tumor produced myostatin. 
One unique and interesting gene is TIE1. Expression of this gene was significantly 
increased in a previous human microarray study and was also upregulated in the 
present study. The TIE1 gene is not well characterized, however, its upregulation in 
two separate genome-wide expression studies certainly warrants further attention.  
7.2 Changes in Gene Expression in Adipose Tissue 
Since cachexia is predominantly associated with skeletal muscle changes, changes 
in adipose tissue have received much less attention with regard to the pathogenesis 
of cachexia. Many of the genes implicated to be involved from the results of the 
present study are either uncharacterized or have not been previously studied in 
adipose tissue. However, several of these encode metabolic enzymes and 
receptors.  
Expression of leptin was downregulated as expected from many previous studies. 
This is indicative of depleted fat stores and should result in increased feeding 
(Figure 14). However, as has been discussed the hypothalamus does not respond 
normally to decreased leptin in the cachectic state. Similar to leptin, tenomodulin 
downregulation is also reflective of fat depletion [330] and further support the 
involvement of fat wasting in the cachectic process. 
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Expression of zinc-α-2-glycoprotein (lipid mobilizing factor) was significantly 
upregulated as expected. On the other hand, the expression of other genes 
previously implicated with cachexia, such as hormone sensitive lipase and adipose 
tissue triglyceride lipase, were unchanged.  
 
Figure 14: Leptin Production and its Function in the Central Nervous System. 
Amended from [400].   
 
Expression of genes that are involved in adipogenesis and implicated in insulin 
resistance were also upregulated. On the other hand, expression of genes that 
resist lipolytic forces were also upregulated, perhaps in an attempt to neutralize the 
cachectic state. With the exception of leptin, there were no changes in expression of 
any genes previously implicated implicated in cachexia, from either clinical or 
preclinical studies, that were reproduced in our the present study on adipose tissue.  
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7.3 Changes in Gene Expression in Both; Muscle and Adipose Tissue 
With two large organs in the body, there must be a cross-talk mediating the 
compensation or decompensation signals leading to wasting. Several altered genes 
were found to be common between these two tissues. Many of these genes are yet 
to be characterized while others need to be investigated at the context of the 
pathogenesis of cachexia.   
7.4 Conclusion 
Progress in cancer cachexia research was, up till now, held back with poor progress 
due to the lack of reliable and representative sample that serve as a "point of 
reference" or a benchmark for future research. Cancer cachexia research continuum 
have either worked in isolated in vitro and in vivo models which outcomes rarely 
been a true reflection of what is seen in the clinic. In addition, studies conducted on 
clinical samples didn't feed enough data reflecting the true complexity of the clinical 
presentation.  
Our enthusiasm took us back to the clinic to extract a meaningful representative 
sample from cachectic cancer patients exhibiting early cachectic changes. We were 
able for the first time to reflect on the big picture of the pathological changes in the 
two major organs affected by cachexia (i.e. muscle and fat). This was achieved by 
combination of factors that starts by looking at expression changes in early stages of 
cachexia using simple diagnostic criteria, building on previous array studies where 
we learnt from their limitations, and finally by utilizing the state-of-the-art technology 
for generating the highest quality data. These studies confirmed that for a 
multifactorial condition, genome wide transcriptome analysis is the method of choice 
to explore the disease complexity. They explain some documented evidence in 
   134 
 
 
 
 
 
cachexia pathogenesis, highlight ambiguous data from animal models, and reveal 
unexpected changes in gene expression that underlie the pathophysiology of the 
cachectic state in cancer. These results bring reliable, representable, and consistent 
data from the clinic and back to the bench with more focused insights to be 
investigated and verified.  
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Chapter 8: Limitations and Future Directions 
 
8.1 Limitations 
We were lucky that couple of genome-wide array studies have been published 
during the time we were collecting our samples. We build part of our success by 
starting at where they have ended. However, no study is limitation free. Due to 
feasibility issues (time and accrual rate), the study couldn't further restrict its 
inclusion criteria further (i.e. same age group, gender, diagnoses, etc). This may 
have in part question the homogeneity of samples. However, we don't believe it is a 
major influence in the major target organ (i.e. skeletal muscle) as was evident in the 
muscle heat map. Functional assessment of subjects was not all done. For example, 
none of the subjects were anorexic or malnourished at the time of obtaining 
samples. On the other hand, other phenotypes (or symptoms) known to accompany 
cachexia were not assessed (e.g. weakness and fatigability). Patients were 
generally with good performance status. Thus, we believe that such symptoms are 
only clearly evident with advanced cachexia. Our data documented the involvement 
of many related genes which is a prerequisite to an evident functional impairment. 
We were also not able to validate the data for all the differentially expressed genes. 
It would have been wise if a larger separate group of samples is collected and to get 
the data cross-validated, however, due to slow accrual rate, we restricted our 
findings to what in hand.  
8.2 Future Directions 
Sample collection will continue using the same simple criteria to identify cachectic 
patients in clinic using meticulous follow-up and recording of weight changes to 
diagnose patients with cancer cachexia and separate them from non-cachectic 
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weight-stable controls. After this logical presentation of the complexity of cachexia 
pathogenesis, the second best step is to be able to verify these changes on a 
different and larger group of patients. Also, all reproducible changes should be 
confirmed at protein level using western blotting and immunohistochemistry. 
Changes in muscular morphology are also worth being investigated via electron 
microscopy.  
In future studies, we would measure circulating factors where changes were seen in 
the present study, including inflammatory cytokines, GAD15, leptin, mysotatin, 
proteolysis inducing factor, lipid mobilizing factor, etc.  
Finally, it would be hard to completely characterize the role of all of these factors in 
the development of cachexia unless we succeed in developing a reliable animal 
model that truly reflects cachexia presentation in humans.  
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